GibsonMK_2016_SRR3131800_bin.2_k141_239_8	SARG|gb|ABO11759.2|ARO:3004573|Acinetobacter	39.4	424	441	429	3.51e-91	281
GibsonMK_2016_SRR3131800_bin.2_k141_239_24	SARG|gi|815842605|ref|WP_046464285.1|	26.8	235	411	388	2.95e-11	63.5
GibsonMK_2016_SRR3131800_bin.2_k141_239_24	SARG|gi|950716651|ref|WP_057492920.1|	27.0	215	411	387	3.92e-11	63.2
GibsonMK_2016_SRR3131800_bin.2_k141_239_24	SARG|NP_390536	23.8	223	411	400	4.10e-11	63.2
GibsonMK_2016_SRR3131800_bin.2_k141_239_24	SARG|gi|686390434|ref|WP_031905541.1|	24.2	207	411	388	6.98e-11	62.4
GibsonMK_2016_SRR3131800_bin.2_k141_239_24	SARG|gi|488426786|ref|WP_002496171.1|	26.0	215	411	387	9.27e-11	62.0
GibsonMK_2016_SRR3131800_bin.2_k141_239_24	SARG|gi|928798706|ref|WP_053871425.1|	24.2	207	411	388	1.24e-10	61.6
GibsonMK_2016_SRR3131800_bin.2_k141_239_24	SARG|gi|686404660|ref|WP_031911321.1|	24.2	207	411	388	1.24e-10	61.6
GibsonMK_2016_SRR3131800_bin.2_k141_239_24	SARG|gi|556618713|ref|WP_023374778.1|	26.4	235	411	388	1.65e-10	61.2
GibsonMK_2016_SRR3131800_bin.2_k141_239_24	SARG|gi|686319989|ref|WP_031875473.1|	22.8	333	411	388	1.65e-10	61.2
GibsonMK_2016_SRR3131800_bin.2_k141_239_24	SARG|gi|686393404|ref|WP_031907214.1|	24.2	207	411	388	1.65e-10	61.2
GibsonMK_2016_SRR3131800_bin.2_k141_1002_28	CARD|gb|AAL19308.1|ARO:3000504|golS	32.8	134	144	154	1.37e-19	78.6
GibsonMK_2016_SRR3131800_bin.2_k141_1002_33	SARG|gi|757799830|ref|WP_043017032.1|	30.5	302	315	660	5.01e-35	133
GibsonMK_2016_SRR3131800_bin.2_k141_1002_33	SARG|gi|1002399350|ref|WP_061382108.1|	30.1	302	315	660	6.84e-35	132
GibsonMK_2016_SRR3131800_bin.2_k141_1002_33	SARG|gi|851935911|ref|WP_048224705.1|	29.8	302	315	660	1.27e-34	132
GibsonMK_2016_SRR3131800_bin.2_k141_1002_33	SARG|gi|851917461|ref|WP_048217311.1|	30.1	302	315	660	1.27e-34	132
GibsonMK_2016_SRR3131800_bin.2_k141_1002_33	SARG|gi|489117806|ref|WP_003027650.1|	30.1	302	315	660	1.27e-34	132
GibsonMK_2016_SRR3131800_bin.2_k141_1002_33	SARG|gi|507086291|ref|WP_016157032.1|	30.1	309	315	660	1.74e-34	131
GibsonMK_2016_SRR3131800_bin.2_k141_1002_33	SARG|gi|696375142|ref|WP_032949690.1|	30.1	302	315	660	2.37e-34	131
GibsonMK_2016_SRR3131800_bin.2_k141_1002_33	SARG|gi|851981245|ref|WP_048240645.1|	30.1	302	315	660	2.37e-34	131
GibsonMK_2016_SRR3131800_bin.2_k141_1002_33	SARG|B1LLK9	29.5	288	315	660	3.23e-34	130
GibsonMK_2016_SRR3131800_bin.2_k141_1002_33	SARG|gi|765458296|ref|WP_044714032.1|	30.1	302	315	660	3.23e-34	130
GibsonMK_2016_SRR3131800_bin.2_k141_1224_5	SARG|gb|QNR09092.1|ARO:3007042|msr(G)	25.7	214	357	485	3.47e-10	60.1
GibsonMK_2016_SRR3131800_bin.2_k141_1224_11	megares|MEG_8019|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CML_1	25.7	152	450	411	1.90e-07	52.0
GibsonMK_2016_SRR3131800_bin.2_k141_1224_11	NCBI|WP_011552636.1|1|1|cml_Myxo|cml_Myxo|efflux|2|CHLORAMPHENICOL|PHENICOL|Cml_family_phenicol_efflux_MFS_transporter|AMR|phenicol	25.7	152	450	411	1.90e-07	52.0
GibsonMK_2016_SRR3131800_bin.2_k141_1224_21	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	32.3	254	413	323	2.80e-27	109
GibsonMK_2016_SRR3131800_bin.2_k141_1224_21	SARG|gi|746609237|ref|WP_039635344.1|	31.1	257	413	322	7.16e-27	108
GibsonMK_2016_SRR3131800_bin.2_k141_1224_21	SARG|DQ018711.1.gene4.p01	30.7	257	413	322	6.62e-26	105
GibsonMK_2016_SRR3131800_bin.2_k141_1224_21	SARG|gi|740152780|ref|WP_037997109.1|	32.2	230	413	322	9.08e-26	105
GibsonMK_2016_SRR3131800_bin.2_k141_1224_21	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	34.8	227	413	351	5.00e-25	103
GibsonMK_2016_SRR3131800_bin.2_k141_1224_21	SARG|AF155139.2.gene6.p01	30.2	255	413	322	6.05e-25	103
GibsonMK_2016_SRR3131800_bin.2_k141_1224_21	SARG|gi|749574782|ref|WP_040203616.1|	33.9	233	413	323	6.14e-25	103
GibsonMK_2016_SRR3131800_bin.2_k141_1224_21	SARG|gi|738848198|ref|WP_036737307.1|	30.0	257	413	323	1.15e-24	102
GibsonMK_2016_SRR3131800_bin.2_k141_1224_21	SARG|gi|737310392|ref|WP_035293250.1|	30.0	257	413	323	2.96e-24	101
GibsonMK_2016_SRR3131800_bin.2_k141_1224_21	SARG|FJ349556.1.gene5.p01	31.8	245	413	326	4.25e-24	100
GibsonMK_2016_SRR3131800_bin.2_k141_1224_40	SARG|gb|ABO11759.2|ARO:3004573|Acinetobacter	39.3	420	442	429	1.66e-101	308
GibsonMK_2016_SRR3131800_bin.2_k141_1224_43	SARG|gb|AAK76137.1|ARO:3000024|patA	26.4	216	506	564	4.54e-14	73.6
GibsonMK_2016_SRR3131800_bin.2_k141_1224_43	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	21.1	521	506	655	1.38e-11	65.9
GibsonMK_2016_SRR3131800_bin.2_k141_1224_43	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	21.1	521	506	655	1.83e-11	65.5
GibsonMK_2016_SRR3131800_bin.2_k141_1224_43	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	21.1	521	506	655	2.41e-11	65.1
GibsonMK_2016_SRR3131800_bin.2_k141_1224_43	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	20.9	521	506	655	7.36e-11	63.5
GibsonMK_2016_SRR3131800_bin.2_k141_1224_43	SARG|gb|AKA86814|ARO:3003746|optrA	20.9	521	506	655	7.36e-11	63.5
GibsonMK_2016_SRR3131800_bin.2_k141_1224_43	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	20.9	521	506	655	1.70e-10	62.4
GibsonMK_2016_SRR3131800_bin.2_k141_1224_43	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	20.9	521	506	655	1.70e-10	62.4
GibsonMK_2016_SRR3131800_bin.2_k141_1224_43	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	20.9	521	506	655	1.70e-10	62.4
GibsonMK_2016_SRR3131800_bin.2_k141_1224_43	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	20.9	521	506	655	1.70e-10	62.4
GibsonMK_2016_SRR3131800_bin.2_k141_1224_57	CARD|gb|AAD51348.1|ARO:3003066|smeR	41.8	220	232	229	6.39e-54	172
GibsonMK_2016_SRR3131800_bin.2_k141_1224_57	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	38.4	224	232	225	6.69e-44	146
GibsonMK_2016_SRR3131800_bin.2_k141_1224_57	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	34.8	233	232	232	1.59e-40	137
GibsonMK_2016_SRR3131800_bin.2_k141_1224_57	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.1	227	232	228	2.01e-40	137
GibsonMK_2016_SRR3131800_bin.2_k141_1224_57	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	35.2	227	232	232	2.24e-40	137
GibsonMK_2016_SRR3131800_bin.2_k141_1224_57	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	36.6	227	232	231	1.22e-39	135
GibsonMK_2016_SRR3131800_bin.2_k141_1224_57	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	35.6	236	232	233	1.81e-39	135
GibsonMK_2016_SRR3131800_bin.2_k141_1224_57	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	34.9	238	232	235	1.06e-38	133
GibsonMK_2016_SRR3131800_bin.2_k141_1224_57	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	35.7	227	232	230	1.45e-37	130
GibsonMK_2016_SRR3131800_bin.2_k141_1224_57	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	33.3	231	232	231	1.49e-37	130
GibsonMK_2016_SRR3131800_bin.2_k141_1224_61	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	32.6	236	312	346	1.22e-20	89.7
GibsonMK_2016_SRR3131800_bin.2_k141_1224_73	SARG|gi|948137056|ref|WP_056795395.1|	38.1	549	591	602	3.74e-88	284
GibsonMK_2016_SRR3131800_bin.2_k141_1224_73	SARG|gi|1045390184|ref|WP_065479071.1|	37.5	547	591	605	4.53e-86	278
GibsonMK_2016_SRR3131800_bin.2_k141_1224_73	SARG|gi|695842130|ref|WP_032755430.1|	37.5	549	591	603	2.33e-85	276
GibsonMK_2016_SRR3131800_bin.2_k141_1224_73	SARG|gi|764446018|ref|WP_044369325.1|	37.5	549	591	605	2.44e-85	276
GibsonMK_2016_SRR3131800_bin.2_k141_1224_73	SARG|gi|695865802|ref|WP_032778631.1|	37.3	549	591	605	3.42e-85	276
GibsonMK_2016_SRR3131800_bin.2_k141_1224_73	SARG|gi|944009777|ref|WP_055601444.1|	35.5	602	591	628	4.21e-85	276
GibsonMK_2016_SRR3131800_bin.2_k141_1224_73	SARG|gi|951183771|ref|WP_057661487.1|	37.7	549	591	603	4.56e-85	276
GibsonMK_2016_SRR3131800_bin.2_k141_1224_73	SARG|gi|948040364|ref|WP_056699531.1|	37.7	549	591	603	4.56e-85	276
GibsonMK_2016_SRR3131800_bin.2_k141_1224_73	SARG|gi|662129758|ref|WP_030081404.1|	37.7	549	591	605	6.70e-85	275
GibsonMK_2016_SRR3131800_bin.2_k141_1224_73	SARG|gi|664180077|ref|WP_030714054.1|	37.3	549	591	605	6.70e-85	275
GibsonMK_2016_SRR3131800_bin.2_k141_1224_85	SARG|gi|949718947|ref|WP_057063453.1|	32.4	238	708	648	2.18e-24	107
GibsonMK_2016_SRR3131800_bin.2_k141_1224_85	SARG|gi|835233765|ref|WP_047410073.1|	32.4	222	708	648	6.72e-24	105
GibsonMK_2016_SRR3131800_bin.2_k141_1224_85	SARG|gi|754951242|ref|WP_042307417.1|	32.4	222	708	648	6.72e-24	105
GibsonMK_2016_SRR3131800_bin.2_k141_1224_85	SARG|gi|851922185|ref|WP_048218206.1|	32.4	222	708	648	6.72e-24	105
GibsonMK_2016_SRR3131800_bin.2_k141_1224_85	SARG|gi|696375069|ref|WP_032949617.1|	32.4	222	708	648	6.72e-24	105
GibsonMK_2016_SRR3131800_bin.2_k141_1224_85	SARG|gi|696361545|ref|WP_032936694.1|	32.4	222	708	648	6.72e-24	105
GibsonMK_2016_SRR3131800_bin.2_k141_1224_85	SARG|gi|489936909|ref|WP_003840216.1|	32.4	222	708	648	6.72e-24	105
GibsonMK_2016_SRR3131800_bin.2_k141_1224_85	SARG|gi|489127020|ref|WP_003036815.1|	32.4	222	708	648	6.72e-24	105
GibsonMK_2016_SRR3131800_bin.2_k141_1224_85	SARG|gi|507079862|ref|WP_016150620.1|	32.4	222	708	648	6.72e-24	105
GibsonMK_2016_SRR3131800_bin.2_k141_1224_85	SARG|gi|949791377|ref|WP_057104572.1|	32.4	222	708	648	6.72e-24	105
GibsonMK_2016_SRR3131800_bin.2_k141_1224_86	SARG|gi|805303886|ref|WP_046093569.1|	37.0	365	376	372	2.22e-67	216
GibsonMK_2016_SRR3131800_bin.2_k141_1224_86	SARG|gi|485947286|ref|WP_001495038.1|	36.7	362	376	371	3.05e-67	216
GibsonMK_2016_SRR3131800_bin.2_k141_1224_86	SARG|gi|554679504|ref|WP_023180493.1|	37.0	365	376	372	3.13e-67	216
GibsonMK_2016_SRR3131800_bin.2_k141_1224_86	SARG|gi|447124500|ref|WP_001201756.1|	37.0	365	376	372	4.41e-67	215
GibsonMK_2016_SRR3131800_bin.2_k141_1224_86	SARG|gi|555268036|ref|WP_023249476.1|	37.0	365	376	372	4.41e-67	215
GibsonMK_2016_SRR3131800_bin.2_k141_1224_86	SARG|gi|447124490|ref|WP_001201746.1|	37.0	365	376	372	8.76e-67	214
GibsonMK_2016_SRR3131800_bin.2_k141_1224_86	SARG|gi|970299366|ref|WP_058671312.1|	37.0	365	376	372	8.76e-67	214
GibsonMK_2016_SRR3131800_bin.2_k141_1224_86	SARG|gi|545261069|ref|WP_021555171.1|	36.7	362	376	371	1.20e-66	214
GibsonMK_2016_SRR3131800_bin.2_k141_1224_86	SARG|gi|447124499|ref|WP_001201755.1|	37.0	365	376	372	1.23e-66	214
GibsonMK_2016_SRR3131800_bin.2_k141_1224_86	SARG|gi|555286087|ref|WP_023260800.1|	37.3	365	376	372	1.23e-66	214
GibsonMK_2016_SRR3131800_bin.2_k141_1224_87	SARG|gi|550712535|ref|WP_022645444.1|	47.4	648	651	648	1.48e-187	544
GibsonMK_2016_SRR3131800_bin.2_k141_1224_87	SARG|gi|754731641|ref|WP_042100724.1|	47.2	648	651	648	2.09e-187	543
GibsonMK_2016_SRR3131800_bin.2_k141_1224_87	SARG|gi|446110305|ref|WP_000188160.1|	47.4	648	651	648	2.09e-187	543
GibsonMK_2016_SRR3131800_bin.2_k141_1224_87	SARG|gi|446110286|ref|WP_000188141.1|	47.2	648	651	648	2.09e-187	543
GibsonMK_2016_SRR3131800_bin.2_k141_1224_87	SARG|gi|545254099|ref|WP_021550525.1|	47.2	648	651	648	2.96e-187	543
GibsonMK_2016_SRR3131800_bin.2_k141_1224_87	SARG|gi|1015927937|ref|WP_062886781.1|	47.2	648	651	648	4.19e-187	543
GibsonMK_2016_SRR3131800_bin.2_k141_1224_87	SARG|gi|446110277|ref|WP_000188132.1|	47.1	648	651	648	4.19e-187	543
GibsonMK_2016_SRR3131800_bin.2_k141_1224_87	SARG|gi|446110264|ref|WP_000188119.1|	47.2	648	651	648	4.19e-187	543
GibsonMK_2016_SRR3131800_bin.2_k141_1224_87	SARG|gi|693054987|ref|WP_032223114.1|	47.1	648	651	648	5.94e-187	542
GibsonMK_2016_SRR3131800_bin.2_k141_1224_87	SARG|gi|1035686596|ref|WP_064530178.1|	47.4	650	651	648	5.94e-187	542
GibsonMK_2016_SRR3131800_bin.2_k141_1224_88	SARG|NC_011595.7058890.p01	33.4	458	460	468	9.63e-67	220
GibsonMK_2016_SRR3131800_bin.2_k141_1224_88	SARG|NC_008702.1.4608931.p01	30.4	450	460	473	2.63e-43	157
GibsonMK_2016_SRR3131800_bin.2_k141_1224_88	SARG|NC_008702.1.4607681.p01	27.5	469	460	469	3.52e-37	140
GibsonMK_2016_SRR3131800_bin.2_k141_1224_88	NCBI|AAY90615.1|1|1|emhC|emhC||1|EFFLUX|EFFLUX|efflux_RND_transporter_outer_membrane_subunit_EmhC|AMR|efflux	28.7	467	460	486	4.46e-31	124
GibsonMK_2016_SRR3131800_bin.2_k141_1224_88	NCBI|AAQ92182.1|1|1|emhC|emhC||1|EFFLUX|EFFLUX|efflux_RND_transporter_outer_membrane_subunit_EmhC|AMR|efflux	29.1	419	460	486	2.09e-30	122
GibsonMK_2016_SRR3131800_bin.2_k141_1224_88	SARG|gb|CAJ77855.1|ARO:3000779|adeH	25.1	430	460	483	6.90e-28	114
GibsonMK_2016_SRR3131800_bin.2_k141_1224_88	SARG|YP_001350570	27.4	456	460	475	2.18e-27	113
GibsonMK_2016_SRR3131800_bin.2_k141_1224_88	SARG|gb|AAG05913.1|ARO:3004072|OpmB	26.7	438	460	498	3.55e-27	112
GibsonMK_2016_SRR3131800_bin.2_k141_1224_88	SARG|gi|759363558|ref|WP_043092439.1|	26.9	464	460	479	4.66e-26	109
GibsonMK_2016_SRR3131800_bin.2_k141_1224_88	SARG|gi|553768013|ref|WP_023100243.1|	26.7	464	460	479	1.56e-25	107
GibsonMK_2016_SRR3131800_bin.2_k141_1224_100	SARG|gb|AAC75271.1|ARO:3003952|yojI	67.6	549	551	547	4.39e-256	710
GibsonMK_2016_SRR3131800_bin.2_k141_1224_100	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	29.4	231	551	579	3.46e-11	64.7
GibsonMK_2016_SRR3131800_bin.2_k141_1224_100	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	28.6	231	551	579	5.59e-10	60.8
GibsonMK_2016_SRR3131800_bin.2_k141_1224_100	SARG|gb|AYV52072.1|ARO:3002882|lmrD	22.9	210	551	664	2.03e-07	52.8
GibsonMK_2016_SRR3131800_bin.2_k141_1224_111	SARG|gb|WP_204376227.1|ARO:3006889|GMB-1	29.2	130	295	270	1.25e-07	50.8
GibsonMK_2016_SRR3131800_bin.2_k141_1224_144	CARD|gb|CAA79966.1|ARO:3003665|NmcR	33.3	291	306	295	3.77e-42	146
GibsonMK_2016_SRR3131800_bin.2_k141_1224_144	megares|MEG_1992|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	30.8	289	306	291	2.28e-38	136
GibsonMK_2016_SRR3131800_bin.2_k141_1224_151	SARG|gi|1000359761|ref|WP_061107064.1|	24.1	349	397	466	3.36e-11	63.5
GibsonMK_2016_SRR3131800_bin.2_k141_1224_151	SARG|gi|504415211|ref|WP_014602313.1|	24.1	349	397	466	5.94e-11	62.8
GibsonMK_2016_SRR3131800_bin.2_k141_1224_151	SARG|HE999704.1.gene3170.p01	24.1	349	397	466	7.90e-11	62.4
GibsonMK_2016_SRR3131800_bin.2_k141_1224_151	SARG|gi|1000360171|ref|WP_061107359.1|	24.1	349	397	466	7.90e-11	62.4
GibsonMK_2016_SRR3131800_bin.2_k141_1224_151	SARG|gi|504744674|ref|WP_014931776.1|	24.1	349	397	466	7.90e-11	62.4
GibsonMK_2016_SRR3131800_bin.2_k141_1224_151	SARG|gi|844765894|ref|WP_047933506.1|	24.1	349	397	466	1.05e-10	62.0
GibsonMK_2016_SRR3131800_bin.2_k141_1224_151	SARG|gi|933593662|ref|WP_054314487.1|	24.1	349	397	466	1.05e-10	62.0
GibsonMK_2016_SRR3131800_bin.2_k141_1224_151	SARG|gi|1005608354|ref|WP_061691305.1|	24.1	349	397	466	1.05e-10	62.0
GibsonMK_2016_SRR3131800_bin.2_k141_1224_151	SARG|gi|502716012|ref|WP_012951063.1|	24.1	349	397	466	1.05e-10	62.0
GibsonMK_2016_SRR3131800_bin.2_k141_1224_151	SARG|gi|489826943|ref|WP_003730711.1|	24.1	349	397	466	1.05e-10	62.0
GibsonMK_2016_SRR3131800_bin.2_k141_1224_195	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	38.6	220	344	255	6.83e-47	158
GibsonMK_2016_SRR3131800_bin.2_k141_1364_2	SARG|CP001918.1.gene3442.p01	43.7	451	472	457	5.51e-118	352
GibsonMK_2016_SRR3131800_bin.2_k141_1364_2	SARG|gi|780037362|ref|WP_045446599.1|	29.8	413	472	512	1.72e-43	159
GibsonMK_2016_SRR3131800_bin.2_k141_1364_2	SARG|gi|835413504|ref|WP_047499457.1|	30.0	413	472	512	2.37e-43	159
GibsonMK_2016_SRR3131800_bin.2_k141_1364_2	SARG|gi|489922618|ref|WP_003825966.1|	29.8	413	472	512	3.27e-43	158
GibsonMK_2016_SRR3131800_bin.2_k141_1364_2	SARG|gi|489127514|ref|WP_003037306.1|	30.0	413	472	512	4.51e-43	158
GibsonMK_2016_SRR3131800_bin.2_k141_1364_2	SARG|gi|757800118|ref|WP_043017320.1|	30.0	413	472	512	4.51e-43	158
GibsonMK_2016_SRR3131800_bin.2_k141_1364_2	SARG|gi|507083411|ref|WP_016154159.1|	29.8	413	472	512	6.22e-43	157
GibsonMK_2016_SRR3131800_bin.2_k141_1364_2	SARG|gi|895960539|ref|WP_049043311.1|	29.8	413	472	512	6.22e-43	157
GibsonMK_2016_SRR3131800_bin.2_k141_1364_2	SARG|gi|835242255|ref|WP_047414775.1|	29.8	413	472	510	1.15e-42	157
GibsonMK_2016_SRR3131800_bin.2_k141_1364_2	SARG|gi|661298237|ref|WP_029991091.1|	29.6	432	472	510	1.59e-42	156
GibsonMK_2016_SRR3131800_bin.2_k141_1364_7	SARG|gi|445996710|ref|WP_000074565.1|	30.8	214	502	309	1.63e-19	88.2
GibsonMK_2016_SRR3131800_bin.2_k141_1364_7	SARG|gi|500465078|gb|EOP76697.1|	29.0	214	502	306	3.87e-19	87.0
GibsonMK_2016_SRR3131800_bin.2_k141_1364_7	SARG|gi|445996719|ref|WP_000074574.1|	29.4	214	502	309	4.03e-19	87.0
GibsonMK_2016_SRR3131800_bin.2_k141_1364_7	SARG|gi|542061059|gb|ERI11611.1|	28.8	215	502	316	1.09e-18	85.9
GibsonMK_2016_SRR3131800_bin.2_k141_1364_7	SARG|gi|445996723|ref|WP_000074578.1|	29.4	214	502	309	1.81e-18	85.1
GibsonMK_2016_SRR3131800_bin.2_k141_1364_7	SARG|gi|814314593|emb|CKF49145.1|	30.4	214	502	309	1.81e-18	85.1
GibsonMK_2016_SRR3131800_bin.2_k141_1364_7	SARG|gi|447057509|ref|WP_001134765.1|	28.5	214	502	309	2.44e-18	84.7
GibsonMK_2016_SRR3131800_bin.2_k141_1364_7	SARG|gi|445996722|ref|WP_000074577.1|	29.0	214	502	309	2.44e-18	84.7
GibsonMK_2016_SRR3131800_bin.2_k141_1364_7	SARG|gi|445996709|ref|WP_000074564.1|	30.4	214	502	309	3.29e-18	84.3
GibsonMK_2016_SRR3131800_bin.2_k141_1364_7	SARG|gi|445996729|ref|WP_000074584.1|	29.0	214	502	309	3.29e-18	84.3
GibsonMK_2016_SRR3131800_bin.2_k141_1364_49	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	34.0	847	805	703	1.34e-138	425
GibsonMK_2016_SRR3131800_bin.2_k141_1364_64	SARG|gi|740152780|ref|WP_037997109.1|	33.2	241	336	322	5.62e-28	110
GibsonMK_2016_SRR3131800_bin.2_k141_1364_64	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	34.1	261	336	323	2.91e-27	108
GibsonMK_2016_SRR3131800_bin.2_k141_1364_64	SARG|AAY52004	32.6	239	336	322	3.66e-25	102
GibsonMK_2016_SRR3131800_bin.2_k141_1364_64	SARG|KF478993.1.gene2.p01	34.8	201	336	350	4.01e-25	102
GibsonMK_2016_SRR3131800_bin.2_k141_1364_64	SARG|AAD51059	32.8	262	336	323	5.12e-25	102
GibsonMK_2016_SRR3131800_bin.2_k141_1364_64	SARG|AAD41881	32.8	262	336	323	9.75e-25	101
GibsonMK_2016_SRR3131800_bin.2_k141_1364_64	SARG|DQ018711.1.gene4.p01	30.1	266	336	322	1.32e-24	100
GibsonMK_2016_SRR3131800_bin.2_k141_1364_64	SARG|AAR37059	32.4	262	336	323	1.85e-24	100
GibsonMK_2016_SRR3131800_bin.2_k141_1364_64	SARG|gi|737310392|ref|WP_035293250.1|	30.9	262	336	323	2.55e-24	100
GibsonMK_2016_SRR3131800_bin.2_k141_1364_64	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	30.1	272	336	348	3.64e-24	100
GibsonMK_2016_SRR3131800_bin.2_k141_1364_97	megares|MEG_1992|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	29.1	292	304	291	1.19e-26	105
GibsonMK_2016_SRR3131800_bin.2_k141_1364_99	SARG|NP_752857	71.4	413	452	420	1.97e-207	578
GibsonMK_2016_SRR3131800_bin.2_k141_1364_99	SARG|gi|526125939|gb|AGR58012.1|	73.0	403	452	418	1.50e-206	575
GibsonMK_2016_SRR3131800_bin.2_k141_1364_99	SARG|gi|332104663|gb|EGJ08009.1|	70.9	413	452	420	1.61e-206	575
GibsonMK_2016_SRR3131800_bin.2_k141_1364_99	SARG|ZP_02775049	72.2	406	452	410	1.85e-205	572
GibsonMK_2016_SRR3131800_bin.2_k141_1364_99	SARG|ACB17400	72.4	406	452	410	1.85e-205	572
GibsonMK_2016_SRR3131800_bin.2_k141_1364_99	SARG|ZP_02903427	72.4	406	452	410	2.62e-205	572
GibsonMK_2016_SRR3131800_bin.2_k141_1364_99	SARG|ZP_03027991	71.9	406	452	410	3.72e-205	572
GibsonMK_2016_SRR3131800_bin.2_k141_1364_99	SARG|BAG76424	71.9	406	452	410	5.27e-205	571
GibsonMK_2016_SRR3131800_bin.2_k141_1364_99	SARG|gi|928824385|ref|WP_053884538.1|	71.9	406	452	410	5.27e-205	571
GibsonMK_2016_SRR3131800_bin.2_k141_1364_99	SARG|CP001138.1.gene894.p01	72.4	406	452	410	7.49e-205	571
GibsonMK_2016_SRR3131800_bin.2_k141_1364_113	NCBI|CAQ45063.1|1|1|emrA-sm|emrA-sm||1|EFFLUX|EFFLUX|multidrug_efflux_MFS_transporter_periplasmic_adaptor_subunit_EmrA|AMR|efflux	30.1	322	348	393	2.71e-34	129
GibsonMK_2016_SRR3131800_bin.2_k141_1364_113	SARG|gb|AAF40763.1|ARO:3003961|farA	32.4	318	348	384	6.00e-32	122
GibsonMK_2016_SRR3131800_bin.2_k141_1364_113	SARG|CP000034.1.gene2563.p01	30.0	323	348	387	1.54e-29	115
GibsonMK_2016_SRR3131800_bin.2_k141_1364_113	SARG|gi|693139804|ref|WP_032281367.1|	30.0	323	348	387	1.54e-29	115
GibsonMK_2016_SRR3131800_bin.2_k141_1364_113	SARG|gi|510924127|ref|WP_016244912.1|	30.0	320	348	387	2.93e-29	115
GibsonMK_2016_SRR3131800_bin.2_k141_1364_113	SARG|gi|742917254|ref|WP_039022713.1|	29.9	321	348	387	2.93e-29	115
GibsonMK_2016_SRR3131800_bin.2_k141_1364_113	SARG|gb|BAA11236.1|ARO:3000206|emrK	29.9	321	348	351	3.24e-29	114
GibsonMK_2016_SRR3131800_bin.2_k141_1364_113	SARG|gi|723050633|ref|WP_033547684.1|	28.4	320	348	387	5.58e-29	114
GibsonMK_2016_SRR3131800_bin.2_k141_1364_113	SARG|gi|486279467|ref|WP_001570159.1|	29.9	321	348	387	5.58e-29	114
GibsonMK_2016_SRR3131800_bin.2_k141_1364_113	SARG|gi|727382096|ref|WP_033804165.1|	28.4	320	348	387	5.58e-29	114
GibsonMK_2016_SRR3131800_bin.2_k141_1364_114	SARG|gb|BAE06009.1|ARO:3003700|opmE	35.4	458	482	491	2.07e-72	236
GibsonMK_2016_SRR3131800_bin.2_k141_1364_114	SARG|YP_001348103	35.0	463	482	472	3.30e-68	224
GibsonMK_2016_SRR3131800_bin.2_k141_1364_114	SARG|gi|685983084|ref|WP_031690280.1|	34.6	463	482	472	9.09e-68	223
GibsonMK_2016_SRR3131800_bin.2_k141_1364_114	SARG|gi|730274062|ref|WP_033966812.1|	34.6	463	482	472	1.27e-67	223
GibsonMK_2016_SRR3131800_bin.2_k141_1364_114	SARG|YP_790742	34.6	463	482	472	1.79e-67	223
GibsonMK_2016_SRR3131800_bin.2_k141_1364_114	SARG|gi|553795209|ref|WP_023125875.1|	34.6	463	482	472	1.79e-67	223
GibsonMK_2016_SRR3131800_bin.2_k141_1364_114	SARG|gi|504415764|ref|WP_014602866.1|	34.6	463	482	472	1.79e-67	223
GibsonMK_2016_SRR3131800_bin.2_k141_1364_114	SARG|NC_002516.2.882885.p01	34.6	463	482	472	1.79e-67	223
GibsonMK_2016_SRR3131800_bin.2_k141_1364_114	SARG|gi|763183668|ref|WP_044062270.1|	34.6	463	482	472	1.79e-67	223
GibsonMK_2016_SRR3131800_bin.2_k141_1364_114	SARG|gi|757699586|ref|WP_042929352.1|	34.6	463	482	472	1.79e-67	223
GibsonMK_2016_SRR3131800_bin.2_k141_1364_118	NCBI|WP_063844229.1|1|1|cmlV|cmlV|efflux|2|CHLORAMPHENICOL|PHENICOL|phenicol_efflux_MFS_transporter_CmlV|AMR|phenicol	35.2	378	389	412	2.17e-60	199
GibsonMK_2016_SRR3131800_bin.2_k141_1364_118	SARG|U09991.1.gene2.p01	35.2	378	389	436	3.89e-60	199
GibsonMK_2016_SRR3131800_bin.2_k141_1364_118	megares|MEG_1780|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMRA_1	33.9	354	389	391	6.11e-52	177
GibsonMK_2016_SRR3131800_bin.2_k141_1364_118	SARG|AF015087.1.gene1.p01	33.8	352	389	391	1.68e-51	176
GibsonMK_2016_SRR3131800_bin.2_k141_1364_118	megares|MEG_1781|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMRA_1	33.8	355	389	391	6.46e-51	174
GibsonMK_2016_SRR3131800_bin.2_k141_1364_118	SARG|gb|CAA78046.1|ARO:3002701|Rfas_cmr	33.7	353	389	391	1.77e-50	173
GibsonMK_2016_SRR3131800_bin.2_k141_1364_118	SARG|AF024666.2.gene33.p01	30.3	383	389	391	1.86e-49	170
GibsonMK_2016_SRR3131800_bin.2_k141_1364_118	SARG|gi|2708772|gb|AAB96371.1|	30.0	383	389	391	2.61e-49	170
GibsonMK_2016_SRR3131800_bin.2_k141_1364_118	SARG|YP_251195	30.3	383	389	391	3.65e-49	169
GibsonMK_2016_SRR3131800_bin.2_k141_1364_118	SARG|NP_044444	30.0	383	389	391	7.13e-49	169
GibsonMK_2016_SRR3131800_bin.2_k141_1364_124	CARD|gb|BAB41874.1|ARO:3000815|mgrA	37.4	131	155	147	6.74e-25	92.4
GibsonMK_2016_SRR3131800_bin.2_k141_1364_126	megares|MEG_8080|Drugs|Lipopeptide|Colistin_phosphoethanolamine_transferase|EPTB_1	65.1	553	565	574	5.31e-265	734
GibsonMK_2016_SRR3131800_bin.2_k141_1364_126	SARG|gb|CCI79240.1|ARO:3005047|eptB	65.1	553	565	574	5.31e-265	734
GibsonMK_2016_SRR3131800_bin.2_k141_1364_126	NCBI|WP_281052475.1|1|1|mcr-4.9|mcr-4||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-4.9|AMR|peptide	32.2	301	565	541	1.33e-37	145
GibsonMK_2016_SRR3131800_bin.2_k141_1364_126	SARG|gb|AUI38915.1|ARO:3004695|MCR-4.3	32.5	302	565	541	3.36e-37	144
GibsonMK_2016_SRR3131800_bin.2_k141_1364_126	NCBI|WP_116786828.1|1|1|mcr-4.6|mcr-4||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-4.6|AMR|peptide	32.5	302	565	541	3.36e-37	144
GibsonMK_2016_SRR3131800_bin.2_k141_1364_126	megares|MEG_3720|Drugs|Lipopeptide|Colistin_phosphoethanolamine_transferase|MCR_1	32.5	302	565	541	3.36e-37	144
GibsonMK_2016_SRR3131800_bin.2_k141_1364_126	megares|MEG_3694|Drugs|Lipopeptide|Colistin_phosphoethanolamine_transferase|MCR_1	32.5	302	565	541	3.36e-37	144
GibsonMK_2016_SRR3131800_bin.2_k141_1364_126	NCBI|WP_311033333.1|1|1|mcr-4.8|mcr-4||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-4.8|AMR|peptide	32.6	301	565	541	6.22e-37	143
GibsonMK_2016_SRR3131800_bin.2_k141_1364_126	ResF|mcr-4.8_1_OR438749_1	32.6	301	565	541	6.22e-37	143
GibsonMK_2016_SRR3131800_bin.2_k141_1364_126	NCBI|WP_223106954.1|1|1|mcr-4.7|mcr-4||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-4.7|AMR|peptide	32.6	301	565	541	8.46e-37	142
GibsonMK_2016_SRR3131800_bin.2_k141_1364_136	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	32.9	222	327	255	1.73e-23	96.3
GibsonMK_2016_SRR3131800_bin.2_k141_1364_136	SARG|gi|554685678|ref|WP_023185565.1|	33.5	239	327	648	1.77e-22	97.1
GibsonMK_2016_SRR3131800_bin.2_k141_1364_136	SARG|gi|657888313|ref|WP_029592374.1|	34.4	227	327	648	1.94e-21	94.0
GibsonMK_2016_SRR3131800_bin.2_k141_1364_136	SARG|gi|639216333|ref|WP_024554080.1|	32.9	234	327	648	2.61e-21	93.6
GibsonMK_2016_SRR3131800_bin.2_k141_1364_136	SARG|gi|922019548|ref|WP_053299973.1|	32.6	239	327	648	6.38e-21	92.4
GibsonMK_2016_SRR3131800_bin.2_k141_1364_136	SARG|gi|1032819400|ref|WP_064325534.1|	30.0	290	327	646	8.58e-21	92.0
GibsonMK_2016_SRR3131800_bin.2_k141_1364_136	SARG|gi|896325272|ref|WP_049294291.1|	32.5	234	327	648	8.60e-21	92.0
GibsonMK_2016_SRR3131800_bin.2_k141_1364_136	SARG|gi|981224618|ref|WP_059445588.1|	32.4	259	327	646	1.16e-20	91.7
GibsonMK_2016_SRR3131800_bin.2_k141_1364_136	SARG|gi|823326845|ref|WP_047080664.1|	31.3	268	327	648	1.16e-20	91.7
GibsonMK_2016_SRR3131800_bin.2_k141_1364_136	SARG|gi|639225329|ref|WP_024561799.1|	33.9	227	327	648	1.16e-20	91.7
GibsonMK_2016_SRR3131800_bin.2_k141_1364_137	SARG|gb|AAK76137.1|ARO:3000024|patA	32.0	225	330	564	1.84e-17	82.0
GibsonMK_2016_SRR3131800_bin.2_k141_1364_178	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	29.0	217	304	346	4.04e-18	82.4
GibsonMK_2016_SRR3131800_bin.2_k141_1364_181	megares|MEG_2421|Drugs|beta-lactam|Class_A_betalactamases|CTX_2	63.7	102	158	107	8.47e-44	139
GibsonMK_2016_SRR3131800_bin.2_k141_1364_208	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	33.9	221	224	255	3.66e-42	142
GibsonMK_2016_SRR3131800_bin.2_k141_1364_208	SARG|gi|694064328|ref|WP_032410816.1|	34.7	219	224	646	4.90e-36	132
GibsonMK_2016_SRR3131800_bin.2_k141_1364_208	SARG|gb|AAK76137.1|ARO:3000024|patA	28.8	226	224	564	4.61e-20	87.0
GibsonMK_2016_SRR3131800_bin.2_k141_1364_208	SARG|gi|507055561|ref|WP_016126482.1|	26.4	216	224	309	1.67e-19	84.0
GibsonMK_2016_SRR3131800_bin.2_k141_1364_208	SARG|gi|488068784|ref|WP_002140181.1|	26.4	216	224	309	1.67e-19	84.0
GibsonMK_2016_SRR3131800_bin.2_k141_1364_208	SARG|gi|447057510|ref|WP_001134766.1|	25.9	216	224	309	1.67e-19	84.0
GibsonMK_2016_SRR3131800_bin.2_k141_1364_208	SARG|gi|488053456|ref|WP_002124853.1|	26.4	216	224	309	2.31e-19	83.6
GibsonMK_2016_SRR3131800_bin.2_k141_1364_208	SARG|gi|488067981|ref|WP_002139378.1|	26.4	216	224	309	3.19e-19	83.2
GibsonMK_2016_SRR3131800_bin.2_k141_1364_208	SARG|gi|488042066|ref|WP_002113463.1|	26.4	216	224	309	3.19e-19	83.2
GibsonMK_2016_SRR3131800_bin.2_k141_1364_208	SARG|gi|447057509|ref|WP_001134765.1|	26.4	216	224	309	3.19e-19	83.2
GibsonMK_2016_SRR3131800_bin.2_k141_1364_217	SARG|gi|447195835|ref|WP_001273091.1|	29.4	231	257	306	2.01e-26	103
GibsonMK_2016_SRR3131800_bin.2_k141_1364_217	SARG|ZP_04081918	29.4	231	257	306	2.80e-26	103
GibsonMK_2016_SRR3131800_bin.2_k141_1364_217	SARG|gi|447195836|ref|WP_001273092.1|	29.4	231	257	306	2.80e-26	103
GibsonMK_2016_SRR3131800_bin.2_k141_1364_217	SARG|gi|500194536|ref|WP_011867743.1|	29.4	231	257	306	7.53e-26	102
GibsonMK_2016_SRR3131800_bin.2_k141_1364_217	SARG|gi|500448961|gb|EOP61695.1|	31.0	216	257	306	1.05e-25	101
GibsonMK_2016_SRR3131800_bin.2_k141_1364_217	SARG|gi|500465078|gb|EOP76697.1|	31.0	216	257	306	3.91e-25	100
GibsonMK_2016_SRR3131800_bin.2_k141_1364_217	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	28.1	199	257	255	1.17e-19	84.3
GibsonMK_2016_SRR3131800_bin.2_k141_1364_218	SARG|gi|895981299|ref|WP_049056431.1|	29.1	206	234	648	3.89e-19	84.7
GibsonMK_2016_SRR3131800_bin.2_k141_1364_218	SARG|gi|823281237|ref|WP_047037467.1|	29.1	206	234	648	3.89e-19	84.7
GibsonMK_2016_SRR3131800_bin.2_k141_1364_218	SARG|gi|895967513|ref|WP_049046752.1|	29.1	206	234	648	3.89e-19	84.7
GibsonMK_2016_SRR3131800_bin.2_k141_1364_218	SARG|gi|779903733|ref|WP_045374054.1|	29.1	206	234	648	3.89e-19	84.7
GibsonMK_2016_SRR3131800_bin.2_k141_1364_218	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	25.2	230	234	579	1.78e-09	56.2
GibsonMK_2016_SRR3131800_bin.2_k141_1364_218	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	23.5	230	234	579	1.42e-08	53.5
GibsonMK_2016_SRR3131800_bin.2_k141_1364_218	SARG|gb|CDO61516.1|ARO:3003949|efrB	26.0	200	234	362	3.75e-08	52.0
GibsonMK_2016_SRR3131800_bin.2_k141_1475_16	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	34.9	215	331	255	1.02e-36	131
GibsonMK_2016_SRR3131800_bin.2_k141_1475_16	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	31.9	216	331	574	1.13e-20	91.7
GibsonMK_2016_SRR3131800_bin.2_k141_1475_16	SARG|gb|WP_104671188.1|ARO:3003948|efrA	26.4	239	331	575	3.74e-20	90.1
GibsonMK_2016_SRR3131800_bin.2_k141_1475_16	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	29.1	223	331	579	1.33e-18	85.5
GibsonMK_2016_SRR3131800_bin.2_k141_1475_16	SARG|gi|930482089|ref|WP_054228897.1|	31.8	211	331	599	1.83e-18	85.1
GibsonMK_2016_SRR3131800_bin.2_k141_1475_16	SARG|gi|985844137|ref|WP_060895163.1|	31.8	211	331	599	1.83e-18	85.1
GibsonMK_2016_SRR3131800_bin.2_k141_1475_16	SARG|gi|817122037|ref|WP_046494699.1|	31.4	220	331	613	3.36e-18	84.3
GibsonMK_2016_SRR3131800_bin.2_k141_1475_16	SARG|gi|953808775|ref|WP_058042812.1|	29.9	241	331	608	6.03e-18	83.6
GibsonMK_2016_SRR3131800_bin.2_k141_1475_16	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	28.7	223	331	579	7.85e-18	83.2
GibsonMK_2016_SRR3131800_bin.2_k141_1475_16	SARG|gi|943909899|ref|WP_055545300.1|	31.1	209	331	601	8.04e-18	83.2
GibsonMK_2016_SRR3131800_bin.2_k141_1475_30	SARG|gi|953808775|ref|WP_058042812.1|	34.9	218	370	608	8.38e-22	95.9
GibsonMK_2016_SRR3131800_bin.2_k141_1475_30	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	31.8	220	370	343	1.20e-21	93.6
GibsonMK_2016_SRR3131800_bin.2_k141_1475_30	SARG|gb|AAK76137.1|ARO:3000024|patA	32.5	209	370	564	2.70e-20	91.3
GibsonMK_2016_SRR3131800_bin.2_k141_1475_30	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	26.5	219	370	307	1.80e-18	84.0
GibsonMK_2016_SRR3131800_bin.2_k141_1475_30	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	27.5	211	370	528	3.92e-09	57.0
GibsonMK_2016_SRR3131800_bin.2_k141_1475_35	SARG|gb|ABO11759.2|ARO:3004573|Acinetobacter	36.3	416	461	429	2.16e-74	239
GibsonMK_2016_SRR3131800_bin.2_k141_1475_49	SARG|AF162694.1.gene4.p01	33.9	369	360	698	7.74e-44	159
GibsonMK_2016_SRR3131800_bin.2_k141_1475_49	SARG|gi|657686198|ref|WP_029487032.1|	33.9	369	360	698	7.74e-44	159
GibsonMK_2016_SRR3131800_bin.2_k141_1475_49	SARG|AAY67970	33.6	369	360	698	2.00e-43	158
GibsonMK_2016_SRR3131800_bin.2_k141_1475_49	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	31.3	361	360	366	1.08e-39	143
GibsonMK_2016_SRR3131800_bin.2_k141_1475_49	SARG|gb|ABA71733.1|ARO:3002972|vanTG	30.2	354	360	712	1.24e-38	145
GibsonMK_2016_SRR3131800_bin.2_k141_1475_49	SARG|JF802084.2.gene3.p01	32.2	366	360	700	1.61e-38	144
GibsonMK_2016_SRR3131800_bin.2_k141_1475_49	SARG|gi|498467693|ref|WP_010773049.1|	32.2	367	360	700	5.74e-36	137
GibsonMK_2016_SRR3131800_bin.2_k141_1475_49	SARG|FJ872411.1.gene43.p01	32.1	368	360	702	7.87e-36	137
GibsonMK_2016_SRR3131800_bin.2_k141_1475_49	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	30.0	370	360	712	1.48e-33	130
GibsonMK_2016_SRR3131800_bin.2_k141_1475_49	megares|MEG_7535|Drugs|Glycopeptide|VanN-type_resistance_protein|VANTN_1	33.7	288	360	656	1.24e-31	124
GibsonMK_2016_SRR3131800_bin.2_k141_1475_55	SARG|gb|AAF63432|ARO:3003744|vatF	52.9	51	186	221	8.08e-10	55.1
GibsonMK_2016_SRR3131800_bin.2_k141_1475_57	SARG|gi|740856590|ref|WP_038641842.1|	30.9	152	943	648	3.21e-12	69.3
GibsonMK_2016_SRR3131800_bin.2_k141_1475_57	SARG|gi|446048013|ref|WP_000125868.1|	35.6	104	943	648	9.64e-12	67.8
GibsonMK_2016_SRR3131800_bin.2_k141_1475_57	SARG|gi|696368937|ref|WP_032943949.1|	30.3	152	943	648	9.64e-12	67.8
GibsonMK_2016_SRR3131800_bin.2_k141_1475_57	SARG|gi|696361545|ref|WP_032936694.1|	30.3	152	943	648	1.27e-11	67.4
GibsonMK_2016_SRR3131800_bin.2_k141_1475_57	SARG|gi|754951242|ref|WP_042307417.1|	30.3	152	943	648	1.67e-11	67.0
GibsonMK_2016_SRR3131800_bin.2_k141_1475_57	SARG|gi|851913025|ref|WP_048215946.1|	30.3	152	943	648	1.67e-11	67.0
GibsonMK_2016_SRR3131800_bin.2_k141_1475_57	SARG|YP_002850060	30.3	152	943	648	1.67e-11	67.0
GibsonMK_2016_SRR3131800_bin.2_k141_1475_57	SARG|gi|489930965|ref|WP_003834285.1|	30.3	152	943	648	1.67e-11	67.0
GibsonMK_2016_SRR3131800_bin.2_k141_1475_57	SARG|gi|754927849|ref|WP_042284850.1|	36.4	99	943	648	1.67e-11	67.0
GibsonMK_2016_SRR3131800_bin.2_k141_1475_57	SARG|gi|654544841|ref|WP_028012549.1|	37.4	99	943	646	2.19e-11	66.6
GibsonMK_2016_SRR3131800_bin.2_k141_2207_37	CARD|gb|CYF42523.1|ARO:3004047|kdpD	26.3	890	899	885	4.50e-95	318
GibsonMK_2016_SRR3131800_bin.2_k141_2207_37	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	27.9	233	899	380	5.26e-21	95.1
GibsonMK_2016_SRR3131800_bin.2_k141_2207_37	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.9	233	899	380	5.26e-21	95.1
GibsonMK_2016_SRR3131800_bin.2_k141_2207_37	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	28.6	231	899	359	4.70e-18	85.9
GibsonMK_2016_SRR3131800_bin.2_k141_2207_37	SARG|gb|AAG05187.1|ARO:3005067|ParS	31.8	233	899	428	2.08e-16	81.6
GibsonMK_2016_SRR3131800_bin.2_k141_2207_38	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	78.9	223	230	225	1.08e-128	361
GibsonMK_2016_SRR3131800_bin.2_k141_2207_38	CARD|gb|AAC73788.1|ARO:3003841|kdpE	78.9	223	230	225	1.08e-128	361
GibsonMK_2016_SRR3131800_bin.2_k141_2207_38	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.6	227	230	232	1.92e-47	155
GibsonMK_2016_SRR3131800_bin.2_k141_2207_38	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.6	227	230	232	1.92e-47	155
GibsonMK_2016_SRR3131800_bin.2_k141_2207_38	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	37.8	222	230	229	3.95e-46	152
GibsonMK_2016_SRR3131800_bin.2_k141_2207_38	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.9	220	230	219	3.34e-45	149
GibsonMK_2016_SRR3131800_bin.2_k141_2207_38	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	35.6	225	230	231	1.05e-43	145
GibsonMK_2016_SRR3131800_bin.2_k141_2207_38	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.6	225	230	231	1.05e-43	145
GibsonMK_2016_SRR3131800_bin.2_k141_2207_38	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.6	225	230	231	8.29e-43	143
GibsonMK_2016_SRR3131800_bin.2_k141_2207_38	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.1	225	230	231	9.25e-42	140
GibsonMK_2016_SRR3131800_bin.2_k141_2207_68	SARG|gb|AEA37904.1|ARO:3003112|lsaC	26.8	209	242	492	1.63e-11	62.4
GibsonMK_2016_SRR3131800_bin.2_k141_2207_73	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	23.3	913	861	1107	8.89e-17	84.3
GibsonMK_2016_SRR3131800_bin.2_k141_2207_73	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	23.3	913	861	1107	8.89e-17	84.3
GibsonMK_2016_SRR3131800_bin.2_k141_2207_73	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	20.5	708	861	1024	3.20e-11	66.2
GibsonMK_2016_SRR3131800_bin.2_k141_2207_73	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	20.5	708	861	1024	3.20e-11	66.2
GibsonMK_2016_SRR3131800_bin.2_k141_2207_73	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	20.5	708	861	1024	3.20e-11	66.2
GibsonMK_2016_SRR3131800_bin.2_k141_2207_73	SARG|gb|CAA53189|ARO:3000521|mupA	20.5	708	861	1024	3.20e-11	66.2
GibsonMK_2016_SRR3131800_bin.2_k141_2207_79	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	82.0	632	632	633	0.0	1060
GibsonMK_2016_SRR3131800_bin.2_k141_2207_82	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	28.5	249	404	346	2.71e-15	75.5
GibsonMK_2016_SRR3131800_bin.2_k141_2207_82	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.2	268	404	356	3.07e-14	72.4
GibsonMK_2016_SRR3131800_bin.2_k141_2207_82	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.2	264	404	356	9.91e-14	70.9
GibsonMK_2016_SRR3131800_bin.2_k141_2207_82	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.2	264	404	356	1.78e-13	70.1
GibsonMK_2016_SRR3131800_bin.2_k141_2207_82	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	27.6	261	404	355	3.17e-13	69.3
GibsonMK_2016_SRR3131800_bin.2_k141_2207_82	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	27.6	261	404	355	3.17e-13	69.3
GibsonMK_2016_SRR3131800_bin.2_k141_2207_82	SARG|ACM47285	27.6	261	404	363	3.32e-13	69.3
GibsonMK_2016_SRR3131800_bin.2_k141_2207_82	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	27.2	261	404	355	1.36e-12	67.4
GibsonMK_2016_SRR3131800_bin.2_k141_2207_82	SARG|BAE96115	27.2	261	404	355	1.36e-12	67.4
GibsonMK_2016_SRR3131800_bin.2_k141_2207_82	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	29.5	200	404	209	7.03e-11	60.5
GibsonMK_2016_SRR3131800_bin.2_k141_2207_91	NCBI|WP_031633255.1|1|1|cmlA_floR|cmlA_floR|efflux|2|CHLORAMPHENICOL|PHENICOL|CmlA/FloR_family_phenicol_efflux_MFS_transporter|AMR|phenicol	31.2	330	397	395	9.07e-31	120
GibsonMK_2016_SRR3131800_bin.2_k141_2207_91	NCBI|WP_115421099.1|1|1|cml_Ensi|cml_Ensi|efflux|2|CHLORAMPHENICOL|PHENICOL|Cml_family_phenicol_efflux_MFS_transporter|AMR|phenicol	30.3	327	397	400	4.81e-30	118
GibsonMK_2016_SRR3131800_bin.2_k141_2207_91	megares|MEG_8021|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CML_1	30.3	327	397	400	4.81e-30	118
GibsonMK_2016_SRR3131800_bin.2_k141_2207_91	megares|MEG_8019|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CML_1	31.2	333	397	411	2.76e-26	108
GibsonMK_2016_SRR3131800_bin.2_k141_2207_91	NCBI|WP_011552636.1|1|1|cml_Myxo|cml_Myxo|efflux|2|CHLORAMPHENICOL|PHENICOL|Cml_family_phenicol_efflux_MFS_transporter|AMR|phenicol	31.2	333	397	411	2.76e-26	108
GibsonMK_2016_SRR3131800_bin.2_k141_2207_91	SARG|gi|695688999|ref|WP_032634100.1|	31.0	281	397	404	7.83e-25	103
GibsonMK_2016_SRR3131800_bin.2_k141_2207_91	SARG|gi|446136270|ref|WP_000214125.1|	31.0	281	397	404	1.98e-24	102
GibsonMK_2016_SRR3131800_bin.2_k141_2207_91	SARG|gi|1028086745|ref|WP_063845118.1|	31.0	281	397	404	2.70e-24	102
GibsonMK_2016_SRR3131800_bin.2_k141_2207_91	SARG|gi|730661043|ref|WP_034065992.1|	31.3	281	397	404	2.70e-24	102
GibsonMK_2016_SRR3131800_bin.2_k141_2207_91	SARG|AF252855.1.gene1.p01	31.2	285	397	404	2.70e-24	102
GibsonMK_2016_SRR3131800_bin.2_k141_2207_97	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.3	245	276	664	3.62e-17	80.1
GibsonMK_2016_SRR3131800_bin.2_k141_2207_113	SARG|gb|AAF40764.1|ARO:3003962|farB	24.5	155	469	508	7.24e-07	50.4
GibsonMK_2016_SRR3131800_bin.2_k141_2207_113	NCBI|AAD54074.1|1|1|farB|farB||1|EFFLUX|EFFLUX|fatty_acid_resistance_MFS_efflux_transporter_permease_subunit_FarB|AMR|efflux	24.5	155	469	507	1.67e-06	49.3
GibsonMK_2016_SRR3131800_bin.2_k141_2207_115	SARG|gi|1035706844|ref|WP_064548272.1|	42.2	173	178	648	6.64e-39	139
GibsonMK_2016_SRR3131800_bin.2_k141_2207_115	SARG|gi|1035670474|ref|WP_064517458.1|	42.2	173	178	648	2.38e-38	137
GibsonMK_2016_SRR3131800_bin.2_k141_2207_115	SARG|gi|1035717981|ref|WP_064557480.1|	42.2	173	178	648	2.38e-38	137
GibsonMK_2016_SRR3131800_bin.2_k141_2207_115	SARG|gi|736472622|ref|WP_034494292.1|	41.0	173	178	648	8.51e-38	135
GibsonMK_2016_SRR3131800_bin.2_k141_2207_115	SARG|gi|896325272|ref|WP_049294291.1|	41.0	173	178	648	2.21e-37	134
GibsonMK_2016_SRR3131800_bin.2_k141_2207_115	SARG|gi|639209604|ref|WP_024547784.1|	40.5	173	178	648	3.04e-37	134
GibsonMK_2016_SRR3131800_bin.2_k141_2207_115	SARG|gi|639216333|ref|WP_024554080.1|	41.0	173	178	648	4.17e-37	134
GibsonMK_2016_SRR3131800_bin.2_k141_2207_115	SARG|gi|723111645|ref|WP_033557217.1|	41.0	173	178	648	7.87e-37	133
GibsonMK_2016_SRR3131800_bin.2_k141_2207_115	SARG|gi|639225329|ref|WP_024561799.1|	40.5	173	178	648	2.04e-36	132
GibsonMK_2016_SRR3131800_bin.2_k141_2207_115	SARG|gi|639218559|ref|WP_024556062.1|	40.5	173	178	648	2.04e-36	132
GibsonMK_2016_SRR3131800_bin.2_k141_2207_124	CARD|gb|AAL19308.1|ARO:3000504|golS	40.5	126	134	154	5.57e-28	99.8
GibsonMK_2016_SRR3131800_bin.2_k141_2207_130	NCBI|WP_252944138.1|1|1|almE|almE||2|COLISTIN|COLISTIN|lipid_A_modification_system_glycine--protein_ligase_AlmE|AMR|peptide	28.5	358	1903	556	1.80e-26	115
GibsonMK_2016_SRR3131800_bin.2_k141_2207_134	NCBI|ABQ18953.1|1|1|emrD3|emrD3||1|EFFLUX|EFFLUX|multidrug_efflux_MFS_transporter_EmrD-3|AMR|efflux	52.6	363	388	379	3.18e-105	314
GibsonMK_2016_SRR3131800_bin.2_k141_2207_134	SARG|CP000647.1.gene4115.p01	26.8	392	388	383	3.55e-27	110
GibsonMK_2016_SRR3131800_bin.2_k141_2207_134	SARG|BAH65866	26.8	392	388	394	1.05e-26	108
GibsonMK_2016_SRR3131800_bin.2_k141_2207_134	SARG|YP_002235907	26.8	392	388	394	1.98e-26	108
GibsonMK_2016_SRR3131800_bin.2_k141_2207_134	SARG|gi|499527904|emb|CCI74263.1|	26.8	392	388	384	2.39e-26	107
GibsonMK_2016_SRR3131800_bin.2_k141_2207_134	SARG|ACN65732	26.5	392	388	394	9.49e-26	106
GibsonMK_2016_SRR3131800_bin.2_k141_2207_134	SARG|CP004022.1.gene3225.p01	30.6	206	388	394	3.32e-25	104
GibsonMK_2016_SRR3131800_bin.2_k141_2207_134	SARG|YP_001451632	26.7	386	388	394	3.32e-25	104
GibsonMK_2016_SRR3131800_bin.2_k141_2207_134	SARG|YP_001174764	25.4	398	388	394	8.45e-25	103
GibsonMK_2016_SRR3131800_bin.2_k141_2207_134	SARG|YP_002217746	25.2	393	388	394	2.93e-24	102
GibsonMK_2016_SRR3131800_bin.2_k141_2207_137	SARG|YP_001477378	94.1	406	407	406	2.42e-265	722
GibsonMK_2016_SRR3131800_bin.2_k141_2207_137	SARG|ZP_04638972	86.1	404	407	404	1.11e-242	664
GibsonMK_2016_SRR3131800_bin.2_k141_2207_137	SARG|ZP_04612558	85.1	404	407	404	6.14e-240	657
GibsonMK_2016_SRR3131800_bin.2_k141_2207_137	SARG|ZP_04631862	85.4	404	407	404	1.24e-239	657
GibsonMK_2016_SRR3131800_bin.2_k141_2207_137	SARG|ZP_04621517	83.2	404	407	404	2.77e-236	648
GibsonMK_2016_SRR3131800_bin.2_k141_2207_137	SARG|YP_001605796	84.4	404	407	404	9.22e-235	644
GibsonMK_2016_SRR3131800_bin.2_k141_2207_137	SARG|YP_001401993	84.2	404	407	404	1.86e-234	644
GibsonMK_2016_SRR3131800_bin.2_k141_2207_137	SARG|YP_001871501	84.2	404	407	404	7.56e-234	642
GibsonMK_2016_SRR3131800_bin.2_k141_2207_137	SARG|ZP_04623896	86.1	380	407	380	1.71e-231	635
GibsonMK_2016_SRR3131800_bin.2_k141_2207_137	SARG|AAC60781	79.1	412	407	410	1.64e-213	591
GibsonMK_2016_SRR3131800_bin.2_k141_2207_138	SARG|gi|896190680|ref|WP_049199932.1|	99.6	563	564	563	0.0	1032
GibsonMK_2016_SRR3131800_bin.2_k141_2207_138	SARG|YP_001477377	97.2	563	564	563	0.0	1011
GibsonMK_2016_SRR3131800_bin.2_k141_2207_138	SARG|gi|1001786599|ref|WP_061324791.1|	93.4	563	564	563	0.0	976
GibsonMK_2016_SRR3131800_bin.2_k141_2207_138	SARG|YP_001007250	88.5	563	564	563	0.0	926
GibsonMK_2016_SRR3131800_bin.2_k141_2207_138	SARG|ZP_04638974	88.3	563	564	563	0.0	923
GibsonMK_2016_SRR3131800_bin.2_k141_2207_138	SARG|gi|544012122|gb|ERK10884.1|	90.6	541	564	541	0.0	920
GibsonMK_2016_SRR3131800_bin.2_k141_2207_138	SARG|AAS61092	87.4	563	564	563	0.0	918
GibsonMK_2016_SRR3131800_bin.2_k141_2207_138	SARG|YP_001401994	87.2	563	564	563	0.0	915
GibsonMK_2016_SRR3131800_bin.2_k141_2207_138	SARG|YP_001605795	87.2	563	564	562	0.0	911
GibsonMK_2016_SRR3131800_bin.2_k141_2207_138	SARG|gi|740410309|ref|WP_038243756.1|	88.0	557	564	563	0.0	910
GibsonMK_2016_SRR3131800_bin.2_k141_2207_155	SARG|NP_459471	81.1	380	396	397	9.95e-209	578
GibsonMK_2016_SRR3131800_bin.2_k141_2207_155	SARG|gi|916127169|ref|WP_050958093.1|	81.1	380	396	397	9.95e-209	578
GibsonMK_2016_SRR3131800_bin.2_k141_2207_155	SARG|ZP_03163985	81.1	380	396	397	1.41e-208	577
GibsonMK_2016_SRR3131800_bin.2_k141_2207_155	SARG|ZP_02656523	80.8	380	396	397	4.04e-208	576
GibsonMK_2016_SRR3131800_bin.2_k141_2207_155	SARG|CAR60299	80.8	380	396	397	5.73e-208	576
GibsonMK_2016_SRR3131800_bin.2_k141_2207_155	SARG|gi|880831881|ref|WP_048668149.1|	80.5	380	396	397	1.64e-207	575
GibsonMK_2016_SRR3131800_bin.2_k141_2207_155	SARG|gi|912530277|ref|WP_050177011.1|	80.5	380	396	397	1.64e-207	575
GibsonMK_2016_SRR3131800_bin.2_k141_2207_155	SARG|YP_002401592	77.9	393	396	397	2.33e-207	574
GibsonMK_2016_SRR3131800_bin.2_k141_2207_155	SARG|gi|817604003|ref|WP_046597369.1|	80.5	380	396	397	2.33e-207	574
GibsonMK_2016_SRR3131800_bin.2_k141_2207_155	SARG|gi|928821234|ref|WP_053881997.1|	77.9	393	396	397	4.69e-207	573
GibsonMK_2016_SRR3131800_bin.2_k141_2207_156	SARG|BAC77251	96.4	1046	1049	1051	0.0	1879
GibsonMK_2016_SRR3131800_bin.2_k141_2207_156	CARD|gb|AAC73564.1|ARO:3000216|acrB	83.8	1049	1049	1049	0.0	1686
GibsonMK_2016_SRR3131800_bin.2_k141_2207_156	SARG|gi|447196024|ref|WP_001273280.1|	81.9	1037	1049	1037	0.0	1626
GibsonMK_2016_SRR3131800_bin.2_k141_2207_156	SARG|gi|817600095|ref|WP_046594084.1|	81.7	1037	1049	1037	0.0	1622
GibsonMK_2016_SRR3131800_bin.2_k141_2207_156	SARG|gi|487663012|ref|WP_001752778.1|	81.6	1037	1049	1037	0.0	1622
GibsonMK_2016_SRR3131800_bin.2_k141_2207_156	SARG|gi|817601660|ref|WP_046595348.1|	81.8	1037	1049	1037	0.0	1622
GibsonMK_2016_SRR3131800_bin.2_k141_2207_156	SARG|gi|817604860|ref|WP_046598079.1|	81.7	1037	1049	1037	0.0	1621
GibsonMK_2016_SRR3131800_bin.2_k141_2207_156	SARG|gi|817600173|ref|WP_046594139.1|	81.7	1037	1049	1037	0.0	1621
GibsonMK_2016_SRR3131800_bin.2_k141_2207_156	SARG|gi|694076105|ref|WP_032421853.1|	81.2	1037	1049	1036	0.0	1603
GibsonMK_2016_SRR3131800_bin.2_k141_2207_156	SARG|CP000647.1.gene3710.p01	81.2	1037	1049	1036	0.0	1603
GibsonMK_2016_SRR3131800_bin.2_k141_2207_187	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	34.0	576	593	579	2.88e-94	299
GibsonMK_2016_SRR3131800_bin.2_k141_2207_187	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	32.8	585	593	579	8.59e-88	282
GibsonMK_2016_SRR3131800_bin.2_k141_2207_187	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.0	585	593	582	2.12e-61	212
GibsonMK_2016_SRR3131800_bin.2_k141_2207_187	SARG|gi|817122037|ref|WP_046494699.1|	28.8	569	593	613	1.36e-59	208
GibsonMK_2016_SRR3131800_bin.2_k141_2207_187	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.5	516	593	664	5.21e-56	199
GibsonMK_2016_SRR3131800_bin.2_k141_2207_187	SARG|gb|AAK76136.1|ARO:3000025|patB	27.9	480	593	588	8.31e-51	183
GibsonMK_2016_SRR3131800_bin.2_k141_2207_187	SARG|gb|CDO61516.1|ARO:3003949|efrB	36.3	262	593	362	1.56e-49	174
GibsonMK_2016_SRR3131800_bin.2_k141_2207_187	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	36.2	207	593	528	2.85e-29	120
GibsonMK_2016_SRR3131800_bin.2_k141_2207_188	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	34.0	571	592	579	1.05e-102	321
GibsonMK_2016_SRR3131800_bin.2_k141_2207_188	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	33.5	571	592	579	8.83e-101	316
GibsonMK_2016_SRR3131800_bin.2_k141_2207_188	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	32.7	562	592	574	1.03e-92	295
GibsonMK_2016_SRR3131800_bin.2_k141_2207_188	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.1	491	592	664	1.08e-57	204
GibsonMK_2016_SRR3131800_bin.2_k141_2207_188	SARG|gb|AAK76136.1|ARO:3000025|patB	28.4	497	592	588	2.01e-55	196
GibsonMK_2016_SRR3131800_bin.2_k141_2207_188	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	29.1	501	592	578	5.64e-48	175
GibsonMK_2016_SRR3131800_bin.2_k141_2207_188	SARG|gb|CDO61516.1|ARO:3003949|efrB	35.2	270	592	362	4.54e-42	154
GibsonMK_2016_SRR3131800_bin.2_k141_2207_210	SARG|gb|AAD08227.1|ARO:3003964|hp1181	32.0	388	455	443	2.71e-44	159
GibsonMK_2016_SRR3131800_bin.2_k141_2207_210	SARG|AAR14158	29.8	141	455	392	8.92e-13	68.6
GibsonMK_2016_SRR3131800_bin.2_k141_2207_210	SARG|CAQ51492	29.8	141	455	393	8.96e-13	68.6
GibsonMK_2016_SRR3131800_bin.2_k141_2207_210	SARG|gi|505141122|ref|WP_015328224.1|	29.8	141	455	393	8.96e-13	68.6
GibsonMK_2016_SRR3131800_bin.2_k141_2207_210	SARG|CAA76069	29.8	141	455	400	9.23e-13	68.6
GibsonMK_2016_SRR3131800_bin.2_k141_2207_210	NCBI|WP_115421099.1|1|1|cml_Ensi|cml_Ensi|efflux|2|CHLORAMPHENICOL|PHENICOL|Cml_family_phenicol_efflux_MFS_transporter|AMR|phenicol	36.0	161	455	400	9.23e-13	68.6
GibsonMK_2016_SRR3131800_bin.2_k141_2207_210	SARG|Y15510.gene.p01	29.8	141	455	400	9.23e-13	68.6
GibsonMK_2016_SRR3131800_bin.2_k141_2207_210	megares|MEG_8021|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CML_1	36.0	161	455	400	9.23e-13	68.6
GibsonMK_2016_SRR3131800_bin.2_k141_2207_210	SARG|YP_002152117	31.5	149	455	398	1.62e-12	67.8
GibsonMK_2016_SRR3131800_bin.2_k141_2207_210	SARG|BAC67142	30.9	136	455	401	1.64e-12	67.8
GibsonMK_2016_SRR3131800_bin.2_k141_2207_230	CARD|gb|TKW44661.1|ARO:3005040|YajC	48.7	113	111	112	5.37e-29	100
GibsonMK_2016_SRR3131800_bin.2_k141_2207_244	CARD|gb|ABD30512.1|ARO:3000839|arlS	28.0	225	439	451	2.27e-19	89.0
GibsonMK_2016_SRR3131800_bin.2_k141_2207_244	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	25.7	261	439	386	1.25e-17	83.2
GibsonMK_2016_SRR3131800_bin.2_k141_2207_244	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	25.7	261	439	386	1.25e-17	83.2
GibsonMK_2016_SRR3131800_bin.2_k141_2207_244	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	25.7	261	439	388	1.70e-17	82.8
GibsonMK_2016_SRR3131800_bin.2_k141_2207_244	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	25.7	261	439	388	1.70e-17	82.8
GibsonMK_2016_SRR3131800_bin.2_k141_2207_244	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	27.3	198	439	384	7.21e-17	80.9
GibsonMK_2016_SRR3131800_bin.2_k141_2207_244	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	27.3	198	439	384	7.21e-17	80.9
GibsonMK_2016_SRR3131800_bin.2_k141_2207_244	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	27.9	215	439	386	1.32e-16	80.1
GibsonMK_2016_SRR3131800_bin.2_k141_2207_244	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	27.9	215	439	386	1.32e-16	80.1
GibsonMK_2016_SRR3131800_bin.2_k141_2207_244	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	26.1	234	439	382	5.54e-16	78.2
GibsonMK_2016_SRR3131800_bin.2_k141_2207_245	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	40.9	225	230	228	2.38e-50	162
GibsonMK_2016_SRR3131800_bin.2_k141_2207_245	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.8	220	230	219	2.93e-49	159
GibsonMK_2016_SRR3131800_bin.2_k141_2207_245	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	38.8	232	230	232	2.71e-47	155
GibsonMK_2016_SRR3131800_bin.2_k141_2207_245	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	38.4	232	230	232	7.64e-47	154
GibsonMK_2016_SRR3131800_bin.2_k141_2207_245	CARD|gb|AAD51348.1|ARO:3003066|smeR	38.6	223	230	229	2.80e-46	152
GibsonMK_2016_SRR3131800_bin.2_k141_2207_245	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	34.6	228	230	231	4.69e-45	149
GibsonMK_2016_SRR3131800_bin.2_k141_2207_245	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.5	231	230	231	9.36e-45	148
GibsonMK_2016_SRR3131800_bin.2_k141_2207_245	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.5	231	230	231	9.36e-45	148
GibsonMK_2016_SRR3131800_bin.2_k141_2207_245	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.5	231	230	231	2.64e-44	147
GibsonMK_2016_SRR3131800_bin.2_k141_2207_245	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	35.2	233	230	252	1.85e-43	145
GibsonMK_2016_SRR3131800_bin.2_k141_2207_260	SARG|gb|AYV52072.1|ARO:3002882|lmrD	32.7	205	584	664	2.37e-27	115
GibsonMK_2016_SRR3131800_bin.2_k141_2207_260	SARG|gb|CDO61516.1|ARO:3003949|efrB	29.5	268	584	362	2.83e-27	112
GibsonMK_2016_SRR3131800_bin.2_k141_2207_260	SARG|gb|AAK76137.1|ARO:3000024|patA	29.6	250	584	564	6.70e-27	114
GibsonMK_2016_SRR3131800_bin.2_k141_2207_260	SARG|gi|981224618|ref|WP_059445588.1|	31.9	254	584	646	9.21e-25	107
GibsonMK_2016_SRR3131800_bin.2_k141_2207_260	SARG|gi|798832510|ref|WP_045890489.1|	31.9	254	584	646	1.63e-24	107
GibsonMK_2016_SRR3131800_bin.2_k141_2207_260	SARG|gi|779793259|ref|WP_045327301.1|	31.9	254	584	646	1.63e-24	107
GibsonMK_2016_SRR3131800_bin.2_k141_2207_260	SARG|gi|1028085645|ref|WP_063844178.1|	32.8	253	584	646	1.63e-24	107
GibsonMK_2016_SRR3131800_bin.2_k141_2207_260	SARG|gi|493862656|ref|WP_006809409.1|	32.8	253	584	646	1.63e-24	107
GibsonMK_2016_SRR3131800_bin.2_k141_2207_260	SARG|gi|695701938|ref|WP_032639200.1|	31.9	254	584	646	1.63e-24	107
GibsonMK_2016_SRR3131800_bin.2_k141_2207_260	SARG|gi|1028176459|ref|WP_063924113.1|	32.8	253	584	646	1.63e-24	107
GibsonMK_2016_SRR3131800_bin.2_k141_2207_287	CARD|gb|ALH22601.1|ARO:3000620|adeL	28.0	304	303	337	3.70e-30	115
GibsonMK_2016_SRR3131800_bin.2_k141_2207_348	SARG|YP_001444376	64.5	152	153	154	7.43e-77	224
GibsonMK_2016_SRR3131800_bin.2_k141_2207_348	SARG|Q8DF90	63.2	152	153	154	1.23e-75	221
GibsonMK_2016_SRR3131800_bin.2_k141_2207_348	SARG|BAB59035	64.5	152	153	154	1.23e-75	221
GibsonMK_2016_SRR3131800_bin.2_k141_2207_348	SARG|BAC58936	61.8	152	153	154	3.52e-75	220
GibsonMK_2016_SRR3131800_bin.2_k141_2207_348	SARG|ZP_02197344	61.2	152	153	154	5.00e-75	219
GibsonMK_2016_SRR3131800_bin.2_k141_2207_348	SARG|YP_002666586	63.2	152	153	154	5.00e-75	219
GibsonMK_2016_SRR3131800_bin.2_k141_2207_348	SARG|ZP_00990220	62.5	152	153	154	7.09e-75	219
GibsonMK_2016_SRR3131800_bin.2_k141_2207_348	SARG|YP_002418004	62.5	152	153	154	1.01e-74	219
GibsonMK_2016_SRR3131800_bin.2_k141_2207_348	SARG|ZP_01813310	62.5	152	153	154	1.43e-74	218
GibsonMK_2016_SRR3131800_bin.2_k141_2207_386	CARD|gb|ALH22601.1|ARO:3000620|adeL	35.1	285	296	337	4.79e-44	152
GibsonMK_2016_SRR3131800_bin.2_k141_2211_1	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	61.2	85	94	703	4.59e-28	104
GibsonMK_2016_SRR3131800_bin.2_k141_2211_6	SARG|gi|908715920|ref|WP_049847444.1|	77.5	506	506	495	1.68e-264	728
GibsonMK_2016_SRR3131800_bin.2_k141_2211_6	SARG|gi|908734982|ref|WP_049857566.1|	77.3	506	506	495	9.70e-264	726
GibsonMK_2016_SRR3131800_bin.2_k141_2211_6	SARG|gi|740324734|ref|WP_038161821.1|	77.5	506	506	494	3.80e-263	724
GibsonMK_2016_SRR3131800_bin.2_k141_2211_6	SARG|gi|930178119|ref|WP_054178867.1|	76.8	505	506	494	3.80e-263	724
GibsonMK_2016_SRR3131800_bin.2_k141_2211_6	SARG|gi|764394645|ref|WP_044347915.1|	78.2	504	506	490	3.81e-262	721
GibsonMK_2016_SRR3131800_bin.2_k141_2211_6	SARG|gi|491006056|ref|WP_004867776.1|	78.2	504	506	490	5.40e-262	721
GibsonMK_2016_SRR3131800_bin.2_k141_2211_6	SARG|gi|695774696|ref|WP_032697552.1|	77.8	504	506	490	5.40e-262	721
GibsonMK_2016_SRR3131800_bin.2_k141_2211_6	SARG|gi|695804140|ref|WP_032718260.1|	78.0	504	506	490	1.54e-261	720
GibsonMK_2016_SRR3131800_bin.2_k141_2211_6	SARG|gi|780039761|ref|WP_045447624.1|	76.6	505	506	494	1.79e-261	720
GibsonMK_2016_SRR3131800_bin.2_k141_2211_6	SARG|gi|695767665|ref|WP_032690679.1|	77.6	504	506	490	3.11e-261	719
GibsonMK_2016_SRR3131800_bin.2_k141_2211_23	SARG|YP_001480516	94.2	274	275	274	1.44e-186	511
GibsonMK_2016_SRR3131800_bin.2_k141_2211_23	SARG|A7FE74	88.7	274	275	272	2.43e-173	478
GibsonMK_2016_SRR3131800_bin.2_k141_2211_23	SARG|YP_001007833	88.7	274	275	272	9.88e-173	476
GibsonMK_2016_SRR3131800_bin.2_k141_2211_23	SARG|ZP_04621202	88.7	274	275	272	1.64e-171	473
GibsonMK_2016_SRR3131800_bin.2_k141_2211_23	SARG|ZP_04623431	88.0	274	275	272	4.68e-171	472
GibsonMK_2016_SRR3131800_bin.2_k141_2211_23	SARG|ZP_04616832	84.7	274	275	274	7.15e-171	472
GibsonMK_2016_SRR3131800_bin.2_k141_2211_23	SARG|ZP_04632979	87.6	274	275	272	5.46e-170	469
GibsonMK_2016_SRR3131800_bin.2_k141_2211_23	SARG|ZP_04612440	86.9	274	275	272	4.48e-169	467
GibsonMK_2016_SRR3131800_bin.2_k141_2211_23	SARG|ZP_03829223	86.5	274	275	272	1.50e-167	463
GibsonMK_2016_SRR3131800_bin.2_k141_2211_23	SARG|ZP_04637931	87.5	271	275	269	2.71e-167	462
GibsonMK_2016_SRR3131800_bin.2_k141_2211_30	SARG|M94066.1.gene1.p01	100	146	147	146	3.40e-106	298
GibsonMK_2016_SRR3131800_bin.2_k141_2211_30	NCBI|WP_047570454.1|1|1|aac(6')_Serra|aac(6')_Serra|acetyltransferase|2|aminoglycoside|aminoglycoside|aminoglycoside_6'-N-acetyltransferase|AMR|aminoglycoside	99.3	146	147	146	1.39e-105	296
GibsonMK_2016_SRR3131800_bin.2_k141_2211_30	NCBI|WP_049212943.1|1|1|aac(6')_Serra|aac(6')_Serra|acetyltransferase|2|aminoglycoside|aminoglycoside|aminoglycoside_6'-N-acetyltransferase|AMR|aminoglycoside	99.3	146	147	146	1.39e-105	296
GibsonMK_2016_SRR3131800_bin.2_k141_2211_30	NCBI|WP_041036791.1|1|1|aac(6')_Serra|aac(6')_Serra|acetyltransferase|2|aminoglycoside|aminoglycoside|aminoglycoside_6'-N-acetyltransferase|AMR|aminoglycoside	98.6	146	147	146	5.64e-105	295
GibsonMK_2016_SRR3131800_bin.2_k141_2211_30	NCBI|WP_033654785.1|1|1|aac(6')_Serra|aac(6')_Serra|acetyltransferase|2|aminoglycoside|aminoglycoside|aminoglycoside_6'-N-acetyltransferase|AMR|aminoglycoside	98.6	146	147	146	5.64e-105	295
GibsonMK_2016_SRR3131800_bin.2_k141_2211_30	NCBI|WP_060706838.1|1|1|aac(6')_Serra|aac(6')_Serra|acetyltransferase|2|aminoglycoside|aminoglycoside|aminoglycoside_6'-N-acetyltransferase|AMR|aminoglycoside	98.6	146	147	146	2.30e-104	293
GibsonMK_2016_SRR3131800_bin.2_k141_2211_30	NCBI|WP_049198488.1|1|1|aac(6')_Serra|aac(6')_Serra|acetyltransferase|2|aminoglycoside|aminoglycoside|aminoglycoside_6'-N-acetyltransferase|AMR|aminoglycoside	97.3	146	147	146	1.89e-103	291
GibsonMK_2016_SRR3131800_bin.2_k141_2211_30	NCBI|WP_039569351.1|1|1|aac(6')_Serra|aac(6')_Serra|acetyltransferase|2|aminoglycoside|aminoglycoside|aminoglycoside_6'-N-acetyltransferase|AMR|aminoglycoside	97.3	146	147	146	2.69e-103	290
GibsonMK_2016_SRR3131800_bin.2_k141_2211_30	NCBI|WP_049270433.1|1|1|aac(6')_Serra|aac(6')_Serra|acetyltransferase|2|aminoglycoside|aminoglycoside|aminoglycoside_6'-N-acetyltransferase|AMR|aminoglycoside	97.2	145	147	146	1.56e-102	288
GibsonMK_2016_SRR3131800_bin.2_k141_2211_30	NCBI|WP_019453091.1|1|1|aac(6')_Serra|aac(6')_Serra|acetyltransferase|2|aminoglycoside|aminoglycoside|aminoglycoside_6'-N-acetyltransferase|AMR|aminoglycoside	95.9	146	147	146	1.56e-102	288
GibsonMK_2016_SRR3131800_bin.2_k141_2211_37	SARG|gb|ABX00624.1|ARO:3002881|lmrC	38.3	532	540	550	4.96e-93	293
GibsonMK_2016_SRR3131800_bin.2_k141_2211_37	megares|MEG_7256|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|TLRC_1	31.4	539	540	540	2.82e-45	166
GibsonMK_2016_SRR3131800_bin.2_k141_2211_37	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.4	519	540	655	1.20e-44	166
GibsonMK_2016_SRR3131800_bin.2_k141_2211_37	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.2	519	540	655	1.64e-44	166
GibsonMK_2016_SRR3131800_bin.2_k141_2211_37	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.4	519	540	655	1.64e-44	166
GibsonMK_2016_SRR3131800_bin.2_k141_2211_37	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.4	519	540	655	2.23e-44	165
GibsonMK_2016_SRR3131800_bin.2_k141_2211_37	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.4	519	540	655	2.23e-44	165
GibsonMK_2016_SRR3131800_bin.2_k141_2211_37	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.4	519	540	655	2.23e-44	165
GibsonMK_2016_SRR3131800_bin.2_k141_2211_37	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.4	519	540	655	2.23e-44	165
GibsonMK_2016_SRR3131800_bin.2_k141_2211_37	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.4	519	540	655	3.05e-44	165
GibsonMK_2016_SRR3131800_bin.2_k141_2211_69	CARD|gb|AAC75429.1|ARO:3000833|evgS	28.5	520	780	1197	1.57e-48	184
GibsonMK_2016_SRR3131800_bin.2_k141_2211_69	SARG|ZP_02848503	32.5	117	780	221	3.25e-08	53.9
GibsonMK_2016_SRR3131800_bin.2_k141_2211_69	CARD|gb|ATC67679.1|ARO:3000838|arlR	29.2	120	780	219	1.04e-07	52.4
GibsonMK_2016_SRR3131800_bin.2_k141_2211_69	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	34.2	114	780	228	3.99e-06	47.8
GibsonMK_2016_SRR3131800_bin.2_k141_2211_89	SARG|gb|ADZ12699.1|ARO:3005091|RanA	36.4	206	272	258	5.69e-39	135
GibsonMK_2016_SRR3131800_bin.2_k141_2211_89	SARG|gb|AAK76136.1|ARO:3000025|patB	26.4	246	272	588	8.63e-19	84.7
GibsonMK_2016_SRR3131800_bin.2_k141_2211_89	SARG|gb|AGN74946|ARO:3003749|salA	37.1	62	272	541	2.33e-07	50.4
GibsonMK_2016_SRR3131800_bin.2_k141_2211_122	SARG|gi|554684122|ref|WP_023184036.1|	30.4	312	312	343	8.80e-26	103
GibsonMK_2016_SRR3131800_bin.2_k141_2211_122	SARG|YP_001572361	29.5	312	312	343	1.22e-25	103
GibsonMK_2016_SRR3131800_bin.2_k141_2211_122	SARG|gi|740611645|ref|WP_038397166.1|	29.2	312	312	343	3.20e-25	102
GibsonMK_2016_SRR3131800_bin.2_k141_2211_122	SARG|gi|979588572|ref|WP_059340812.1|	33.3	138	312	343	4.47e-16	76.6
GibsonMK_2016_SRR3131800_bin.2_k141_2211_122	SARG|YP_691420	34.1	138	312	323	4.39e-15	73.6
GibsonMK_2016_SRR3131800_bin.2_k141_2211_122	SARG|gi|332752007|gb|EGJ82400.1|	34.1	138	312	323	4.39e-15	73.6
GibsonMK_2016_SRR3131800_bin.2_k141_2211_122	SARG|NP_709857	34.1	138	312	343	5.08e-15	73.6
GibsonMK_2016_SRR3131800_bin.2_k141_2211_122	SARG|gi|984670524|ref|WP_060773951.1|	33.3	138	312	343	6.88e-15	73.2
GibsonMK_2016_SRR3131800_bin.2_k141_2211_122	SARG|gi|949798405|ref|WP_057108582.1|	33.3	138	312	343	6.88e-15	73.2
GibsonMK_2016_SRR3131800_bin.2_k141_2211_122	SARG|gi|803576054|ref|WP_046082052.1|	32.8	128	312	343	9.31e-15	72.8
GibsonMK_2016_SRR3131800_bin.2_k141_2275_4	CARD|gb|AAC75429.1|ARO:3000833|evgS	31.5	457	1067	1197	1.48e-52	200
GibsonMK_2016_SRR3131800_bin.2_k141_2275_5	CARD|gb|BAB36671.1|ARO:3000832|evgA	29.9	204	202	204	2.99e-23	91.3
GibsonMK_2016_SRR3131800_bin.2_k141_2275_5	CARD|gb|ADM92605.1|ARO:3000553|adeR	34.5	87	202	247	1.86e-07	48.9
GibsonMK_2016_SRR3131800_bin.2_k141_2275_5	CARD|gb|AAD51348.1|ARO:3003066|smeR	27.9	204	202	229	7.76e-07	47.0
GibsonMK_2016_SRR3131800_bin.2_k141_2275_5	CARD|gb|ATC67679.1|ARO:3000838|arlR	30.0	120	202	219	1.83e-06	45.8
GibsonMK_2016_SRR3131800_bin.2_k141_2275_16	SARG|gi|542061059|gb|ERI11611.1|	29.9	214	496	316	2.43e-15	75.9
GibsonMK_2016_SRR3131800_bin.2_k141_2275_16	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.5	176	496	655	1.70e-07	52.8
GibsonMK_2016_SRR3131800_bin.2_k141_2275_16	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	24.4	213	496	307	2.81e-07	51.2
GibsonMK_2016_SRR3131800_bin.2_k141_2275_16	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.0	176	496	655	1.18e-06	50.1
GibsonMK_2016_SRR3131800_bin.2_k141_2275_16	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.0	176	496	655	1.18e-06	50.1
GibsonMK_2016_SRR3131800_bin.2_k141_2275_22	SARG|gi|694064328|ref|WP_032410816.1|	30.3	211	263	646	2.03e-14	71.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_22	SARG|gb|WP_104671188.1|ARO:3003948|efrA	25.0	224	263	575	2.58e-10	59.3
GibsonMK_2016_SRR3131800_bin.2_k141_2275_22	SARG|gi|493394434|ref|WP_006350564.1|	28.6	241	263	602	2.62e-10	59.3
GibsonMK_2016_SRR3131800_bin.2_k141_2275_22	SARG|gi|497748188|ref|WP_010062372.1|	25.7	241	263	605	2.63e-10	59.3
GibsonMK_2016_SRR3131800_bin.2_k141_2275_22	SARG|gi|1045390184|ref|WP_065479071.1|	26.2	237	263	605	3.53e-10	58.9
GibsonMK_2016_SRR3131800_bin.2_k141_2275_22	SARG|gi|501350226|ref|WP_012381861.1|	27.0	237	263	603	4.73e-10	58.5
GibsonMK_2016_SRR3131800_bin.2_k141_2275_22	SARG|gi|664317010|ref|WP_030845774.1|	26.7	232	263	605	8.52e-10	57.8
GibsonMK_2016_SRR3131800_bin.2_k141_2275_22	SARG|gi|663286402|ref|WP_030292859.1|	26.7	232	263	605	8.52e-10	57.8
GibsonMK_2016_SRR3131800_bin.2_k141_2275_22	SARG|gi|663342223|ref|WP_030341347.1|	26.7	232	263	605	8.52e-10	57.8
GibsonMK_2016_SRR3131800_bin.2_k141_2275_22	SARG|gi|759527374|ref|WP_043247487.1|	26.7	232	263	605	8.52e-10	57.8
GibsonMK_2016_SRR3131800_bin.2_k141_2275_26	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	30.9	165	356	255	1.69e-17	80.1
GibsonMK_2016_SRR3131800_bin.2_k141_2275_26	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	27.1	210	356	307	1.32e-12	66.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_26	SARG|gb|WP_104671188.1|ARO:3003948|efrA	25.6	195	356	575	9.17e-11	62.0
GibsonMK_2016_SRR3131800_bin.2_k141_2275_48	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	41.2	226	579	343	4.01e-51	178
GibsonMK_2016_SRR3131800_bin.2_k141_2275_48	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	38.1	231	579	325	8.82e-44	157
GibsonMK_2016_SRR3131800_bin.2_k141_2275_48	SARG|gb|AAA26793|ARO:3003748|oleC	38.8	227	579	325	1.22e-43	157
GibsonMK_2016_SRR3131800_bin.2_k141_2275_48	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	36.6	224	579	307	2.01e-42	153
GibsonMK_2016_SRR3131800_bin.2_k141_2275_48	SARG|gi|510143239|gb|AGN36970.1|	32.6	230	579	313	5.38e-39	144
GibsonMK_2016_SRR3131800_bin.2_k141_2275_48	SARG|gi|507055561|ref|WP_016126482.1|	32.6	233	579	309	9.30e-39	143
GibsonMK_2016_SRR3131800_bin.2_k141_2275_48	SARG|P42332	33.0	224	579	306	1.19e-38	143
GibsonMK_2016_SRR3131800_bin.2_k141_2275_48	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	33.0	224	579	306	1.19e-38	143
GibsonMK_2016_SRR3131800_bin.2_k141_2275_48	SARG|ABB80128	33.0	224	579	306	1.65e-38	142
GibsonMK_2016_SRR3131800_bin.2_k141_2275_48	SARG|gi|488053456|ref|WP_002124853.1|	32.6	233	579	309	4.62e-38	141
GibsonMK_2016_SRR3131800_bin.2_k141_2275_49	SARG|gi|829911587|ref|WP_047362787.1|	26.0	311	329	371	6.84e-11	61.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_49	SARG|gi|1028091955|ref|WP_063849202.1|	26.0	292	329	371	9.16e-11	61.2
GibsonMK_2016_SRR3131800_bin.2_k141_2275_49	SARG|gi|1022656032|ref|WP_063413405.1|	26.0	292	329	371	9.16e-11	61.2
GibsonMK_2016_SRR3131800_bin.2_k141_2275_49	SARG|gi|556409769|ref|WP_023305794.1|	26.0	292	329	371	9.16e-11	61.2
GibsonMK_2016_SRR3131800_bin.2_k141_2275_49	SARG|gi|527038925|ref|WP_020884838.1|	26.0	292	329	371	1.23e-10	60.8
GibsonMK_2016_SRR3131800_bin.2_k141_2275_49	SARG|gi|895875287|ref|WP_048981676.1|	26.0	292	329	371	1.23e-10	60.8
GibsonMK_2016_SRR3131800_bin.2_k141_2275_49	SARG|gi|550714720|ref|WP_022647609.1|	26.0	292	329	371	1.23e-10	60.8
GibsonMK_2016_SRR3131800_bin.2_k141_2275_49	SARG|gi|1028177781|ref|WP_063925205.1|	26.0	292	329	371	1.23e-10	60.8
GibsonMK_2016_SRR3131800_bin.2_k141_2275_49	SARG|gi|823296743|ref|WP_047052327.1|	26.0	292	329	371	1.23e-10	60.8
GibsonMK_2016_SRR3131800_bin.2_k141_2275_49	SARG|gi|365748673|gb|AEW72900.1|	26.0	292	329	380	1.26e-10	60.8
GibsonMK_2016_SRR3131800_bin.2_k141_2275_55	SARG|gb|AAK76137.1|ARO:3000024|patA	28.3	212	349	564	4.87e-20	90.1
GibsonMK_2016_SRR3131800_bin.2_k141_2275_63	CARD|gb|CAA79966.1|ARO:3003665|NmcR	32.1	249	299	295	8.29e-26	102
GibsonMK_2016_SRR3131800_bin.2_k141_2275_80	SARG|gb|AAP26981.1|ARO:3005045|SatA	44.5	110	181	184	1.16e-29	106
GibsonMK_2016_SRR3131800_bin.2_k141_2275_80	NCBI|WP_003242546.1|1|1|satA_Bsub|satA_Bsub|acetyltransferase|2|streptothricin|streptothricin|streptothricin_N-acetyltransferase_SatA|AMR|nucleoside	40.5	131	181	173	4.87e-29	104
GibsonMK_2016_SRR3131800_bin.2_k141_2275_80	SARG|gb|AAB53445.1|ARO:3002897|SAT-4	43.9	114	181	180	3.26e-28	102
GibsonMK_2016_SRR3131800_bin.2_k141_2275_80	megares|MEG_6169|Drugs|Nucleosides|Streptothricin_acetyltransferase|SAT_1	43.9	114	181	180	3.26e-28	102
GibsonMK_2016_SRR3131800_bin.2_k141_2275_80	NCBI|WP_000627290.1|1|1|sat4|sat4|acetyltransferase|2|streptothricin|streptothricin|streptothricin_N-acetyltransferase_Sat4|AMR|nucleoside	43.9	114	181	180	3.26e-28	102
GibsonMK_2016_SRR3131800_bin.2_k141_2275_80	megares|MEG_6166|Drugs|Nucleosides|Streptothricin_acetyltransferase|SAT_1	43.9	114	181	180	3.26e-28	102
GibsonMK_2016_SRR3131800_bin.2_k141_2275_80	NCBI|WP_063854935.1|1|1|sat4|sat4|acetyltransferase|2|streptothricin|streptothricin|streptothricin_N-acetyltransferase_Sat4|AMR|nucleoside	44.7	114	181	180	6.49e-28	102
GibsonMK_2016_SRR3131800_bin.2_k141_2275_80	megares|MEG_6165|Drugs|Nucleosides|Streptothricin_acetyltransferase|SAT_1	44.7	114	181	180	6.49e-28	102
GibsonMK_2016_SRR3131800_bin.2_k141_2275_92	SARG|gi|752682279|ref|WP_041330231.1|	39.3	359	368	349	1.24e-80	249
GibsonMK_2016_SRR3131800_bin.2_k141_2275_92	SARG|DQ212986.1.gene8.p01	39.1	361	368	349	4.92e-80	248
GibsonMK_2016_SRR3131800_bin.2_k141_2275_92	SARG|gi|405945042|pdb|4FU0|A	39.1	361	368	357	6.25e-80	248
GibsonMK_2016_SRR3131800_bin.2_k141_2275_92	NCBI|WP_015943583.1|1|1|vanI|vanI|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--(R)-lactate_ligase_VanI|AMR|glycopeptide	38.5	356	368	341	7.72e-80	247
GibsonMK_2016_SRR3131800_bin.2_k141_2275_92	SARG|gi|765411304|ref|WP_044689514.1|	39.1	361	368	349	9.83e-80	247
GibsonMK_2016_SRR3131800_bin.2_k141_2275_92	SARG|AAF71281	38.8	361	368	349	2.77e-79	246
GibsonMK_2016_SRR3131800_bin.2_k141_2275_92	SARG|gb|KTE89608.1|ARO:3003723|vanI	38.3	358	368	348	1.20e-77	241
GibsonMK_2016_SRR3131800_bin.2_k141_2275_92	SARG|gi|985522334|ref|WP_060811963.1|	39.4	358	368	342	1.42e-77	241
GibsonMK_2016_SRR3131800_bin.2_k141_2275_92	SARG|Q06893	39.4	358	368	342	1.42e-77	241
GibsonMK_2016_SRR3131800_bin.2_k141_2275_92	SARG|gi|1028100561|ref|WP_063856696.1|	38.2	359	368	349	1.75e-77	241
GibsonMK_2016_SRR3131800_bin.2_k141_2275_102	SARG|P42332	33.2	187	260	306	1.95e-20	87.4
GibsonMK_2016_SRR3131800_bin.2_k141_2275_102	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	33.2	187	260	306	1.95e-20	87.4
GibsonMK_2016_SRR3131800_bin.2_k141_2275_102	SARG|gi|510143239|gb|AGN36970.1|	33.2	187	260	313	2.13e-20	87.4
GibsonMK_2016_SRR3131800_bin.2_k141_2275_102	SARG|ABB80128	33.9	180	260	306	2.69e-20	87.0
GibsonMK_2016_SRR3131800_bin.2_k141_2275_102	SARG|AAD21213	32.6	187	260	306	1.34e-19	85.1
GibsonMK_2016_SRR3131800_bin.2_k141_2275_102	SARG|gi|446048013|ref|WP_000125868.1|	31.7	208	260	648	3.53e-17	79.7
GibsonMK_2016_SRR3131800_bin.2_k141_2275_102	SARG|gb|AAC75271.1|ARO:3003952|yojI	30.5	203	260	547	3.64e-16	76.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_102	SARG|gi|921979807|ref|WP_053271336.1|	29.2	219	260	648	1.92e-14	71.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_102	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	32.1	224	260	579	3.64e-13	67.8
GibsonMK_2016_SRR3131800_bin.2_k141_2275_102	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	34.7	173	260	579	4.90e-13	67.4
GibsonMK_2016_SRR3131800_bin.2_k141_2275_109	CARD|gb|ALH22601.1|ARO:3000620|adeL	41.9	289	298	337	5.52e-74	229
GibsonMK_2016_SRR3131800_bin.2_k141_2275_110	megares|MEG_1780|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMRA_1	28.6	377	395	391	3.51e-28	113
GibsonMK_2016_SRR3131800_bin.2_k141_2275_110	SARG|AF015087.1.gene1.p01	28.6	377	395	391	3.51e-28	113
GibsonMK_2016_SRR3131800_bin.2_k141_2275_110	SARG|gb|CAA78046.1|ARO:3002701|Rfas_cmr	29.0	372	395	391	4.83e-25	104
GibsonMK_2016_SRR3131800_bin.2_k141_2275_110	megares|MEG_1781|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMRA_1	29.0	372	395	391	4.83e-25	104
GibsonMK_2016_SRR3131800_bin.2_k141_2275_130	SARG|gi|446026113|ref|WP_000103968.1|	34.4	221	342	306	9.26e-32	120
GibsonMK_2016_SRR3131800_bin.2_k141_2275_130	SARG|gi|500194536|ref|WP_011867743.1|	31.2	221	342	306	6.41e-27	107
GibsonMK_2016_SRR3131800_bin.2_k141_2275_138	SARG|gb|ADZ12699.1|ARO:3005091|RanA	25.5	251	278	258	9.17e-19	82.4
GibsonMK_2016_SRR3131800_bin.2_k141_2275_138	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	26.9	238	278	293	1.09e-18	82.8
GibsonMK_2016_SRR3131800_bin.2_k141_2275_138	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	21.7	240	278	568	1.07e-06	48.5
GibsonMK_2016_SRR3131800_bin.2_k141_2275_150	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	27.7	224	269	293	1.64e-14	70.9
GibsonMK_2016_SRR3131800_bin.2_k141_2275_151	SARG|gi|500194536|ref|WP_011867743.1|	32.7	214	233	306	3.91e-28	107
GibsonMK_2016_SRR3131800_bin.2_k141_2275_151	SARG|gi|446026113|ref|WP_000103968.1|	31.2	218	233	306	5.61e-27	104
GibsonMK_2016_SRR3131800_bin.2_k141_2275_151	SARG|gi|507044560|ref|WP_016115614.1|	30.0	217	233	306	5.61e-27	104
GibsonMK_2016_SRR3131800_bin.2_k141_2275_151	SARG|P42332	31.6	215	233	306	1.09e-26	103
GibsonMK_2016_SRR3131800_bin.2_k141_2275_151	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	31.6	215	233	306	1.09e-26	103
GibsonMK_2016_SRR3131800_bin.2_k141_2275_151	SARG|gi|510143239|gb|AGN36970.1|	31.6	215	233	313	1.23e-26	103
GibsonMK_2016_SRR3131800_bin.2_k141_2275_151	SARG|gi|542061059|gb|ERI11611.1|	30.4	214	233	316	1.29e-26	103
GibsonMK_2016_SRR3131800_bin.2_k141_2275_151	SARG|ABB80128	31.6	215	233	306	2.12e-26	102
GibsonMK_2016_SRR3131800_bin.2_k141_2275_151	SARG|gi|445996708|ref|WP_000074563.1|	32.1	215	233	309	2.23e-26	102
GibsonMK_2016_SRR3131800_bin.2_k141_2275_151	SARG|gi|488042066|ref|WP_002113463.1|	31.2	215	233	309	2.23e-26	102
GibsonMK_2016_SRR3131800_bin.2_k141_2275_157	megares|MEG_1992|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	30.2	159	290	291	2.65e-10	58.9
GibsonMK_2016_SRR3131800_bin.2_k141_2275_172	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	33.2	211	312	343	1.80e-27	108
GibsonMK_2016_SRR3131800_bin.2_k141_2275_172	SARG|Q83LR7	35.3	224	312	648	2.52e-27	110
GibsonMK_2016_SRR3131800_bin.2_k141_2275_172	SARG|gi|647325472|ref|WP_025760953.1|	35.3	224	312	648	2.52e-27	110
GibsonMK_2016_SRR3131800_bin.2_k141_2275_172	SARG|gi|647323678|ref|WP_025760497.1|	35.3	224	312	648	2.52e-27	110
GibsonMK_2016_SRR3131800_bin.2_k141_2275_172	SARG|gi|495067432|ref|WP_007792257.1|	34.5	206	312	647	4.62e-27	110
GibsonMK_2016_SRR3131800_bin.2_k141_2275_172	SARG|gi|823326845|ref|WP_047080664.1|	37.5	208	312	648	4.62e-27	110
GibsonMK_2016_SRR3131800_bin.2_k141_2275_172	SARG|gi|695793471|ref|WP_032707680.1|	37.5	208	312	648	8.49e-27	109
GibsonMK_2016_SRR3131800_bin.2_k141_2275_172	SARG|gi|823302270|ref|WP_047057473.1|	37.5	208	312	648	8.49e-27	109
GibsonMK_2016_SRR3131800_bin.2_k141_2275_172	SARG|gi|976146774|ref|WP_059305359.1|	37.5	208	312	648	8.49e-27	109
GibsonMK_2016_SRR3131800_bin.2_k141_2275_172	SARG|gi|1022664304|ref|WP_063420886.1|	37.5	208	312	648	8.49e-27	109
GibsonMK_2016_SRR3131800_bin.2_k141_2275_179	SARG|gi|543582710|emb|CCU69833.1|	28.3	191	485	475	6.24e-16	79.0
GibsonMK_2016_SRR3131800_bin.2_k141_2275_179	SARG|gi|446633752|ref|WP_000711098.1|	28.3	191	485	475	1.10e-15	78.2
GibsonMK_2016_SRR3131800_bin.2_k141_2275_179	SARG|AAA67509	23.8	298	485	538	3.06e-15	77.0
GibsonMK_2016_SRR3131800_bin.2_k141_2275_179	SARG|gi|686169996|ref|WP_031795084.1|	28.3	191	485	475	3.46e-15	76.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_179	SARG|AJ549214.1.gene2.p01	28.3	191	485	475	3.46e-15	76.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_179	SARG|CAJ31068	28.3	191	485	475	3.46e-15	76.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_179	SARG|CAL64024	27.9	190	485	475	6.12e-15	75.9
GibsonMK_2016_SRR3131800_bin.2_k141_2275_179	SARG|gi|526667538|gb|AGR88940.1|	27.7	191	485	475	1.91e-14	74.3
GibsonMK_2016_SRR3131800_bin.2_k141_2275_179	SARG|gi|526667488|gb|AGR88919.1|	27.7	191	485	475	1.05e-13	72.0
GibsonMK_2016_SRR3131800_bin.2_k141_2275_179	SARG|YP_002181880	23.6	335	485	536	1.21e-13	72.0
GibsonMK_2016_SRR3131800_bin.2_k141_2275_185	SARG|gb|CAA09666.1|ARO:3004122|Klebsiella	57.5	386	366	374	1.62e-151	431
GibsonMK_2016_SRR3131800_bin.2_k141_2275_185	megares|MEG_4285|Drugs|beta-lactam|Mutant_porin_proteins|OMPD_1	48.1	370	366	357	1.04e-105	313
GibsonMK_2016_SRR3131800_bin.2_k141_2275_192	CARD|gb|AAK37618.1|ARO:3005008|TxR	41.2	323	530	318	1.76e-58	196
GibsonMK_2016_SRR3131800_bin.2_k141_2275_198	SARG|JQ768046.1.gene8.p1	38.1	431	475	559	2.11e-66	222
GibsonMK_2016_SRR3131800_bin.2_k141_2275_198	SARG|P42670	32.3	468	475	503	5.16e-41	152
GibsonMK_2016_SRR3131800_bin.2_k141_2275_198	SARG|YP_002203876	32.6	427	475	539	4.76e-38	144
GibsonMK_2016_SRR3131800_bin.2_k141_2275_198	SARG|NP_826974	31.4	436	475	540	6.60e-38	144
GibsonMK_2016_SRR3131800_bin.2_k141_2275_198	SARG|YP_002196817	31.7	438	475	536	1.18e-37	143
GibsonMK_2016_SRR3131800_bin.2_k141_2275_198	SARG|YP_002193132	31.9	433	475	537	2.24e-37	142
GibsonMK_2016_SRR3131800_bin.2_k141_2275_198	SARG|AAA67509	31.6	433	475	538	2.78e-36	139
GibsonMK_2016_SRR3131800_bin.2_k141_2275_198	SARG|YP_002181880	30.9	456	475	536	9.50e-36	138
GibsonMK_2016_SRR3131800_bin.2_k141_2275_198	SARG|YP_002188856	30.8	439	475	537	2.15e-34	134
GibsonMK_2016_SRR3131800_bin.2_k141_2275_198	SARG|NP_733568	31.2	420	475	536	1.86e-33	131
GibsonMK_2016_SRR3131800_bin.2_k141_2275_211	SARG|gi|896325272|ref|WP_049294291.1|	43.8	219	241	648	5.84e-45	158
GibsonMK_2016_SRR3131800_bin.2_k141_2275_211	SARG|gi|639225329|ref|WP_024561799.1|	42.0	226	241	648	8.07e-45	157
GibsonMK_2016_SRR3131800_bin.2_k141_2275_211	SARG|gi|639218559|ref|WP_024556062.1|	42.0	226	241	648	8.07e-45	157
GibsonMK_2016_SRR3131800_bin.2_k141_2275_211	SARG|gi|657888313|ref|WP_029592374.1|	40.9	230	241	648	1.54e-44	157
GibsonMK_2016_SRR3131800_bin.2_k141_2275_211	SARG|gi|639216333|ref|WP_024554080.1|	43.8	210	241	648	2.94e-44	156
GibsonMK_2016_SRR3131800_bin.2_k141_2275_211	SARG|gi|754951242|ref|WP_042307417.1|	40.1	227	241	648	1.07e-43	154
GibsonMK_2016_SRR3131800_bin.2_k141_2275_211	SARG|gi|740856590|ref|WP_038641842.1|	40.1	227	241	648	1.07e-43	154
GibsonMK_2016_SRR3131800_bin.2_k141_2275_211	SARG|gi|493734654|ref|WP_006683876.1|	40.1	227	241	648	1.07e-43	154
GibsonMK_2016_SRR3131800_bin.2_k141_2275_211	SARG|gi|992380339|ref|WP_061067665.1|	37.8	251	241	648	5.35e-43	152
GibsonMK_2016_SRR3131800_bin.2_k141_2275_211	SARG|gi|491270241|ref|WP_005128370.1|	39.8	226	241	648	7.38e-43	152
GibsonMK_2016_SRR3131800_bin.2_k141_2275_234	CARD|gb|ATC67679.1|ARO:3000838|arlR	39.9	218	224	219	5.28e-51	164
GibsonMK_2016_SRR3131800_bin.2_k141_2275_234	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	40.3	221	224	228	1.24e-48	158
GibsonMK_2016_SRR3131800_bin.2_k141_2275_234	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	40.4	218	224	233	1.15e-44	148
GibsonMK_2016_SRR3131800_bin.2_k141_2275_234	SARG|ZP_02848503	38.2	220	224	221	2.07e-42	142
GibsonMK_2016_SRR3131800_bin.2_k141_2275_234	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.8	220	224	219	3.90e-42	141
GibsonMK_2016_SRR3131800_bin.2_k141_2275_234	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.4	220	224	219	1.55e-41	139
GibsonMK_2016_SRR3131800_bin.2_k141_2275_234	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.4	220	224	220	1.59e-41	139
GibsonMK_2016_SRR3131800_bin.2_k141_2275_234	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.4	220	224	220	1.59e-41	139
GibsonMK_2016_SRR3131800_bin.2_k141_2275_234	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.4	220	224	220	2.25e-41	139
GibsonMK_2016_SRR3131800_bin.2_k141_2275_234	CARD|gb|AAG06465.1|ARO:3005063|cprR	35.3	221	224	223	2.15e-39	134
GibsonMK_2016_SRR3131800_bin.2_k141_2275_235	NCBI|WP_002368696.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	28.2	287	474	447	1.67e-15	77.4
GibsonMK_2016_SRR3131800_bin.2_k141_2275_235	NCBI|WP_002382867.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	29.1	230	474	447	2.93e-14	73.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_235	NCBI|WP_012579101.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	29.1	230	474	447	2.93e-14	73.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_235	NCBI|WP_063856739.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	29.1	230	474	447	2.93e-14	73.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_235	NCBI|WP_063856751.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	29.3	191	474	454	5.30e-14	72.8
GibsonMK_2016_SRR3131800_bin.2_k141_2275_235	NCBI|WP_063856737.1|1|1|vanS-B-Delta|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|VanB-type_glycopeptide_resistance_histidine_kinase_VanS-B-Delta|AMR|glycopeptide	28.7	230	474	441	2.74e-12	67.4
GibsonMK_2016_SRR3131800_bin.2_k141_2275_243	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	30.9	236	489	370	2.18e-27	112
GibsonMK_2016_SRR3131800_bin.2_k141_2275_243	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.0	221	489	381	3.69e-22	97.1
GibsonMK_2016_SRR3131800_bin.2_k141_2275_243	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.0	221	489	381	3.69e-22	97.1
GibsonMK_2016_SRR3131800_bin.2_k141_2275_243	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	29.7	236	489	365	4.16e-22	96.7
GibsonMK_2016_SRR3131800_bin.2_k141_2275_243	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	28.0	236	489	359	1.92e-20	91.7
GibsonMK_2016_SRR3131800_bin.2_k141_2275_243	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.9	222	489	381	1.44e-19	89.4
GibsonMK_2016_SRR3131800_bin.2_k141_2275_243	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.9	222	489	381	1.44e-19	89.4
GibsonMK_2016_SRR3131800_bin.2_k141_2275_243	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	28.4	204	489	380	1.91e-19	89.0
GibsonMK_2016_SRR3131800_bin.2_k141_2275_243	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.4	204	489	380	1.91e-19	89.0
GibsonMK_2016_SRR3131800_bin.2_k141_2275_243	megares|MEG_7502|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.4	299	489	361	2.14e-19	88.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_244	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	44.7	226	240	228	5.34e-60	187
GibsonMK_2016_SRR3131800_bin.2_k141_2275_244	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	41.3	225	240	231	2.44e-56	178
GibsonMK_2016_SRR3131800_bin.2_k141_2275_244	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	40.7	226	240	232	1.42e-55	176
GibsonMK_2016_SRR3131800_bin.2_k141_2275_244	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.0	227	240	231	2.84e-52	168
GibsonMK_2016_SRR3131800_bin.2_k141_2275_244	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.0	227	240	231	2.84e-52	168
GibsonMK_2016_SRR3131800_bin.2_k141_2275_244	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	37.3	228	240	233	1.92e-50	163
GibsonMK_2016_SRR3131800_bin.2_k141_2275_244	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.9	225	240	219	2.55e-50	162
GibsonMK_2016_SRR3131800_bin.2_k141_2275_244	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.0	227	240	231	2.56e-50	163
GibsonMK_2016_SRR3131800_bin.2_k141_2275_244	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.6	227	240	231	1.02e-49	161
GibsonMK_2016_SRR3131800_bin.2_k141_2275_244	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.6	227	240	231	2.88e-49	160
GibsonMK_2016_SRR3131800_bin.2_k141_2275_260	CARD|gb|BAA15221.2|ARO:3000263|marA	52.0	100	153	127	9.25e-34	114
GibsonMK_2016_SRR3131800_bin.2_k141_2275_267	CARD|gb|ALH22601.1|ARO:3000620|adeL	32.6	288	299	337	4.86e-45	154
GibsonMK_2016_SRR3131800_bin.2_k141_2275_267	CARD|gb|CAA79966.1|ARO:3003665|NmcR	26.4	144	299	295	3.34e-08	52.8
GibsonMK_2016_SRR3131800_bin.2_k141_2275_271	CARD|gb|VWQ00850.1|ARO:3003843|leuO	22.7	247	300	314	8.44e-09	54.7
GibsonMK_2016_SRR3131800_bin.2_k141_2275_272	SARG|gb|ABO11759.2|ARO:3004573|Acinetobacter	26.6	417	435	429	4.86e-40	147
GibsonMK_2016_SRR3131800_bin.2_k141_2275_273	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.8	532	531	655	1.06e-79	261
GibsonMK_2016_SRR3131800_bin.2_k141_2275_273	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.8	532	531	655	1.06e-79	261
GibsonMK_2016_SRR3131800_bin.2_k141_2275_273	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.6	532	531	655	4.04e-79	259
GibsonMK_2016_SRR3131800_bin.2_k141_2275_273	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.6	532	531	655	5.65e-79	259
GibsonMK_2016_SRR3131800_bin.2_k141_2275_273	SARG|gb|AKA86814|ARO:3003746|optrA	31.6	532	531	655	5.65e-79	259
GibsonMK_2016_SRR3131800_bin.2_k141_2275_273	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.8	532	531	655	1.10e-78	258
GibsonMK_2016_SRR3131800_bin.2_k141_2275_273	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.6	532	531	655	1.54e-78	258
GibsonMK_2016_SRR3131800_bin.2_k141_2275_273	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.6	532	531	655	1.54e-78	258
GibsonMK_2016_SRR3131800_bin.2_k141_2275_273	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.6	532	531	655	1.54e-78	258
GibsonMK_2016_SRR3131800_bin.2_k141_2275_273	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.6	532	531	655	1.54e-78	258
GibsonMK_2016_SRR3131800_bin.2_k141_2275_278	SARG|gi|1035686596|ref|WP_064530178.1|	33.6	235	626	648	2.83e-19	90.9
GibsonMK_2016_SRR3131800_bin.2_k141_2275_278	SARG|gi|898532714|ref|WP_049595067.1|	32.9	237	626	648	1.15e-18	89.0
GibsonMK_2016_SRR3131800_bin.2_k141_2275_278	SARG|gi|693054987|ref|WP_032223114.1|	32.5	237	626	648	1.52e-18	88.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_278	SARG|gi|1001720867|ref|WP_061274204.1|	32.6	239	626	648	1.52e-18	88.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_278	SARG|Q83LR7	33.3	237	626	648	2.01e-18	88.2
GibsonMK_2016_SRR3131800_bin.2_k141_2275_278	SARG|gi|647325472|ref|WP_025760953.1|	33.3	237	626	648	2.01e-18	88.2
GibsonMK_2016_SRR3131800_bin.2_k141_2275_278	SARG|gi|647323678|ref|WP_025760497.1|	33.3	237	626	648	2.01e-18	88.2
GibsonMK_2016_SRR3131800_bin.2_k141_2275_278	SARG|gi|446110295|ref|WP_000188150.1|	32.2	242	626	648	2.01e-18	88.2
GibsonMK_2016_SRR3131800_bin.2_k141_2275_278	SARG|gi|510923671|ref|WP_016244456.1|	32.5	237	626	648	2.01e-18	88.2
GibsonMK_2016_SRR3131800_bin.2_k141_2275_278	SARG|gi|486425021|ref|WP_001614493.1|	32.9	237	626	648	2.01e-18	88.2
GibsonMK_2016_SRR3131800_bin.2_k141_2275_291	SARG|gi|445996710|ref|WP_000074565.1|	28.8	233	503	309	7.06e-16	77.4
GibsonMK_2016_SRR3131800_bin.2_k141_2275_291	SARG|gi|446110087|ref|WP_000187942.1|	28.8	233	503	309	1.28e-15	76.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_291	SARG|gi|542061059|gb|ERI11611.1|	30.0	227	503	316	1.85e-15	76.3
GibsonMK_2016_SRR3131800_bin.2_k141_2275_291	SARG|gi|445996719|ref|WP_000074574.1|	28.3	233	503	309	2.31e-15	75.9
GibsonMK_2016_SRR3131800_bin.2_k141_2275_291	SARG|gi|814314593|emb|CKF49145.1|	28.8	233	503	309	2.31e-15	75.9
GibsonMK_2016_SRR3131800_bin.2_k141_2275_291	SARG|gi|445996709|ref|WP_000074564.1|	28.8	233	503	309	4.17e-15	75.1
GibsonMK_2016_SRR3131800_bin.2_k141_2275_291	SARG|gi|895736250|emb|COF64653.1|	28.3	233	503	309	4.17e-15	75.1
GibsonMK_2016_SRR3131800_bin.2_k141_2275_291	SARG|gi|445996714|ref|WP_000074569.1|	28.3	233	503	309	4.17e-15	75.1
GibsonMK_2016_SRR3131800_bin.2_k141_2275_291	SARG|gi|445996722|ref|WP_000074577.1|	28.3	233	503	309	4.17e-15	75.1
GibsonMK_2016_SRR3131800_bin.2_k141_2275_291	SARG|gi|445996723|ref|WP_000074578.1|	28.3	233	503	309	5.60e-15	74.7
GibsonMK_2016_SRR3131800_bin.2_k141_2275_305	megares|MEG_1179|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|ASMA_1	49.9	609	611	607	1.07e-195	561
GibsonMK_2016_SRR3131800_bin.2_k141_2275_305	megares|MEG_1180|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|ASMA_1	48.3	619	611	617	1.72e-194	559
GibsonMK_2016_SRR3131800_bin.2_k141_2275_328	SARG|gb|AAK76137.1|ARO:3000024|patA	28.7	296	550	564	9.08e-28	116
GibsonMK_2016_SRR3131800_bin.2_k141_2275_328	SARG|gb|AYV52072.1|ARO:3002882|lmrD	31.5	203	550	664	2.44e-25	109
GibsonMK_2016_SRR3131800_bin.2_k141_2275_328	SARG|AF024666.2.gene6.p01	27.3	278	550	513	3.87e-15	77.0
GibsonMK_2016_SRR3131800_bin.2_k141_2275_328	SARG|gi|736993687|ref|WP_034989673.1|	27.0	278	550	513	6.80e-15	76.3
GibsonMK_2016_SRR3131800_bin.2_k141_2275_328	SARG|gi|171851258|emb|CAQ04234.1|	25.4	279	550	483	1.46e-14	75.1
GibsonMK_2016_SRR3131800_bin.2_k141_2275_328	SARG|gi|491465657|ref|WP_005323423.1|	25.4	389	550	513	6.48e-14	73.2
GibsonMK_2016_SRR3131800_bin.2_k141_2275_328	SARG|U82085.gene.p01	24.3	202	550	552	2.44e-07	52.4
GibsonMK_2016_SRR3131800_bin.2_k141_2275_330	SARG|gi|493932882|ref|WP_006877374.1|	28.3	441	459	436	2.57e-44	159
GibsonMK_2016_SRR3131800_bin.2_k141_2275_330	SARG|gi|495352880|ref|WP_008077604.1|	27.9	441	459	436	4.95e-44	159
GibsonMK_2016_SRR3131800_bin.2_k141_2275_330	SARG|gi|446657998|ref|WP_000735344.1|	27.8	443	459	438	1.90e-43	157
GibsonMK_2016_SRR3131800_bin.2_k141_2275_330	SARG|gi|940838987|ref|WP_055029065.1|	27.8	443	459	438	3.66e-43	156
GibsonMK_2016_SRR3131800_bin.2_k141_2275_330	SARG|gi|515610071|ref|WP_017042671.1|	27.2	441	459	435	1.77e-42	154
GibsonMK_2016_SRR3131800_bin.2_k141_2275_330	SARG|gi|941039122|ref|WP_055051514.1|	27.9	444	459	438	1.87e-42	154
GibsonMK_2016_SRR3131800_bin.2_k141_2275_330	SARG|gi|446657977|ref|WP_000735323.1|	27.3	443	459	438	2.59e-42	154
GibsonMK_2016_SRR3131800_bin.2_k141_2275_330	SARG|gi|941010916|ref|WP_055044168.1|	27.5	443	459	438	2.59e-42	154
GibsonMK_2016_SRR3131800_bin.2_k141_2275_330	SARG|gi|694133591|ref|WP_032473590.1|	28.6	444	459	438	2.59e-42	154
GibsonMK_2016_SRR3131800_bin.2_k141_2275_330	SARG|gi|446657990|ref|WP_000735336.1|	28.6	444	459	438	2.59e-42	154
GibsonMK_2016_SRR3131800_bin.2_k141_2275_335	SARG|YP_001373621	31.1	196	406	318	3.22e-17	80.9
GibsonMK_2016_SRR3131800_bin.2_k141_2275_335	SARG|gi|488120365|ref|WP_002191762.1|	30.4	217	406	309	9.76e-17	79.3
GibsonMK_2016_SRR3131800_bin.2_k141_2275_335	SARG|gi|500448961|gb|EOP61695.1|	29.5	217	406	306	1.28e-16	79.0
GibsonMK_2016_SRR3131800_bin.2_k141_2275_335	SARG|gi|500465078|gb|EOP76697.1|	29.5	217	406	306	1.28e-16	79.0
GibsonMK_2016_SRR3131800_bin.2_k141_2275_335	SARG|gi|507050365|ref|WP_016121371.1|	30.0	217	406	309	1.32e-16	79.0
GibsonMK_2016_SRR3131800_bin.2_k141_2275_335	SARG|gi|507055561|ref|WP_016126482.1|	30.0	217	406	309	1.78e-16	78.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_335	SARG|gi|488042066|ref|WP_002113463.1|	30.0	217	406	309	1.78e-16	78.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_335	SARG|gi|445996696|ref|WP_000074551.1|	29.9	197	406	309	1.78e-16	78.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_335	SARG|gi|542061059|gb|ERI11611.1|	33.0	179	406	316	1.92e-16	78.6
GibsonMK_2016_SRR3131800_bin.2_k141_2275_335	SARG|P42332	32.2	143	406	306	2.33e-16	78.2
GibsonMK_2016_SRR3131800_bin.2_k141_2275_365	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	26.5	272	402	346	1.37e-16	79.3
GibsonMK_2016_SRR3131800_bin.2_k141_2275_365	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	28.0	261	402	356	2.00e-16	79.0
GibsonMK_2016_SRR3131800_bin.2_k141_2275_365	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	28.0	257	402	356	4.87e-16	77.8
GibsonMK_2016_SRR3131800_bin.2_k141_2275_365	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	28.0	257	402	356	6.55e-16	77.4
GibsonMK_2016_SRR3131800_bin.2_k141_2275_365	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	27.6	261	402	355	8.74e-16	77.0
GibsonMK_2016_SRR3131800_bin.2_k141_2275_365	SARG|BAE96115	27.6	261	402	355	8.74e-16	77.0
GibsonMK_2016_SRR3131800_bin.2_k141_2275_365	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	26.8	261	402	355	1.67e-14	73.2
GibsonMK_2016_SRR3131800_bin.2_k141_2275_365	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	26.8	261	402	355	1.67e-14	73.2
GibsonMK_2016_SRR3131800_bin.2_k141_2275_365	SARG|ACM47285	26.8	261	402	363	1.76e-14	73.2
GibsonMK_2016_SRR3131800_bin.2_k141_2275_365	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	30.1	196	402	209	3.98e-13	67.0
GibsonMK_2016_SRR3131800_bin.2_k141_2275_383	CARD|gb|AAA99503.1|ARO:3003250|bcrC	28.7	188	202	203	1.07e-14	68.6
GibsonMK_2016_SRR3131800_bin.2_k141_2504_6	SARG|gi|895865878|ref|WP_048974758.1|	35.9	223	343	646	7.10e-33	127
GibsonMK_2016_SRR3131800_bin.2_k141_2504_6	SARG|gi|814314593|emb|CKF49145.1|	27.7	206	343	309	4.82e-26	104
GibsonMK_2016_SRR3131800_bin.2_k141_2504_6	SARG|gi|445996709|ref|WP_000074564.1|	27.2	206	343	309	3.35e-25	102
GibsonMK_2016_SRR3131800_bin.2_k141_2504_31	SARG|gb|BAH45481.1|ARO:3002815|clbB	34.5	345	399	343	2.61e-51	174
GibsonMK_2016_SRR3131800_bin.2_k141_2504_31	NCBI|WP_111690898.1|1|1|cfr(C)|cfr(C)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN/TIAMULIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(C)|AMR|multidrug	33.8	355	399	379	2.27e-43	154
GibsonMK_2016_SRR3131800_bin.2_k141_2504_31	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	33.5	355	399	416	1.30e-42	153
GibsonMK_2016_SRR3131800_bin.2_k141_2504_31	SARG|gb|BAD63613.1|ARO:3002816|clbC	30.7	349	399	350	6.56e-42	149
GibsonMK_2016_SRR3131800_bin.2_k141_2504_31	SARG|CP001581.1.gene3143.p01	29.9	348	399	344	1.56e-41	148
GibsonMK_2016_SRR3131800_bin.2_k141_2504_31	SARG|gb|CAL84423.1|ARO:3004146|cfrC	29.1	347	399	344	3.10e-40	145
GibsonMK_2016_SRR3131800_bin.2_k141_2504_31	SARG|VXQ21601.1	30.7	349	399	344	2.30e-38	140
GibsonMK_2016_SRR3131800_bin.2_k141_2504_75	SARG|gb|ABO11759.2|ARO:3004573|Acinetobacter	40.0	418	444	429	1.99e-100	305
GibsonMK_2016_SRR3131800_bin.2_k141_2504_75	SARG|ZP_02903427	29.4	136	444	410	5.43e-06	47.4
GibsonMK_2016_SRR3131800_bin.2_k141_2504_75	SARG|gi|555231380|ref|WP_023218596.1|	29.1	141	444	413	9.58e-06	46.6
GibsonMK_2016_SRR3131800_bin.2_k141_2504_85	CARD|gb|AAD51348.1|ARO:3003066|smeR	60.3	219	239	229	1.64e-91	268
GibsonMK_2016_SRR3131800_bin.2_k141_2504_85	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	41.3	218	239	228	3.21e-50	162
GibsonMK_2016_SRR3131800_bin.2_k141_2504_85	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	39.5	243	239	252	3.56e-46	153
GibsonMK_2016_SRR3131800_bin.2_k141_2504_85	CARD|gb|AAG05188.1|ARO:3005068|ParR	37.9	219	239	235	6.25e-46	152
GibsonMK_2016_SRR3131800_bin.2_k141_2504_85	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	36.6	235	239	239	1.39e-45	151
GibsonMK_2016_SRR3131800_bin.2_k141_2504_85	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.0	227	239	232	1.62e-45	150
GibsonMK_2016_SRR3131800_bin.2_k141_2504_85	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.0	227	239	232	1.62e-45	150
GibsonMK_2016_SRR3131800_bin.2_k141_2504_85	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	36.8	228	239	233	1.86e-44	148
GibsonMK_2016_SRR3131800_bin.2_k141_2504_85	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.0	230	239	235	3.92e-44	147
GibsonMK_2016_SRR3131800_bin.2_k141_2504_85	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.9	227	239	231	1.39e-43	145
GibsonMK_2016_SRR3131800_bin.2_k141_2504_86	CARD|gb|AAD51347.1|ARO:3003067|smeS	42.0	462	461	467	2.66e-115	345
GibsonMK_2016_SRR3131800_bin.2_k141_2504_86	CARD|gb|ADM92606.1|ARO:3000549|adeS	30.2	275	461	361	1.36e-35	134
GibsonMK_2016_SRR3131800_bin.2_k141_2504_86	CARD|gb|BAB38260.1|ARO:3000830|cpxA	29.3	290	461	457	6.86e-32	125
GibsonMK_2016_SRR3131800_bin.2_k141_2504_86	CARD|gb|AEX49906.1|ARO:3003583|basS	29.2	267	461	477	2.20e-20	92.4
GibsonMK_2016_SRR3131800_bin.2_k141_2504_86	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	26.9	201	461	359	5.88e-19	87.0
GibsonMK_2016_SRR3131800_bin.2_k141_2504_87	SARG|CP001918.1.gene3442.p01	71.3	457	477	457	1.13e-231	642
GibsonMK_2016_SRR3131800_bin.2_k141_2504_87	SARG|gb|BAA11237.1|ARO:3000254|emrY	28.9	429	477	512	1.48e-39	148
GibsonMK_2016_SRR3131800_bin.2_k141_2504_87	SARG|gi|851904449|ref|WP_048213009.1|	28.3	431	477	512	6.07e-37	141
GibsonMK_2016_SRR3131800_bin.2_k141_2504_87	SARG|NC_010410.6003262.p01	30.6	340	477	507	7.82e-37	140
GibsonMK_2016_SRR3131800_bin.2_k141_2504_87	SARG|gi|692126801|ref|WP_032082759.1|	28.3	410	477	512	8.32e-37	140
GibsonMK_2016_SRR3131800_bin.2_k141_2504_87	SARG|gi|693264691|ref|WP_032363351.1|	28.3	410	477	512	1.56e-36	140
GibsonMK_2016_SRR3131800_bin.2_k141_2504_87	SARG|gi|491042801|ref|WP_004904467.1|	28.1	417	477	510	2.09e-36	139
GibsonMK_2016_SRR3131800_bin.2_k141_2504_87	SARG|gi|817112355|ref|WP_046485582.1|	28.6	412	477	512	2.14e-36	139
GibsonMK_2016_SRR3131800_bin.2_k141_2504_87	SARG|gi|544880697|ref|WP_021293434.1|	28.3	410	477	512	2.14e-36	139
GibsonMK_2016_SRR3131800_bin.2_k141_2504_87	SARG|gi|545246045|ref|WP_021544659.1|	28.3	410	477	512	2.14e-36	139
GibsonMK_2016_SRR3131800_bin.2_k141_2504_88	CARD|gb|AAC75137.1|ARO:3000794|mdtC	81.6	1018	1027	1025	0.0	1582
GibsonMK_2016_SRR3131800_bin.2_k141_2504_88	SARG|gb|AAG05914|ARO:3004075|MuxC	62.5	1012	1027	1036	0.0	1171
GibsonMK_2016_SRR3131800_bin.2_k141_2504_88	SARG|gb|AAG05915.1|ARO:3004074|MuxB	51.8	1014	1027	1043	0.0	941
GibsonMK_2016_SRR3131800_bin.2_k141_2504_88	CARD|gb|AAC75136.1|ARO:3000793|mdtB	50.8	1026	1027	1040	0.0	919
GibsonMK_2016_SRR3131800_bin.2_k141_2504_88	SARG|gb|BAE06006.1|ARO:3003705|mexN	49.0	1014	1027	1036	2.16e-290	835
GibsonMK_2016_SRR3131800_bin.2_k141_2504_88	SARG|gb|CAH14033.1|ARO:3004100|LpeB	31.2	1014	1027	1014	4.19e-135	432
GibsonMK_2016_SRR3131800_bin.2_k141_2504_88	SARG|YP_350221	29.5	1002	1027	1009	7.71e-133	426
GibsonMK_2016_SRR3131800_bin.2_k141_2504_88	SARG|YP_001350280	29.9	1012	1027	1018	2.56e-132	424
GibsonMK_2016_SRR3131800_bin.2_k141_2504_88	SARG|CAY51926	29.6	1010	1027	1008	3.98e-132	424
GibsonMK_2016_SRR3131800_bin.2_k141_2504_88	SARG|YP_606823	30.2	1002	1027	1011	1.18e-130	420
GibsonMK_2016_SRR3131800_bin.2_k141_2504_89	CARD|gb|AAC75136.1|ARO:3000793|mdtB	82.8	1026	1040	1040	0.0	1600
GibsonMK_2016_SRR3131800_bin.2_k141_2504_89	SARG|gb|AAG05915.1|ARO:3004074|MuxB	67.8	1016	1040	1043	0.0	1285
GibsonMK_2016_SRR3131800_bin.2_k141_2504_89	CARD|gb|AAC75137.1|ARO:3000794|mdtC	49.6	1023	1040	1025	1.15e-312	892
GibsonMK_2016_SRR3131800_bin.2_k141_2504_89	SARG|gb|BAE06006.1|ARO:3003705|mexN	49.5	1018	1040	1036	3.16e-307	879
GibsonMK_2016_SRR3131800_bin.2_k141_2504_89	SARG|gb|AAG05914|ARO:3004075|MuxC	48.7	1012	1040	1036	1.79e-306	877
GibsonMK_2016_SRR3131800_bin.2_k141_2504_89	CARD|gb|AAG07594.1|ARO:3000808|MexI	31.5	1035	1040	1029	4.74e-141	448
GibsonMK_2016_SRR3131800_bin.2_k141_2504_89	SARG|ZP_02357857	32.3	1041	1040	1061	2.12e-137	439
GibsonMK_2016_SRR3131800_bin.2_k141_2504_89	SARG|CAR56416	32.1	1042	1040	1066	1.28e-135	435
GibsonMK_2016_SRR3131800_bin.2_k141_2504_89	SARG|ZP_02889083	31.9	1049	1040	1071	1.43e-135	435
GibsonMK_2016_SRR3131800_bin.2_k141_2504_89	SARG|YP_001811890	31.9	1049	1040	1066	1.78e-135	434
GibsonMK_2016_SRR3131800_bin.2_k141_2504_90	CARD|gb|AAC75135.2|ARO:3000792|mdtA	74.6	339	418	415	3.77e-171	484
GibsonMK_2016_SRR3131800_bin.2_k141_2504_90	SARG|gb|AAG05916.1|ARO:3004073|MuxA	45.6	333	418	426	6.76e-87	270
GibsonMK_2016_SRR3131800_bin.2_k141_2504_90	SARG|gb|BAE06005.1|ARO:3003704|mexM	39.9	343	418	385	1.49e-70	226
GibsonMK_2016_SRR3131800_bin.2_k141_2504_90	SARG|ZP_02904981	33.8	358	418	405	5.23e-56	189
GibsonMK_2016_SRR3131800_bin.2_k141_2504_90	SARG|gi|746321235|ref|WP_039367880.1|	33.8	358	418	405	5.23e-56	189
GibsonMK_2016_SRR3131800_bin.2_k141_2504_90	SARG|YP_371055	34.1	358	418	405	7.33e-56	188
GibsonMK_2016_SRR3131800_bin.2_k141_2504_90	SARG|YP_002235155	33.5	358	418	405	1.03e-55	188
GibsonMK_2016_SRR3131800_bin.2_k141_2504_90	SARG|gi|736027032|ref|WP_034187788.1|	33.8	358	418	405	1.03e-55	188
GibsonMK_2016_SRR3131800_bin.2_k141_2504_90	SARG|gi|759459593|ref|WP_043180924.1|	34.1	358	418	405	1.44e-55	187
GibsonMK_2016_SRR3131800_bin.2_k141_2504_90	SARG|gi|654275318|ref|WP_027790469.1|	34.1	358	418	405	2.01e-55	187
GibsonMK_2016_SRR3131800_bin.2_k141_2504_104	megares|MEG_7256|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|TLRC_1	30.5	177	271	540	5.03e-10	58.5
GibsonMK_2016_SRR3131800_bin.2_k141_2504_147	CARD|gb|BAA16344.1|ARO:3000491|acrD	81.3	1036	1046	1037	0.0	1636
GibsonMK_2016_SRR3131800_bin.2_k141_2504_147	CARD|gb|AAC73564.1|ARO:3000216|acrB	67.1	1036	1046	1049	0.0	1313
GibsonMK_2016_SRR3131800_bin.2_k141_2504_147	SARG|gi|487663012|ref|WP_001752778.1|	65.5	1032	1046	1037	0.0	1277
GibsonMK_2016_SRR3131800_bin.2_k141_2504_147	SARG|gi|447196024|ref|WP_001273280.1|	65.5	1032	1046	1037	0.0	1276
GibsonMK_2016_SRR3131800_bin.2_k141_2504_147	SARG|CP000647.1.gene3710.p01	65.3	1036	1046	1036	0.0	1275
GibsonMK_2016_SRR3131800_bin.2_k141_2504_147	SARG|gi|817600095|ref|WP_046594084.1|	65.4	1032	1046	1037	0.0	1274
GibsonMK_2016_SRR3131800_bin.2_k141_2504_147	SARG|gi|817601660|ref|WP_046595348.1|	65.5	1032	1046	1037	0.0	1273
GibsonMK_2016_SRR3131800_bin.2_k141_2504_147	SARG|gi|556290479|ref|WP_023291164.1|	65.4	1036	1046	1036	0.0	1273
GibsonMK_2016_SRR3131800_bin.2_k141_2504_147	SARG|gi|817604860|ref|WP_046598079.1|	65.4	1032	1046	1037	0.0	1273
GibsonMK_2016_SRR3131800_bin.2_k141_2504_147	SARG|gi|694076105|ref|WP_032421853.1|	65.2	1036	1046	1036	0.0	1273
GibsonMK_2016_SRR3131800_bin.2_k141_2504_149	CARD|gb|BAB36671.1|ARO:3000832|evgA	25.1	187	211	204	4.63e-19	80.5
GibsonMK_2016_SRR3131800_bin.2_k141_2504_149	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	27.0	226	211	228	1.82e-13	65.9
GibsonMK_2016_SRR3131800_bin.2_k141_2504_149	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	32.2	115	211	231	1.87e-09	54.7
GibsonMK_2016_SRR3131800_bin.2_k141_2504_149	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	31.1	119	211	233	2.59e-09	54.3
GibsonMK_2016_SRR3131800_bin.2_k141_2504_149	CARD|gb|ATC67679.1|ARO:3000838|arlR	31.3	115	211	219	1.09e-08	52.4
GibsonMK_2016_SRR3131800_bin.2_k141_2504_149	CARD|gb|ADM92605.1|ARO:3000553|adeR	28.4	88	211	247	1.76e-06	46.2
GibsonMK_2016_SRR3131800_bin.2_k141_2716_2	CARD|gb|AAK37618.1|ARO:3005008|TxR	40.1	302	447	318	3.31e-68	219
GibsonMK_2016_SRR3131800_bin.2_k141_2716_4	CARD|gb|CYF42523.1|ARO:3004047|kdpD	23.3	266	479	885	3.03e-10	61.6
GibsonMK_2016_SRR3131800_bin.2_k141_2716_20	SARG|gi|1004359922|gb|AMP42228.1|	25.7	436	600	639	5.78e-27	114
GibsonMK_2016_SRR3131800_bin.2_k141_2716_20	SARG|gb|AMP42147.1|ARO:3004442|tet(W/N/W)	25.2	436	600	639	4.29e-26	112
GibsonMK_2016_SRR3131800_bin.2_k141_2716_20	SARG|gi|104303742|gb|ABF72138.1|	25.5	436	600	639	1.35e-25	110
GibsonMK_2016_SRR3131800_bin.2_k141_2716_20	SARG|ACI02041	26.7	438	600	639	1.35e-25	110
GibsonMK_2016_SRR3131800_bin.2_k141_2716_20	SARG|ABN80187	26.5	438	600	640	1.35e-25	110
GibsonMK_2016_SRR3131800_bin.2_k141_2716_20	SARG|WP_000691721.1	26.7	438	600	639	2.38e-25	109
GibsonMK_2016_SRR3131800_bin.2_k141_2716_20	SARG|ABC18245	26.7	438	600	639	2.38e-25	109
GibsonMK_2016_SRR3131800_bin.2_k141_2716_20	SARG|AAL30847	26.7	438	600	639	2.38e-25	109
GibsonMK_2016_SRR3131800_bin.2_k141_2716_20	SARG|DQ294299.gene.p01	26.7	438	600	639	2.38e-25	109
GibsonMK_2016_SRR3131800_bin.2_k141_2716_20	SARG|ACA23187	25.5	436	600	639	2.38e-25	109
GibsonMK_2016_SRR3131800_bin.2_k141_2716_46	SARG|gi|757561912|ref|WP_042818315.1|	39.4	99	166	189	1.03e-12	62.0
GibsonMK_2016_SRR3131800_bin.2_k141_2716_46	SARG|P08457	39.4	99	166	189	1.03e-12	62.0
GibsonMK_2016_SRR3131800_bin.2_k141_2716_59	SARG|NC_002951.3237419.p01	25.3	411	461	480	9.13e-35	134
GibsonMK_2016_SRR3131800_bin.2_k141_2716_59	NCBI|WP_113334341.1|1|1|qepA10|qepA|efflux|2|||quinolone_efflux_MFS_transporter_QepA10|AMR|quinolone	28.7	418	461	506	2.97e-31	124
GibsonMK_2016_SRR3131800_bin.2_k141_2716_59	NCBI|WP_112021705.1|1|1|qepA9|qepA|efflux|2|quinolone|quinolone|quinolone_efflux_MFS_transporter_QepA9|AMR|quinolone	28.9	387	461	511	5.76e-31	124
GibsonMK_2016_SRR3131800_bin.2_k141_2716_59	SARG|gi|1039004533|ref|WP_064760451.1|	28.9	387	461	511	7.83e-31	123
GibsonMK_2016_SRR3131800_bin.2_k141_2716_59	SARG|gi|1039291348|ref|WP_064768701.1|	28.7	387	461	511	1.45e-30	122
GibsonMK_2016_SRR3131800_bin.2_k141_2716_59	SARG|gi|917770481|ref|WP_052284485.1|	27.7	408	461	512	1.46e-30	122
GibsonMK_2016_SRR3131800_bin.2_k141_2716_59	SARG|gi|1028098233|ref|WP_063854778.1|	28.7	387	461	511	1.97e-30	122
GibsonMK_2016_SRR3131800_bin.2_k141_2716_59	SARG|NC_010558.1.6275948.p01	28.7	387	461	511	1.97e-30	122
GibsonMK_2016_SRR3131800_bin.2_k141_2716_59	NCBI|WP_096941464.1|1|1|qepA6|qepA|efflux|2|||quinolone_efflux_MFS_transporter_QepA6|AMR|quinolone	28.7	387	461	511	2.68e-30	122
GibsonMK_2016_SRR3131800_bin.2_k141_2716_59	SARG|gi|828164785|ref|WP_047255785.1|	28.8	416	461	513	2.72e-30	122
GibsonMK_2016_SRR3131800_bin.2_k141_2716_77	SARG|gi|542061059|gb|ERI11611.1|	30.1	236	401	316	3.20e-29	114
GibsonMK_2016_SRR3131800_bin.2_k141_2716_77	SARG|gi|500194536|ref|WP_011867743.1|	30.4	207	401	306	3.12e-26	106
GibsonMK_2016_SRR3131800_bin.2_k141_2716_77	SARG|gi|507035724|ref|WP_016107411.1|	30.0	207	401	309	8.56e-26	105
GibsonMK_2016_SRR3131800_bin.2_k141_2716_77	SARG|gi|447057509|ref|WP_001134765.1|	30.4	207	401	309	8.56e-26	105
GibsonMK_2016_SRR3131800_bin.2_k141_2716_77	SARG|gi|445996697|ref|WP_000074552.1|	30.0	207	401	309	1.18e-25	104
GibsonMK_2016_SRR3131800_bin.2_k141_2716_77	SARG|gi|488068784|ref|WP_002140181.1|	30.4	207	401	309	1.62e-25	104
GibsonMK_2016_SRR3131800_bin.2_k141_2716_77	SARG|gi|445996696|ref|WP_000074551.1|	30.0	207	401	309	1.62e-25	104
GibsonMK_2016_SRR3131800_bin.2_k141_2716_77	SARG|YP_001373621	30.7	215	401	318	1.88e-25	104
GibsonMK_2016_SRR3131800_bin.2_k141_2716_77	SARG|gi|488120365|ref|WP_002191762.1|	30.7	202	401	309	2.22e-25	103
GibsonMK_2016_SRR3131800_bin.2_k141_2716_77	SARG|gi|507055561|ref|WP_016126482.1|	30.0	207	401	309	2.22e-25	103
GibsonMK_2016_SRR3131800_bin.2_k141_2716_84	CARD|gb|AAC75731.1|ARO:3000516|emrR	83.1	166	173	176	7.73e-96	274
GibsonMK_2016_SRR3131800_bin.2_k141_2716_85	SARG|gi|553774750|ref|WP_023106587.1|	28.8	465	484	472	7.50e-37	140
GibsonMK_2016_SRR3131800_bin.2_k141_2716_85	SARG|YP_001348103	28.0	472	484	472	5.01e-36	138
GibsonMK_2016_SRR3131800_bin.2_k141_2716_85	SARG|gi|727761884|ref|WP_033867230.1|	28.5	473	484	472	5.01e-36	138
GibsonMK_2016_SRR3131800_bin.2_k141_2716_85	SARG|gi|686099038|ref|WP_031755887.1|	28.5	473	484	472	6.87e-36	137
GibsonMK_2016_SRR3131800_bin.2_k141_2716_85	SARG|gi|685898668|ref|WP_031639304.1|	28.5	473	484	472	6.87e-36	137
GibsonMK_2016_SRR3131800_bin.2_k141_2716_85	SARG|gi|730274062|ref|WP_033966812.1|	28.5	473	484	472	6.87e-36	137
GibsonMK_2016_SRR3131800_bin.2_k141_2716_85	SARG|gi|553765230|ref|WP_023097551.1|	28.5	473	484	472	6.87e-36	137
GibsonMK_2016_SRR3131800_bin.2_k141_2716_85	SARG|gi|730312025|ref|WP_033980978.1|	28.3	473	484	472	1.29e-35	137
GibsonMK_2016_SRR3131800_bin.2_k141_2716_85	SARG|YP_790742	28.3	473	484	472	1.77e-35	136
GibsonMK_2016_SRR3131800_bin.2_k141_2716_85	SARG|gi|553795209|ref|WP_023125875.1|	28.3	473	484	472	1.77e-35	136
GibsonMK_2016_SRR3131800_bin.2_k141_2716_86	SARG|gi|647319818|ref|WP_025757133.1|	72.6	390	391	390	1.55e-195	544
GibsonMK_2016_SRR3131800_bin.2_k141_2716_86	SARG|gi|895897108|ref|WP_048998549.1|	72.3	390	391	390	4.43e-195	543
GibsonMK_2016_SRR3131800_bin.2_k141_2716_86	SARG|gi|979845550|ref|WP_059355016.1|	72.1	390	391	390	1.27e-194	541
GibsonMK_2016_SRR3131800_bin.2_k141_2716_86	SARG|gi|495778000|ref|WP_008502579.1|	72.1	390	391	390	1.80e-194	541
GibsonMK_2016_SRR3131800_bin.2_k141_2716_86	SARG|gi|695709491|ref|WP_032642979.1|	72.1	390	391	390	2.55e-194	541
GibsonMK_2016_SRR3131800_bin.2_k141_2716_86	SARG|gi|556483549|ref|WP_023333175.1|	72.8	390	391	390	3.63e-194	540
GibsonMK_2016_SRR3131800_bin.2_k141_2716_86	SARG|gi|695720550|ref|WP_032648001.1|	72.8	390	391	390	5.15e-194	540
GibsonMK_2016_SRR3131800_bin.2_k141_2716_86	SARG|gi|895872568|ref|WP_048979803.1|	71.8	390	391	390	1.04e-193	539
GibsonMK_2016_SRR3131800_bin.2_k141_2716_86	SARG|gi|1028866969|ref|WP_064034812.1|	71.0	390	391	390	1.04e-193	539
GibsonMK_2016_SRR3131800_bin.2_k141_2716_86	SARG|gi|1016942650|ref|WP_063144178.1|	72.6	390	391	390	1.47e-193	539
GibsonMK_2016_SRR3131800_bin.2_k141_2716_87	SARG|gi|917770481|ref|WP_052284485.1|	83.5	502	513	512	4.73e-312	849
GibsonMK_2016_SRR3131800_bin.2_k141_2716_87	SARG|gi|754956999|ref|WP_042313106.1|	83.6	501	513	512	1.92e-311	847
GibsonMK_2016_SRR3131800_bin.2_k141_2716_87	SARG|gi|955473785|ref|WP_058101257.1|	83.6	501	513	512	2.73e-311	847
GibsonMK_2016_SRR3131800_bin.2_k141_2716_87	SARG|gi|740320277|ref|WP_038157443.1|	83.4	501	513	512	3.88e-311	847
GibsonMK_2016_SRR3131800_bin.2_k141_2716_87	SARG|gi|485809243|ref|WP_001429309.1|	83.6	501	513	512	3.88e-311	847
GibsonMK_2016_SRR3131800_bin.2_k141_2716_87	SARG|gi|485663835|ref|WP_001305258.1|	83.6	501	513	512	3.88e-311	847
GibsonMK_2016_SRR3131800_bin.2_k141_2716_87	SARG|gi|928881684|ref|WP_053918316.1|	83.4	501	513	512	5.51e-311	846
GibsonMK_2016_SRR3131800_bin.2_k141_2716_87	SARG|gi|485777471|ref|WP_001400788.1|	83.6	501	513	512	5.51e-311	846
GibsonMK_2016_SRR3131800_bin.2_k141_2716_87	SARG|gi|851904449|ref|WP_048213009.1|	83.8	501	513	512	1.11e-310	845
GibsonMK_2016_SRR3131800_bin.2_k141_2716_87	SARG|gi|486183889|ref|WP_001539415.1|	83.6	501	513	512	1.11e-310	845
GibsonMK_2016_SRR3131800_bin.2_k141_2736_1	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	33.6	548	516	703	1.62e-72	243
GibsonMK_2016_SRR3131800_bin.2_k141_2736_2	megares|MEG_1992|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	27.9	240	305	291	3.04e-10	58.9
GibsonMK_2016_SRR3131800_bin.2_k141_2736_79	megares|MEG_7070|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|TETD_1	61.2	98	289	138	2.85e-34	120
GibsonMK_2016_SRR3131800_bin.2_k141_2736_79	CARD|gb|BAA15221.2|ARO:3000263|marA	45.8	118	289	127	1.31e-27	102
GibsonMK_2016_SRR3131800_bin.2_k141_2736_96	SARG|BAB59035	34.2	114	172	154	4.30e-06	43.5
GibsonMK_2016_SRR3131800_bin.2_k141_2736_98	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	31.5	311	308	343	7.71e-44	152
GibsonMK_2016_SRR3131800_bin.2_k141_2736_98	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	31.6	285	308	293	1.28e-38	137
GibsonMK_2016_SRR3131800_bin.2_k141_2736_98	SARG|gi|447057509|ref|WP_001134765.1|	31.9	320	308	309	7.51e-37	132
GibsonMK_2016_SRR3131800_bin.2_k141_2736_98	SARG|ABB80128	31.9	317	308	306	1.44e-35	129
GibsonMK_2016_SRR3131800_bin.2_k141_2736_98	SARG|gi|445996708|ref|WP_000074563.1|	31.5	317	308	309	1.54e-35	129
GibsonMK_2016_SRR3131800_bin.2_k141_2736_98	SARG|gi|447057510|ref|WP_001134766.1|	31.0	310	308	309	1.54e-35	129
GibsonMK_2016_SRR3131800_bin.2_k141_2736_98	SARG|gi|500194536|ref|WP_011867743.1|	31.6	313	308	306	2.82e-35	128
GibsonMK_2016_SRR3131800_bin.2_k141_2736_98	SARG|P42332	31.5	317	308	306	3.94e-35	128
GibsonMK_2016_SRR3131800_bin.2_k141_2736_98	SARG|gi|507023808|ref|WP_016095885.1|	31.0	310	308	309	4.20e-35	128
GibsonMK_2016_SRR3131800_bin.2_k141_2736_98	SARG|gi|507035724|ref|WP_016107411.1|	30.4	312	308	309	5.87e-35	127
GibsonMK_2016_SRR3131800_bin.2_k141_2736_104	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.5	219	221	219	1.12e-43	145
GibsonMK_2016_SRR3131800_bin.2_k141_2736_104	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.5	219	221	219	1.58e-43	144
GibsonMK_2016_SRR3131800_bin.2_k141_2736_104	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.5	219	221	220	1.63e-43	144
GibsonMK_2016_SRR3131800_bin.2_k141_2736_104	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.1	219	221	220	6.47e-43	143
GibsonMK_2016_SRR3131800_bin.2_k141_2736_104	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.6	219	221	220	2.04e-41	139
GibsonMK_2016_SRR3131800_bin.2_k141_2736_104	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	33.9	221	221	233	5.09e-39	133
GibsonMK_2016_SRR3131800_bin.2_k141_2736_104	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	33.5	221	221	228	1.20e-35	124
GibsonMK_2016_SRR3131800_bin.2_k141_2736_104	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	33.6	232	221	252	1.66e-30	112
GibsonMK_2016_SRR3131800_bin.2_k141_2736_104	CARD|gb|AAG05188.1|ARO:3005068|ParR	34.4	224	221	235	4.13e-26	100
GibsonMK_2016_SRR3131800_bin.2_k141_2736_105	CARD|gb|AEX49906.1|ARO:3003583|basS	33.2	434	453	477	1.87e-49	174
GibsonMK_2016_SRR3131800_bin.2_k141_2736_105	CARD|gb|BAB38260.1|ARO:3000830|cpxA	26.8	235	453	457	4.89e-16	79.0
GibsonMK_2016_SRR3131800_bin.2_k141_2736_115	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	29.4	228	266	579	8.10e-21	90.5
GibsonMK_2016_SRR3131800_bin.2_k141_2736_115	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	29.5	227	266	579	1.49e-20	89.7
GibsonMK_2016_SRR3131800_bin.2_k141_2873_2	SARG|NP_348076	26.8	699	705	652	1.79e-74	252
GibsonMK_2016_SRR3131800_bin.2_k141_2873_2	SARG|YP_002850805	26.4	701	705	652	2.49e-74	251
GibsonMK_2016_SRR3131800_bin.2_k141_2873_2	SARG|ZP_02952732	26.2	701	705	652	3.44e-73	248
GibsonMK_2016_SRR3131800_bin.2_k141_2873_2	SARG|ZP_02632674	26.2	701	705	660	4.04e-73	248
GibsonMK_2016_SRR3131800_bin.2_k141_2873_2	SARG|L20800.gene.p01	26.2	701	705	652	9.19e-73	247
GibsonMK_2016_SRR3131800_bin.2_k141_2873_2	SARG|L42544.gene.p01	27.3	682	705	651	3.34e-72	246
GibsonMK_2016_SRR3131800_bin.2_k141_2873_2	SARG|AAV80410	27.1	682	705	651	4.57e-71	243
GibsonMK_2016_SRR3131800_bin.2_k141_2873_2	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.5	683	705	629	2.49e-64	224
GibsonMK_2016_SRR3131800_bin.2_k141_2873_2	ResF|tet(O/W)_5_AM889122_1	27.5	683	705	639	3.00e-64	224
GibsonMK_2016_SRR3131800_bin.2_k141_2873_2	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	25.4	665	705	641	8.19e-64	223
GibsonMK_2016_SRR3131800_bin.2_k141_2873_16	SARG|YP_001401994	30.5	547	603	563	5.99e-56	197
GibsonMK_2016_SRR3131800_bin.2_k141_2873_16	SARG|AAS61092	30.5	547	603	563	8.28e-56	197
GibsonMK_2016_SRR3131800_bin.2_k141_2873_16	SARG|YP_001605795	30.2	546	603	562	5.68e-55	194
GibsonMK_2016_SRR3131800_bin.2_k141_2873_16	SARG|gi|740410309|ref|WP_038243756.1|	29.7	545	603	563	5.56e-54	192
GibsonMK_2016_SRR3131800_bin.2_k141_2873_16	SARG|ZP_04638974	30.5	545	603	563	7.67e-54	191
GibsonMK_2016_SRR3131800_bin.2_k141_2873_16	SARG|ZP_04615639	30.0	524	603	543	1.41e-53	190
GibsonMK_2016_SRR3131800_bin.2_k141_2873_16	SARG|ZP_04631861	30.2	524	603	543	1.95e-53	190
GibsonMK_2016_SRR3131800_bin.2_k141_2873_16	SARG|ZP_04635128	29.6	523	603	543	1.95e-53	190
GibsonMK_2016_SRR3131800_bin.2_k141_2873_16	SARG|YP_001007250	29.2	544	603	563	3.85e-53	189
GibsonMK_2016_SRR3131800_bin.2_k141_2873_16	SARG|ZP_04630103	30.5	524	603	543	5.14e-53	189
GibsonMK_2016_SRR3131800_bin.2_k141_2873_18	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.2	518	638	655	1.42e-90	293
GibsonMK_2016_SRR3131800_bin.2_k141_2873_18	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.2	518	638	655	1.42e-90	293
GibsonMK_2016_SRR3131800_bin.2_k141_2873_18	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	518	638	655	3.88e-90	292
GibsonMK_2016_SRR3131800_bin.2_k141_2873_18	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	518	638	655	7.60e-90	291
GibsonMK_2016_SRR3131800_bin.2_k141_2873_18	SARG|gb|AKA86814|ARO:3003746|optrA	34.0	518	638	655	7.60e-90	291
GibsonMK_2016_SRR3131800_bin.2_k141_2873_18	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	518	638	655	2.08e-89	290
GibsonMK_2016_SRR3131800_bin.2_k141_2873_18	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	518	638	655	2.08e-89	290
GibsonMK_2016_SRR3131800_bin.2_k141_2873_18	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	518	638	655	2.08e-89	290
GibsonMK_2016_SRR3131800_bin.2_k141_2873_18	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	518	638	655	2.08e-89	290
GibsonMK_2016_SRR3131800_bin.2_k141_2873_18	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.0	518	638	655	2.08e-89	290
GibsonMK_2016_SRR3131800_bin.2_k141_2873_21	SARG|gi|896325272|ref|WP_049294291.1|	38.9	190	256	648	9.90e-31	119
GibsonMK_2016_SRR3131800_bin.2_k141_2873_21	SARG|gi|639216333|ref|WP_024554080.1|	35.9	220	256	648	9.90e-31	119
GibsonMK_2016_SRR3131800_bin.2_k141_2873_21	SARG|gi|895872463|ref|WP_048979698.1|	35.1	205	256	646	2.49e-30	117
GibsonMK_2016_SRR3131800_bin.2_k141_2873_21	SARG|gi|746253210|ref|WP_039301529.1|	38.7	181	256	648	2.51e-30	117
GibsonMK_2016_SRR3131800_bin.2_k141_2873_21	SARG|gi|740610794|ref|WP_038396317.1|	38.7	181	256	648	2.51e-30	117
GibsonMK_2016_SRR3131800_bin.2_k141_2873_21	SARG|gi|779866095|ref|WP_045354445.1|	34.6	205	256	646	3.40e-30	117
GibsonMK_2016_SRR3131800_bin.2_k141_2873_21	SARG|gi|556487375|ref|WP_023335108.1|	35.1	205	256	646	4.63e-30	117
GibsonMK_2016_SRR3131800_bin.2_k141_2873_21	SARG|gi|695701476|ref|WP_032638992.1|	35.1	205	256	646	4.63e-30	117
GibsonMK_2016_SRR3131800_bin.2_k141_2873_21	SARG|gi|696368937|ref|WP_032943949.1|	35.6	205	256	648	4.65e-30	117
GibsonMK_2016_SRR3131800_bin.2_k141_2873_21	SARG|gi|851913025|ref|WP_048215946.1|	35.6	205	256	648	4.65e-30	117
GibsonMK_2016_SRR3131800_bin.2_k141_2873_29	CARD|gb|BAE77933.1|ARO:3000518|CRP	99.0	210	211	210	3.90e-150	414
GibsonMK_2016_SRR3131800_bin.2_k141_2873_68	CARD|gb|BAB38260.1|ARO:3000830|cpxA	29.9	274	457	457	3.46e-32	126
GibsonMK_2016_SRR3131800_bin.2_k141_2873_69	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	45.6	237	240	252	2.65e-63	197
GibsonMK_2016_SRR3131800_bin.2_k141_2873_69	CARD|gb|AAG05188.1|ARO:3005068|ParR	42.0	231	240	235	1.37e-56	179
GibsonMK_2016_SRR3131800_bin.2_k141_2873_69	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.4	225	240	232	9.14e-54	172
GibsonMK_2016_SRR3131800_bin.2_k141_2873_69	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.4	225	240	232	9.14e-54	172
GibsonMK_2016_SRR3131800_bin.2_k141_2873_69	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	39.5	228	240	231	1.60e-51	166
GibsonMK_2016_SRR3131800_bin.2_k141_2873_69	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.5	228	240	231	1.60e-51	166
GibsonMK_2016_SRR3131800_bin.2_k141_2873_69	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.3	226	240	231	1.81e-50	163
GibsonMK_2016_SRR3131800_bin.2_k141_2873_69	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.3	226	240	231	2.56e-50	163
GibsonMK_2016_SRR3131800_bin.2_k141_2873_69	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.4	226	240	231	5.11e-50	162
GibsonMK_2016_SRR3131800_bin.2_k141_2873_69	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	39.9	228	240	225	1.71e-49	160
GibsonMK_2016_SRR3131800_bin.2_k141_2873_122	SARG|gi|657632362|ref|WP_029442980.1|	22.8	180	226	492	7.40e-11	60.1
GibsonMK_2016_SRR3131800_bin.2_k141_2873_122	megares|MEG_7256|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|TLRC_1	30.3	175	226	540	1.03e-10	59.7
GibsonMK_2016_SRR3131800_bin.2_k141_2873_122	SARG|gb|MBW0764195.1|ARO:3007027|salC	28.9	187	226	541	1.88e-10	58.9
GibsonMK_2016_SRR3131800_bin.2_k141_2873_122	SARG|gi|445983936|ref|WP_000061791.1|	22.2	180	226	492	2.45e-10	58.5
GibsonMK_2016_SRR3131800_bin.2_k141_2873_122	SARG|gi|915546417|ref|WP_050844389.1|	22.2	180	226	492	3.31e-10	58.2
GibsonMK_2016_SRR3131800_bin.2_k141_2873_122	SARG|gi|506990141|ref|WP_016080735.1|	22.2	180	226	492	3.31e-10	58.2
GibsonMK_2016_SRR3131800_bin.2_k141_2873_122	SARG|gi|445983937|ref|WP_000061792.1|	22.2	180	226	492	3.31e-10	58.2
GibsonMK_2016_SRR3131800_bin.2_k141_2873_122	SARG|gi|1024915484|ref|WP_063548266.1|	21.7	180	226	492	1.09e-09	56.6
GibsonMK_2016_SRR3131800_bin.2_k141_2873_122	SARG|gi|558693259|ref|WP_023522676.1|	21.1	180	226	492	1.98e-09	55.8
GibsonMK_2016_SRR3131800_bin.2_k141_2873_132	NCBI|CAQ45063.1|1|1|emrA-sm|emrA-sm||1|EFFLUX|EFFLUX|multidrug_efflux_MFS_transporter_periplasmic_adaptor_subunit_EmrA|AMR|efflux	31.7	331	336	393	1.26e-43	153
GibsonMK_2016_SRR3131800_bin.2_k141_2873_132	SARG|gi|896193189|ref|WP_049201850.1|	31.2	349	336	391	1.76e-42	150
GibsonMK_2016_SRR3131800_bin.2_k141_2873_132	SARG|gi|896195525|ref|WP_049203604.1|	31.2	349	336	391	2.46e-42	150
GibsonMK_2016_SRR3131800_bin.2_k141_2873_132	SARG|gi|896186420|ref|WP_049196554.1|	31.2	349	336	391	9.35e-42	148
GibsonMK_2016_SRR3131800_bin.2_k141_2873_132	SARG|gi|896217236|ref|WP_049220241.1|	30.9	349	336	391	9.35e-42	148
GibsonMK_2016_SRR3131800_bin.2_k141_2873_132	SARG|gi|1012702223|ref|WP_062814406.1|	30.9	349	336	391	1.31e-41	148
GibsonMK_2016_SRR3131800_bin.2_k141_2873_132	SARG|gi|490366423|ref|WP_004246087.1|	30.9	349	336	391	1.31e-41	148
GibsonMK_2016_SRR3131800_bin.2_k141_2873_132	SARG|CP004022.1.gene547.p01	30.9	349	336	391	1.31e-41	148
GibsonMK_2016_SRR3131800_bin.2_k141_2873_132	SARG|gi|1036665295|ref|WP_064719275.1|	31.5	349	336	391	9.64e-41	145
GibsonMK_2016_SRR3131800_bin.2_k141_2873_132	SARG|gi|739067214|ref|WP_036938621.1|	30.8	354	336	392	5.30e-39	141
GibsonMK_2016_SRR3131800_bin.2_k141_2873_135	SARG|NC_010410.6003262.p01	29.6	483	499	507	1.49e-69	229
GibsonMK_2016_SRR3131800_bin.2_k141_2873_135	NCBI|CAQ45064.1|1|1|emrB-sm|emrB-sm||1|EFFLUX|EFFLUX|multidrug_efflux_MFS_transporter_permease_subunit_EmrB|AMR|efflux	28.1	488	499	528	3.58e-68	226
GibsonMK_2016_SRR3131800_bin.2_k141_2873_135	SARG|gi|1016518516|ref|WP_063098254.1|	29.4	483	499	507	4.32e-68	226
GibsonMK_2016_SRR3131800_bin.2_k141_2873_135	SARG|gi|496192662|ref|WP_008914998.1|	28.8	497	499	513	3.73e-67	223
GibsonMK_2016_SRR3131800_bin.2_k141_2873_135	SARG|gi|873899935|ref|WP_048606368.1|	29.6	497	499	498	7.21e-67	222
GibsonMK_2016_SRR3131800_bin.2_k141_2873_135	SARG|gi|915327072|ref|WP_050763760.1|	29.2	497	499	499	1.45e-66	221
GibsonMK_2016_SRR3131800_bin.2_k141_2873_135	SARG|gi|828164785|ref|WP_047255785.1|	29.6	497	499	513	3.90e-66	221
GibsonMK_2016_SRR3131800_bin.2_k141_2873_135	SARG|gi|928870254|ref|WP_053909077.1|	28.8	497	499	513	3.90e-66	221
GibsonMK_2016_SRR3131800_bin.2_k141_2873_135	SARG|gi|491055941|ref|WP_004917586.1|	28.8	497	499	498	2.07e-65	218
GibsonMK_2016_SRR3131800_bin.2_k141_2873_135	SARG|gi|916240285|ref|WP_050979645.1|	28.8	497	499	498	2.90e-65	218
GibsonMK_2016_SRR3131800_bin.2_k141_2873_138	NCBI|WP_252944138.1|1|1|almE|almE||2|COLISTIN|COLISTIN|lipid_A_modification_system_glycine--protein_ligase_AlmE|AMR|peptide	31.0	352	600	556	5.94e-39	149
GibsonMK_2016_SRR3131800_bin.2_k141_2873_145	SARG|gi|518299227|ref|WP_019469435.1|	25.4	126	138	139	1.90e-06	43.5
GibsonMK_2016_SRR3131800_bin.2_k141_2873_145	NCBI|WP_053019115.1|1|1|fosS|fosS|thiol_transferase|2|phosphonic	24.6	126	138	138	2.60e-06	43.1
GibsonMK_2016_SRR3131800_bin.2_k141_2873_145	SARG|gi|872022881|emb|CRV27548.1|	27.6	127	138	139	3.66e-06	42.7
GibsonMK_2016_SRR3131800_bin.2_k141_2873_153	CARD|gb|ALH22601.1|ARO:3000620|adeL	42.4	288	303	337	2.34e-71	223
GibsonMK_2016_SRR3131800_bin.2_k141_2873_157	SARG|gi|447195835|ref|WP_001273091.1|	29.4	221	500	306	5.57e-21	92.4
GibsonMK_2016_SRR3131800_bin.2_k141_2873_157	SARG|gi|447195836|ref|WP_001273092.1|	29.0	221	500	306	1.38e-20	91.3
GibsonMK_2016_SRR3131800_bin.2_k141_2873_157	SARG|ZP_04081918	28.1	221	500	306	3.43e-20	90.1
GibsonMK_2016_SRR3131800_bin.2_k141_2873_157	SARG|gi|500448961|gb|EOP61695.1|	28.1	221	500	306	1.55e-19	88.2
GibsonMK_2016_SRR3131800_bin.2_k141_2873_157	SARG|gi|500465078|gb|EOP76697.1|	28.8	222	500	306	2.84e-19	87.4
GibsonMK_2016_SRR3131800_bin.2_k141_2873_157	SARG|gb|AAK76137.1|ARO:3000024|patA	24.4	213	500	564	2.26e-12	68.2
GibsonMK_2016_SRR3131800_bin.2_k141_2873_157	SARG|gb|AYV52072.1|ARO:3002882|lmrD	25.3	221	500	664	4.45e-12	67.4
GibsonMK_2016_SRR3131800_bin.2_k141_2873_157	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	25.7	292	500	579	1.16e-10	62.8
GibsonMK_2016_SRR3131800_bin.2_k141_2873_157	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	25.1	287	500	579	1.54e-10	62.4
GibsonMK_2016_SRR3131800_bin.2_k141_2873_157	SARG|gb|AVI44920.1|ARO:3004470|poxtA	29.3	167	500	542	5.93e-10	60.5
GibsonMK_2016_SRR3131800_bin.2_k141_2873_171	CARD|gb|AAC75429.1|ARO:3000833|evgS	28.5	390	595	1197	2.70e-38	150
GibsonMK_2016_SRR3131800_bin.2_k141_2920_12	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	33.9	248	390	356	6.13e-21	92.0
GibsonMK_2016_SRR3131800_bin.2_k141_2920_12	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	33.9	248	390	356	8.34e-21	91.7
GibsonMK_2016_SRR3131800_bin.2_k141_2920_12	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	33.9	248	390	356	1.13e-20	91.3
GibsonMK_2016_SRR3131800_bin.2_k141_2920_12	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	31.7	259	390	355	2.07e-20	90.5
GibsonMK_2016_SRR3131800_bin.2_k141_2920_12	SARG|BAE96115	31.7	259	390	355	2.07e-20	90.5
GibsonMK_2016_SRR3131800_bin.2_k141_2920_12	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	32.0	247	390	355	3.82e-20	89.7
GibsonMK_2016_SRR3131800_bin.2_k141_2920_12	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	32.0	247	390	355	3.82e-20	89.7
GibsonMK_2016_SRR3131800_bin.2_k141_2920_12	SARG|ACM47285	32.0	247	390	363	4.14e-20	89.7
GibsonMK_2016_SRR3131800_bin.2_k141_2920_12	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	31.9	248	390	346	2.95e-19	87.0
GibsonMK_2016_SRR3131800_bin.2_k141_2920_12	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	33.9	192	390	209	1.38e-17	79.7
GibsonMK_2016_SRR3131800_bin.2_k141_2920_17	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	27.0	222	271	578	1.13e-18	84.3
GibsonMK_2016_SRR3131800_bin.2_k141_2920_17	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	28.4	215	271	579	2.29e-17	80.5
GibsonMK_2016_SRR3131800_bin.2_k141_2920_17	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	27.7	213	271	579	1.39e-16	78.2
GibsonMK_2016_SRR3131800_bin.2_k141_2920_17	SARG|gb|AAK76136.1|ARO:3000025|patB	24.0	221	271	588	2.78e-15	74.3
GibsonMK_2016_SRR3131800_bin.2_k141_2920_17	SARG|gi|664556405|ref|WP_031071225.1|	24.6	224	271	602	1.68e-14	72.0
GibsonMK_2016_SRR3131800_bin.2_k141_2920_17	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	22.0	200	271	550	3.10e-07	50.1
GibsonMK_2016_SRR3131800_bin.2_k141_2920_17	SARG|AXF35727.1	31.5	162	271	497	7.09e-07	48.9
GibsonMK_2016_SRR3131800_bin.2_k141_2920_18	SARG|gi|554685678|ref|WP_023185565.1|	27.2	243	331	648	5.08e-21	92.8
GibsonMK_2016_SRR3131800_bin.2_k141_2920_18	SARG|gi|922019548|ref|WP_053299973.1|	27.2	243	331	648	4.07e-20	90.1
GibsonMK_2016_SRR3131800_bin.2_k141_2920_18	SARG|gi|446048013|ref|WP_000125868.1|	27.6	243	331	648	4.07e-20	90.1
GibsonMK_2016_SRR3131800_bin.2_k141_2920_18	SARG|YP_002044935	27.2	243	331	648	7.37e-20	89.4
GibsonMK_2016_SRR3131800_bin.2_k141_2920_18	SARG|gi|835666879|ref|WP_047606339.1|	27.2	243	331	648	7.37e-20	89.4
GibsonMK_2016_SRR3131800_bin.2_k141_2920_18	SARG|gi|555254264|ref|WP_023237471.1|	27.2	243	331	648	7.37e-20	89.4
GibsonMK_2016_SRR3131800_bin.2_k141_2920_18	SARG|gi|959101689|ref|WP_058107049.1|	27.2	243	331	648	7.37e-20	89.4
GibsonMK_2016_SRR3131800_bin.2_k141_2920_18	SARG|YP_001571041	27.2	243	331	648	7.37e-20	89.4
GibsonMK_2016_SRR3131800_bin.2_k141_2920_18	SARG|gi|960873409|ref|WP_058345546.1|	27.2	243	331	648	7.37e-20	89.4
GibsonMK_2016_SRR3131800_bin.2_k141_2920_18	SARG|gi|923061916|ref|WP_053445667.1|	27.2	243	331	648	7.37e-20	89.4
GibsonMK_2016_SRR3131800_bin.2_k141_2920_32	CARD|gb|AAK37618.1|ARO:3005008|TxR	36.2	307	524	318	3.36e-56	189
GibsonMK_2016_SRR3131800_bin.2_k141_2920_45	SARG|gb|AEH26330.1|ARO:3005009|qacE	56.6	106	107	110	1.34e-37	121
GibsonMK_2016_SRR3131800_bin.2_k141_2920_45	SARG|gb|AAZ42322.1|ARO:3003836|qacH	57.1	105	107	110	1.81e-35	116
GibsonMK_2016_SRR3131800_bin.2_k141_2920_45	SARG|gb|AAG08375.1|ARO:3004038|Pseudomonas	60.4	106	107	110	7.35e-35	114
GibsonMK_2016_SRR3131800_bin.2_k141_2920_45	SARG|ZP_03048536	58.1	105	107	110	6.01e-34	112
GibsonMK_2016_SRR3131800_bin.2_k141_2920_45	SARG|NC_002695.1.913273.p01	57.1	105	107	110	8.52e-34	112
GibsonMK_2016_SRR3131800_bin.2_k141_2920_45	SARG|P23895	57.1	105	107	110	8.52e-34	112
GibsonMK_2016_SRR3131800_bin.2_k141_2920_45	SARG|gi|643599925|ref|WP_025237077.1|	56.2	105	107	110	1.72e-33	111
GibsonMK_2016_SRR3131800_bin.2_k141_2920_45	SARG|gi|116668015|pdb|2I68|A	57.1	105	107	137	1.86e-33	112
GibsonMK_2016_SRR3131800_bin.2_k141_2920_45	SARG|ZP_04003442	57.1	105	107	117	4.23e-33	110
GibsonMK_2016_SRR3131800_bin.2_k141_2920_45	SARG|ABG69871	57.1	105	107	165	1.64e-32	110
GibsonMK_2016_SRR3131800_bin.2_k141_2920_48	SARG|AAD41881	34.3	318	331	323	5.08e-59	191
GibsonMK_2016_SRR3131800_bin.2_k141_2920_48	SARG|gi|552942232|ref|WP_023043160.1|	33.3	318	331	323	1.57e-57	187
GibsonMK_2016_SRR3131800_bin.2_k141_2920_48	SARG|AAD51059	33.6	318	331	323	8.71e-57	186
GibsonMK_2016_SRR3131800_bin.2_k141_2920_48	SARG|AAR37059	33.4	320	331	323	8.71e-57	186
GibsonMK_2016_SRR3131800_bin.2_k141_2920_48	SARG|AY082011.1.gene6.p01	33.0	318	331	323	1.23e-56	185
GibsonMK_2016_SRR3131800_bin.2_k141_2920_48	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	34.8	302	331	323	2.67e-55	182
GibsonMK_2016_SRR3131800_bin.2_k141_2920_48	SARG|AAD42183	33.6	318	331	322	3.66e-55	181
GibsonMK_2016_SRR3131800_bin.2_k141_2920_48	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	34.9	301	331	343	1.38e-53	178
GibsonMK_2016_SRR3131800_bin.2_k141_2920_48	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	34.9	301	331	348	6.11e-53	176
GibsonMK_2016_SRR3131800_bin.2_k141_2920_48	SARG|gi|740152780|ref|WP_037997109.1|	32.4	321	331	322	6.18e-53	176
GibsonMK_2016_SRR3131800_bin.2_k141_2920_60	SARG|gb|AAG05187.1|ARO:3005067|ParS	34.9	375	435	428	6.45e-68	221
GibsonMK_2016_SRR3131800_bin.2_k141_2920_60	CARD|gb|BAB38260.1|ARO:3000830|cpxA	34.5	284	435	457	2.06e-39	146
GibsonMK_2016_SRR3131800_bin.2_k141_2920_60	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	28.2	216	435	357	2.06e-14	73.2
GibsonMK_2016_SRR3131800_bin.2_k141_2920_60	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	28.2	216	435	357	2.06e-14	73.2
GibsonMK_2016_SRR3131800_bin.2_k141_2920_61	CARD|gb|AAG05188.1|ARO:3005068|ParR	45.8	236	242	235	1.99e-67	207
GibsonMK_2016_SRR3131800_bin.2_k141_2920_61	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	39.5	233	242	252	3.14e-48	158
GibsonMK_2016_SRR3131800_bin.2_k141_2920_61	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	31.7	227	242	232	3.20e-36	127
GibsonMK_2016_SRR3131800_bin.2_k141_2920_61	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	31.7	227	242	232	3.20e-36	127
GibsonMK_2016_SRR3131800_bin.2_k141_2920_61	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	33.3	231	242	228	2.25e-35	124
GibsonMK_2016_SRR3131800_bin.2_k141_2920_61	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.5	228	242	231	1.22e-31	115
GibsonMK_2016_SRR3131800_bin.2_k141_2920_61	CARD|gb|AAD51348.1|ARO:3003066|smeR	32.9	231	242	229	1.63e-31	114
GibsonMK_2016_SRR3131800_bin.2_k141_2920_61	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	31.0	226	242	233	7.00e-31	113
GibsonMK_2016_SRR3131800_bin.2_k141_2920_61	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	30.3	234	242	225	1.60e-30	112
GibsonMK_2016_SRR3131800_bin.2_k141_2920_61	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	30.7	231	242	231	1.85e-30	112
GibsonMK_2016_SRR3131800_bin.2_k141_2920_94	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	26.8	231	238	574	1.63e-14	71.2
GibsonMK_2016_SRR3131800_bin.2_k141_2920_94	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	29.3	208	238	255	1.71e-14	69.7
GibsonMK_2016_SRR3131800_bin.2_k141_2920_94	SARG|gb|CDO61516.1|ARO:3003949|efrB	27.5	149	238	362	1.74e-07	50.1
GibsonMK_2016_SRR3131800_bin.2_k141_2920_94	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.8	235	238	655	2.21e-07	50.1
GibsonMK_2016_SRR3131800_bin.2_k141_2920_94	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.8	235	238	655	2.21e-07	50.1
GibsonMK_2016_SRR3131800_bin.2_k141_2920_94	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.8	235	238	655	2.21e-07	50.1
GibsonMK_2016_SRR3131800_bin.2_k141_2920_94	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.4	235	238	655	1.72e-06	47.4
GibsonMK_2016_SRR3131800_bin.2_k141_2920_94	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.4	235	238	655	1.72e-06	47.4
GibsonMK_2016_SRR3131800_bin.2_k141_2920_94	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.4	235	238	655	1.72e-06	47.4
GibsonMK_2016_SRR3131800_bin.2_k141_2920_94	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.4	235	238	655	1.72e-06	47.4
GibsonMK_2016_SRR3131800_bin.2_k141_2920_95	SARG|gi|447195835|ref|WP_001273091.1|	26.3	243	257	306	1.91e-21	90.1
GibsonMK_2016_SRR3131800_bin.2_k141_2920_95	SARG|gi|447195836|ref|WP_001273092.1|	25.9	243	257	306	5.04e-21	89.0
GibsonMK_2016_SRR3131800_bin.2_k141_2920_95	SARG|ZP_04081918	25.5	243	257	306	1.83e-20	87.4
GibsonMK_2016_SRR3131800_bin.2_k141_2920_95	SARG|gi|500194536|ref|WP_011867743.1|	27.7	235	257	306	2.53e-20	87.0
GibsonMK_2016_SRR3131800_bin.2_k141_2920_95	SARG|gi|500465078|gb|EOP76697.1|	26.9	238	257	306	3.49e-20	86.7
GibsonMK_2016_SRR3131800_bin.2_k141_2920_95	SARG|gi|500448961|gb|EOP61695.1|	26.2	237	257	306	9.17e-20	85.5
GibsonMK_2016_SRR3131800_bin.2_k141_2920_95	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	20.5	268	257	255	3.76e-16	74.7
GibsonMK_2016_SRR3131800_bin.2_k141_2920_102	NCBI|WP_011906899.1|1|1|estDL136|estDL136||2|CHLORAMPHENICOL/FLORFENICOL|PHENICOL|phenicol_hydrolase|AMR|phenicol	47.1	310	301	308	2.83e-76	234
GibsonMK_2016_SRR3131800_bin.2_k141_2920_102	megares|MEG_2865|Drugs|Phenicol|Chloramphenicol_hydrolase|ESTD_1	44.3	298	301	310	4.45e-70	218
GibsonMK_2016_SRR3131800_bin.2_k141_2920_106	SARG|NP_348076	27.6	684	702	652	8.74e-75	253
GibsonMK_2016_SRR3131800_bin.2_k141_2920_106	SARG|L42544.gene.p01	27.8	672	702	651	6.15e-74	250
GibsonMK_2016_SRR3131800_bin.2_k141_2920_106	SARG|AAV80410	27.8	672	702	651	1.19e-73	249
GibsonMK_2016_SRR3131800_bin.2_k141_2920_106	SARG|YP_002850805	27.4	676	702	652	3.24e-73	248
GibsonMK_2016_SRR3131800_bin.2_k141_2920_106	SARG|ZP_02952732	27.1	676	702	652	1.65e-71	244
GibsonMK_2016_SRR3131800_bin.2_k141_2920_106	SARG|ZP_02632674	27.1	676	702	660	1.93e-71	244
GibsonMK_2016_SRR3131800_bin.2_k141_2920_106	SARG|L20800.gene.p01	27.1	676	702	652	6.10e-71	242
GibsonMK_2016_SRR3131800_bin.2_k141_2920_106	SARG|AJ514254.gene.p01	26.6	689	702	640	2.90e-64	224
GibsonMK_2016_SRR3131800_bin.2_k141_2920_106	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.5	683	702	629	3.14e-63	221
GibsonMK_2016_SRR3131800_bin.2_k141_2920_106	ResF|tet(O/W)_5_AM889122_1	26.5	683	702	639	3.76e-63	221
GibsonMK_2016_SRR3131800_bin.2_k141_2920_115	NCBI|AAN38824.2|1|1|adeE|adeE|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_AdeE|AMR|efflux	71.5	1035	1035	1036	0.0	1376
GibsonMK_2016_SRR3131800_bin.2_k141_2920_115	CARD|gb|BAA16344.1|ARO:3000491|acrD	55.0	1028	1035	1037	0.0	1045
GibsonMK_2016_SRR3131800_bin.2_k141_2920_115	CARD|gb|AAC73564.1|ARO:3000216|acrB	54.3	1033	1035	1049	0.0	1039
GibsonMK_2016_SRR3131800_bin.2_k141_2920_115	SARG|CAW25151	54.0	1025	1035	1046	0.0	1031
GibsonMK_2016_SRR3131800_bin.2_k141_2920_115	SARG|gi|447196024|ref|WP_001273280.1|	54.4	1034	1035	1037	0.0	1031
GibsonMK_2016_SRR3131800_bin.2_k141_2920_115	SARG|gi|489213017|ref|WP_003121760.1|	54.0	1025	1035	1046	0.0	1030
GibsonMK_2016_SRR3131800_bin.2_k141_2920_115	SARG|gi|237823426|pdb|2V50|A	54.0	1025	1035	1052	0.0	1029
GibsonMK_2016_SRR3131800_bin.2_k141_2920_115	SARG|NC_002516.2.877852.p01	54.0	1025	1035	1046	0.0	1029
GibsonMK_2016_SRR3131800_bin.2_k141_2920_115	SARG|gi|489234352|ref|WP_003142649.1|	54.0	1025	1035	1046	0.0	1028
GibsonMK_2016_SRR3131800_bin.2_k141_2920_115	SARG|gb|AAA74437.1|ARO:3000378|MexB	53.9	1025	1035	1046	0.0	1027
GibsonMK_2016_SRR3131800_bin.2_k141_2920_117	SARG|gb|NP_388442.1|ARO:3004476|vmlR	29.5	511	577	547	1.96e-56	197
GibsonMK_2016_SRR3131800_bin.2_k141_2920_117	SARG|gb|APB03219.1|ARO:3003986|TaeA	27.6	558	577	648	7.22e-50	181
GibsonMK_2016_SRR3131800_bin.2_k141_2920_117	SARG|gb|WP_082039181.1|ARO:3007028|salD	28.0	503	577	544	2.27e-46	170
GibsonMK_2016_SRR3131800_bin.2_k141_2920_117	SARG|AAG08983	28.0	497	577	524	5.91e-46	168
GibsonMK_2016_SRR3131800_bin.2_k141_2920_117	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	28.3	494	577	461	6.63e-45	164
GibsonMK_2016_SRR3131800_bin.2_k141_2920_117	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	28.9	498	577	461	8.59e-44	161
GibsonMK_2016_SRR3131800_bin.2_k141_2920_117	SARG|gb|AEO25219.1|ARO:3004651|lin	27.0	496	577	523	3.33e-43	160
GibsonMK_2016_SRR3131800_bin.2_k141_2920_117	NCBI|WP_000420313.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	26.6	489	577	487	1.97e-40	152
GibsonMK_2016_SRR3131800_bin.2_k141_2920_117	NCBI|WP_000420317.1|1|1|msr(D)|msr(D)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(D)|AMR|multidrug	26.2	489	577	487	5.07e-40	151
GibsonMK_2016_SRR3131800_bin.2_k141_2920_117	SARG|M80346.gene.p01	30.5	534	577	551	6.61e-40	152
GibsonMK_2016_SRR3131800_bin.2_k141_2920_122	SARG|NC_007622.3793623.p01	22.0	191	307	388	4.72e-08	52.8
GibsonMK_2016_SRR3131800_bin.2_k141_2920_133	SARG|gi|487135433|ref|WP_001627390.1|	29.2	120	452	388	1.07e-08	55.8
GibsonMK_2016_SRR3131800_bin.2_k141_2920_133	SARG|gi|1005595863|ref|WP_061683938.1|	29.2	120	452	388	1.07e-08	55.8
GibsonMK_2016_SRR3131800_bin.2_k141_2920_133	SARG|gi|881076539|ref|WP_048792533.1|	28.9	152	452	388	1.89e-08	55.1
GibsonMK_2016_SRR3131800_bin.2_k141_2920_133	SARG|gi|920553663|ref|WP_052999888.1|	29.2	120	452	388	2.51e-08	54.7
GibsonMK_2016_SRR3131800_bin.2_k141_2920_133	SARG|gi|686128012|ref|WP_031771611.1|	25.9	147	452	388	2.51e-08	54.7
GibsonMK_2016_SRR3131800_bin.2_k141_2920_133	SARG|gi|1006176696|ref|WP_061739505.1|	29.2	120	452	388	3.33e-08	54.3
GibsonMK_2016_SRR3131800_bin.2_k141_2920_133	SARG|gi|446964030|ref|WP_001041286.1|	28.3	120	452	388	3.33e-08	54.3
GibsonMK_2016_SRR3131800_bin.2_k141_2920_133	SARG|gi|446964014|ref|WP_001041270.1|	28.3	120	452	388	4.42e-08	53.9
GibsonMK_2016_SRR3131800_bin.2_k141_2920_133	SARG|gi|1006695136|ref|WP_061822033.1|	28.3	120	452	388	4.42e-08	53.9
GibsonMK_2016_SRR3131800_bin.2_k141_2920_133	SARG|gi|1002473411|ref|WP_061389367.1|	26.5	147	452	385	5.81e-08	53.5
GibsonMK_2016_SRR3131800_bin.2_k141_2920_134	NCBI|WP_015031687.1|1|1|rox_sv|rox_sv||2|rifamycin|rifamycin|rifampin_monooxygenase_Rox|AMR|rifamycin	29.1	316	393	476	1.93e-14	73.6
GibsonMK_2016_SRR3131800_bin.2_k141_2920_134	NCBI|WP_011210071.1|1|1|rox_nf|rox_nf||2|RIFAMPIN|rifamycin|rifampin_monooxygenase_Rox|AMR|rifamycin	28.4	331	393	473	1.44e-13	70.9
GibsonMK_2016_SRR3131800_bin.2_k141_2920_134	megares|MEG_6085|Drugs|Rifampin|Monooxygenase|ROX_1	28.4	331	393	473	1.44e-13	70.9
GibsonMK_2016_SRR3131800_bin.2_k141_2920_145	CARD|gb|CAA79966.1|ARO:3003665|NmcR	29.1	285	288	295	3.39e-27	106
GibsonMK_2016_SRR3131800_bin.2_k141_2920_148	SARG|gi|553762722|ref|WP_023095117.1|	56.6	339	381	383	2.00e-113	335
GibsonMK_2016_SRR3131800_bin.2_k141_2920_148	SARG|gi|759812131|ref|WP_043509561.1|	56.3	339	381	383	4.01e-113	334
GibsonMK_2016_SRR3131800_bin.2_k141_2920_148	SARG|gi|896372078|ref|WP_049317199.1|	56.3	339	381	383	5.68e-113	333
GibsonMK_2016_SRR3131800_bin.2_k141_2920_148	SARG|gi|384397570|gb|EIE43981.1|	56.3	339	381	377	6.63e-113	333
GibsonMK_2016_SRR3131800_bin.2_k141_2920_148	SARG|gi|950484392|ref|WP_057379444.1|	56.3	339	381	383	8.05e-113	333
GibsonMK_2016_SRR3131800_bin.2_k141_2920_148	SARG|gi|553772752|ref|WP_023104683.1|	56.3	339	381	383	8.05e-113	333
GibsonMK_2016_SRR3131800_bin.2_k141_2920_148	SARG|gi|553784544|ref|WP_023116004.1|	56.3	339	381	383	8.05e-113	333
GibsonMK_2016_SRR3131800_bin.2_k141_2920_148	SARG|gi|757606897|ref|WP_042853548.1|	56.3	339	381	383	8.05e-113	333
GibsonMK_2016_SRR3131800_bin.2_k141_2920_148	SARG|gi|685985750|ref|WP_031692208.1|	56.3	339	381	383	8.05e-113	333
GibsonMK_2016_SRR3131800_bin.2_k141_2920_148	SARG|NC_002516.2.877855.p01	56.3	339	381	383	8.05e-113	333
GibsonMK_2016_SRR3131800_bin.2_k141_2920_149	SARG|gi|487663012|ref|WP_001752778.1|	59.6	1038	1046	1037	0.0	1150
GibsonMK_2016_SRR3131800_bin.2_k141_2920_149	SARG|gi|447196024|ref|WP_001273280.1|	59.4	1038	1046	1037	0.0	1148
GibsonMK_2016_SRR3131800_bin.2_k141_2920_149	SARG|gi|817604860|ref|WP_046598079.1|	59.4	1038	1046	1037	0.0	1145
GibsonMK_2016_SRR3131800_bin.2_k141_2920_149	SARG|gi|817600095|ref|WP_046594084.1|	59.3	1038	1046	1037	0.0	1145
GibsonMK_2016_SRR3131800_bin.2_k141_2920_149	SARG|gi|694076105|ref|WP_032421853.1|	59.2	1037	1046	1036	0.0	1145
GibsonMK_2016_SRR3131800_bin.2_k141_2920_149	SARG|CP000647.1.gene3710.p01	59.1	1037	1046	1036	0.0	1144
GibsonMK_2016_SRR3131800_bin.2_k141_2920_149	SARG|gi|817600173|ref|WP_046594139.1|	59.3	1038	1046	1037	0.0	1144
GibsonMK_2016_SRR3131800_bin.2_k141_2920_149	SARG|gi|496667122|ref|WP_009309612.1|	59.1	1037	1046	1036	0.0	1144
GibsonMK_2016_SRR3131800_bin.2_k141_2920_149	SARG|gi|817601660|ref|WP_046595348.1|	59.3	1038	1046	1037	0.0	1143
GibsonMK_2016_SRR3131800_bin.2_k141_2920_149	SARG|gi|556290479|ref|WP_023291164.1|	59.0	1037	1046	1036	0.0	1142
GibsonMK_2016_SRR3131800_bin.2_k141_2920_150	SARG|gi|553749675|ref|WP_023082630.1|	44.8	397	475	485	5.21e-93	289
GibsonMK_2016_SRR3131800_bin.2_k141_2920_150	SARG|YP_002083353	44.8	397	475	485	5.21e-93	289
GibsonMK_2016_SRR3131800_bin.2_k141_2920_150	SARG|YP_001345922	44.6	397	475	485	5.21e-93	289
GibsonMK_2016_SRR3131800_bin.2_k141_2920_150	SARG|NC_002516.2.877851.p01	44.6	397	475	485	1.46e-92	288
GibsonMK_2016_SRR3131800_bin.2_k141_2920_150	SARG|gi|553757603|ref|WP_023090259.1|	44.3	397	475	485	8.11e-92	286
GibsonMK_2016_SRR3131800_bin.2_k141_2920_150	NCBI|AAY90615.1|1|1|emhC|emhC||1|EFFLUX|EFFLUX|efflux_RND_transporter_outer_membrane_subunit_EmhC|AMR|efflux	44.1	395	475	486	1.83e-90	283
GibsonMK_2016_SRR3131800_bin.2_k141_2920_150	SARG|NC_008702.1.4606278.p01	44.8	393	475	467	2.12e-90	282
GibsonMK_2016_SRR3131800_bin.2_k141_2920_150	CARD|gb|AAD51346.1|ARO:3003053|smeC	40.5	462	475	471	3.49e-86	271
GibsonMK_2016_SRR3131800_bin.2_k141_2920_150	NCBI|AAQ92182.1|1|1|emhC|emhC||1|EFFLUX|EFFLUX|efflux_RND_transporter_outer_membrane_subunit_EmhC|AMR|efflux	42.3	395	475	486	1.05e-85	270
GibsonMK_2016_SRR3131800_bin.2_k141_2920_150	SARG|gi|475005571|emb|CCP13702.1|	40.2	463	475	471	1.93e-85	269
GibsonMK_2016_SRR3131800_bin.2_k141_2920_153	CARD|gb|AAL19308.1|ARO:3000504|golS	61.2	129	157	154	3.90e-47	149
GibsonMK_2016_SRR3131800_bin.2_k141_2920_155	SARG|gb|BAE06009.1|ARO:3003700|opmE	66.2	462	493	491	5.23e-197	556
GibsonMK_2016_SRR3131800_bin.2_k141_2920_155	SARG|gi|730274062|ref|WP_033966812.1|	35.7	462	493	472	1.62e-73	239
GibsonMK_2016_SRR3131800_bin.2_k141_2920_155	SARG|gi|553774750|ref|WP_023106587.1|	35.5	462	493	472	2.27e-73	238
GibsonMK_2016_SRR3131800_bin.2_k141_2920_155	SARG|gi|504415764|ref|WP_014602866.1|	35.6	464	493	472	3.18e-73	238
GibsonMK_2016_SRR3131800_bin.2_k141_2920_155	SARG|gi|740617797|ref|WP_038403311.1|	35.5	462	493	472	3.18e-73	238
GibsonMK_2016_SRR3131800_bin.2_k141_2920_155	SARG|YP_790742	35.5	462	493	472	4.47e-73	238
GibsonMK_2016_SRR3131800_bin.2_k141_2920_155	SARG|NC_002516.2.882885.p01	35.5	462	493	472	4.47e-73	238
GibsonMK_2016_SRR3131800_bin.2_k141_2920_155	SARG|gi|730611402|ref|WP_034052379.1|	35.5	462	493	472	4.47e-73	238
GibsonMK_2016_SRR3131800_bin.2_k141_2920_155	SARG|gi|553784490|ref|WP_023115951.1|	35.5	462	493	472	4.47e-73	238
GibsonMK_2016_SRR3131800_bin.2_k141_2920_155	SARG|gi|640511711|ref|WP_024947557.1|	35.5	462	493	472	4.47e-73	238
GibsonMK_2016_SRR3131800_bin.2_k141_2920_156	SARG|gb|BAE06008.1|ARO:3003699|mexQ	84.2	1039	1057	1053	0.0	1652
GibsonMK_2016_SRR3131800_bin.2_k141_2920_156	SARG|gb|AAL19305.1|ARO:3000790|mdsB	68.9	1045	1057	1055	0.0	1357
GibsonMK_2016_SRR3131800_bin.2_k141_2920_156	SARG|gi|489273629|ref|WP_003181339.1|	61.5	1049	1057	1059	0.0	1235
GibsonMK_2016_SRR3131800_bin.2_k141_2920_156	SARG|gi|496340078|ref|WP_009049256.1|	61.7	1049	1057	1059	0.0	1234
GibsonMK_2016_SRR3131800_bin.2_k141_2920_156	SARG|gi|496334960|ref|WP_009044138.1|	61.6	1049	1057	1059	0.0	1233
GibsonMK_2016_SRR3131800_bin.2_k141_2920_156	SARG|gi|489294780|ref|WP_003202298.1|	61.4	1049	1057	1059	0.0	1232
GibsonMK_2016_SRR3131800_bin.2_k141_2920_156	SARG|gi|751651551|ref|WP_041118420.1|	61.7	1049	1057	1059	0.0	1231
GibsonMK_2016_SRR3131800_bin.2_k141_2920_156	SARG|YP_260346	61.7	1049	1057	1059	0.0	1231
GibsonMK_2016_SRR3131800_bin.2_k141_2920_156	SARG|gi|985599614|ref|WP_060839111.1|	61.6	1049	1057	1059	0.0	1231
GibsonMK_2016_SRR3131800_bin.2_k141_2920_156	SARG|gi|504104202|ref|WP_014338188.1|	61.7	1049	1057	1059	0.0	1231
GibsonMK_2016_SRR3131800_bin.2_k141_2920_157	SARG|gb|BAE06007.1|ARO:3003698|mexP	62.8	384	387	385	1.23e-161	457
GibsonMK_2016_SRR3131800_bin.2_k141_2920_157	SARG|gb|AAL19306.1|ARO:3000789|mdsA	49.1	381	387	408	1.49e-107	321
GibsonMK_2016_SRR3131800_bin.2_k141_2920_157	SARG|gi|730727091|ref|WP_034083588.1|	42.6	366	387	414	1.98e-86	267
GibsonMK_2016_SRR3131800_bin.2_k141_2920_157	SARG|gi|505289665|ref|WP_015476767.1|	43.3	365	387	411	3.62e-86	266
GibsonMK_2016_SRR3131800_bin.2_k141_2920_157	SARG|gi|515716486|ref|WP_017149086.1|	42.6	366	387	414	5.57e-86	266
GibsonMK_2016_SRR3131800_bin.2_k141_2920_157	SARG|gi|685895166|ref|WP_031636099.1|	42.6	366	387	414	1.11e-85	265
GibsonMK_2016_SRR3131800_bin.2_k141_2920_157	SARG|gi|730265746|ref|WP_033963465.1|	42.6	366	387	414	1.11e-85	265
GibsonMK_2016_SRR3131800_bin.2_k141_2920_157	SARG|gi|550043910|ref|WP_022580473.1|	42.6	366	387	414	1.11e-85	265
GibsonMK_2016_SRR3131800_bin.2_k141_2920_157	SARG|gi|746321235|ref|WP_039367880.1|	40.2	383	387	405	1.21e-85	265
GibsonMK_2016_SRR3131800_bin.2_k141_2920_157	SARG|gi|730340959|ref|WP_033991001.1|	42.3	366	387	414	1.57e-85	265
GibsonMK_2016_SRR3131800_bin.2_k141_2920_166	NCBI|WP_070509550.1|1|1|mef(H)|mef(H)|efflux|2|ERYTHROMYCIN|MACROLIDE|macrolide_efflux_MFS_transporter_Mef(H)|AMR|macrolide	23.4	381	428	412	7.48e-08	53.1
GibsonMK_2016_SRR3131800_bin.2_k141_2920_184	megares|MEG_1246|Drugs|beta-lactam|Class_A_betalactamases|BLAA_1	58.7	317	341	339	9.53e-148	419
GibsonMK_2016_SRR3131800_bin.2_k141_2920_190	SARG|gb|AAF40763.1|ARO:3003961|farA	31.0	248	292	384	2.79e-17	80.1
GibsonMK_2016_SRR3131800_bin.2_k141_2920_190	SARG|gi|1036665295|ref|WP_064719275.1|	34.6	133	292	391	2.44e-16	77.4
GibsonMK_2016_SRR3131800_bin.2_k141_2920_190	SARG|gi|740320274|ref|WP_038157440.1|	34.3	134	292	390	1.11e-15	75.5
GibsonMK_2016_SRR3131800_bin.2_k141_2920_190	SARG|gi|1033042764|ref|WP_064355128.1|	34.8	132	292	365	3.29e-15	73.9
GibsonMK_2016_SRR3131800_bin.2_k141_2920_190	SARG|gi|1033088368|ref|WP_064397954.1|	34.8	132	292	390	3.70e-15	73.9
GibsonMK_2016_SRR3131800_bin.2_k141_2920_190	SARG|gi|1033061324|ref|WP_064372453.1|	34.8	132	292	390	3.70e-15	73.9
GibsonMK_2016_SRR3131800_bin.2_k141_2920_190	SARG|gi|930176935|ref|WP_054177683.1|	32.8	134	292	390	3.70e-15	73.9
GibsonMK_2016_SRR3131800_bin.2_k141_2920_190	SARG|gi|739067214|ref|WP_036938621.1|	33.3	132	292	392	3.73e-15	73.9
GibsonMK_2016_SRR3131800_bin.2_k141_2920_190	SARG|gi|1035701600|ref|WP_064543230.1|	34.1	132	292	390	4.99e-15	73.6
GibsonMK_2016_SRR3131800_bin.2_k141_2920_190	SARG|gi|896186420|ref|WP_049196554.1|	33.3	132	292	391	6.77e-15	73.2
GibsonMK_2016_SRR3131800_bin.2_k141_2920_203	CARD|gb|AAG05661.1|ARO:3004107|Paer_soxR	37.3	67	141	156	6.94e-08	47.8
GibsonMK_2016_SRR3131800_bin.2_k141_2920_240	SARG|CP001581.1.gene725.p01	28.6	451	459	477	7.04e-42	154
GibsonMK_2016_SRR3131800_bin.2_k141_2920_240	SARG|JQ768046.1.gene8.p1	28.4	444	459	559	6.85e-30	121
GibsonMK_2016_SRR3131800_bin.2_k141_2920_240	SARG|YP_001486998	24.3	407	459	530	1.09e-21	96.7
GibsonMK_2016_SRR3131800_bin.2_k141_2920_240	SARG|ZP_03053667	24.1	407	459	506	3.19e-21	95.1
GibsonMK_2016_SRR3131800_bin.2_k141_2920_240	SARG|BAA07390	29.8	430	459	512	4.58e-18	85.5
GibsonMK_2016_SRR3131800_bin.2_k141_2920_240	SARG|gb|CCP45647.1|ARO:3003955|efpA	30.5	249	459	530	8.47e-17	81.6
GibsonMK_2016_SRR3131800_bin.2_k141_2920_240	SARG|AAD04032	28.4	457	459	563	2.09e-15	77.4
GibsonMK_2016_SRR3131800_bin.2_k141_2920_240	megares|MEG_4381|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|OTRB_1	28.4	457	459	563	2.09e-15	77.4
GibsonMK_2016_SRR3131800_bin.2_k141_2920_240	SARG|AAC15775	28.4	433	459	536	4.66e-15	76.3
GibsonMK_2016_SRR3131800_bin.2_k141_2920_240	megares|MEG_4380|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|OTRB_1	28.4	457	459	563	4.90e-15	76.3
GibsonMK_2016_SRR3131800_bin.2_k141_2920_250	ResF|penA_1_AF515059_1	31.2	536	550	581	6.78e-85	273
GibsonMK_2016_SRR3131800_bin.2_k141_2920_251	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	60.3	612	642	633	5.97e-265	740
GibsonMK_2016_SRR3131800_bin.2_k141_2920_251	ResF|penA_1_AF515059_1	23.1	614	642	581	7.58e-27	114
GibsonMK_2016_SRR3131800_bin.2_k141_2920_254	CARD|gb|ABV18113.1|ARO:3001329|mdtG	64.0	381	400	408	1.02e-164	467
GibsonMK_2016_SRR3131800_bin.2_k141_2920_254	SARG|WP_000136147.1	41.8	395	400	399	9.47e-99	298
GibsonMK_2016_SRR3131800_bin.2_k141_2920_254	NCBI|EHE72460.1|1|1|pmrA|pmrA|efflux|1|quinolone|quinolone|multidrug_efflux_MFS_transporter_PmrA|AMR|quinolone	40.0	395	400	371	2.65e-88	271
GibsonMK_2016_SRR3131800_bin.2_k141_2920_254	SARG|CAD11599	27.1	376	400	399	3.09e-18	84.7
GibsonMK_2016_SRR3131800_bin.2_k141_2920_254	megares|MEG_7028|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|TETA_1	27.1	376	400	399	3.09e-18	84.7
GibsonMK_2016_SRR3131800_bin.2_k141_2920_254	SARG|gi|692946992|ref|WP_032140893.1|	27.1	376	400	399	7.53e-18	83.6
GibsonMK_2016_SRR3131800_bin.2_k141_2920_254	SARG|gi|960294978|ref|WP_058214444.1|	26.9	376	400	399	1.01e-17	83.2
GibsonMK_2016_SRR3131800_bin.2_k141_2920_254	SARG|gi|922044596|ref|WP_053320764.1|	26.9	376	400	399	1.36e-17	82.8
GibsonMK_2016_SRR3131800_bin.2_k141_2920_254	SARG|ABS19068	27.2	389	400	399	1.36e-17	82.8
GibsonMK_2016_SRR3131800_bin.2_k141_2920_254	megares|MEG_7021|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|TETA_1	27.2	389	400	399	1.36e-17	82.8
GibsonMK_2016_SRR3131800_bin.2_k141_3130_1	CARD|gb|AAC16242.1|ARO:3005069|rsmA	85.2	61	62	61	6.51e-31	101
GibsonMK_2016_SRR3131800_bin.2_k141_3130_28	SARG|gi|491270241|ref|WP_005128370.1|	37.3	228	241	648	2.52e-41	148
GibsonMK_2016_SRR3131800_bin.2_k141_3130_28	SARG|gi|851902043|ref|WP_048212057.1|	37.3	228	241	648	2.52e-41	148
GibsonMK_2016_SRR3131800_bin.2_k141_3130_28	SARG|gi|992380339|ref|WP_061067665.1|	37.3	228	241	648	2.52e-41	148
GibsonMK_2016_SRR3131800_bin.2_k141_3130_28	SARG|gi|1022698495|ref|WP_063449190.1|	39.0	213	241	646	3.21e-40	145
GibsonMK_2016_SRR3131800_bin.2_k141_3130_28	SARG|gi|1028112073|ref|WP_063866263.1|	39.0	213	241	646	6.09e-40	144
GibsonMK_2016_SRR3131800_bin.2_k141_3130_28	SARG|gi|829908959|ref|WP_047362283.1|	38.3	214	241	646	8.38e-40	144
GibsonMK_2016_SRR3131800_bin.2_k141_3130_28	SARG|gi|1006477526|ref|WP_061771940.1|	38.3	214	241	646	8.38e-40	144
GibsonMK_2016_SRR3131800_bin.2_k141_3130_28	SARG|gi|1032819400|ref|WP_064325534.1|	36.7	229	241	646	1.15e-39	143
GibsonMK_2016_SRR3131800_bin.2_k141_3130_28	SARG|gi|779850732|ref|WP_045348329.1|	38.5	213	241	646	1.15e-39	143
GibsonMK_2016_SRR3131800_bin.2_k141_3130_28	SARG|gi|1028090136|ref|WP_063847814.1|	38.5	213	241	646	1.59e-39	143
GibsonMK_2016_SRR3131800_bin.2_k141_3130_40	SARG|ZP_03053667	30.9	162	447	506	1.16e-11	65.5
GibsonMK_2016_SRR3131800_bin.2_k141_3130_40	SARG|YP_001486998	31.4	137	447	530	1.60e-11	65.1
GibsonMK_2016_SRR3131800_bin.2_k141_3130_40	SARG|CAB12101	29.2	161	447	512	4.79e-11	63.5
GibsonMK_2016_SRR3131800_bin.2_k141_3130_40	SARG|gb|ALV80601.1|ARO:3003801|bcr-1	35.0	137	447	402	1.16e-10	62.0
GibsonMK_2016_SRR3131800_bin.2_k141_3130_40	SARG|YP_001419960	28.6	161	447	510	1.96e-10	61.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_40	NCBI|WP_115421099.1|1|1|cml_Ensi|cml_Ensi|efflux|2|CHLORAMPHENICOL|PHENICOL|Cml_family_phenicol_efflux_MFS_transporter|AMR|phenicol	28.5	172	447	400	6.15e-09	56.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_40	megares|MEG_8021|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CML_1	28.5	172	447	400	6.15e-09	56.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_40	megares|MEG_8019|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CML_1	27.7	166	447	411	6.33e-09	56.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_40	NCBI|WP_011552636.1|1|1|cml_Myxo|cml_Myxo|efflux|2|CHLORAMPHENICOL|PHENICOL|Cml_family_phenicol_efflux_MFS_transporter|AMR|phenicol	27.7	166	447	411	6.33e-09	56.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_40	SARG|gi|730661043|ref|WP_034065992.1|	27.2	169	447	404	3.40e-08	54.3
GibsonMK_2016_SRR3131800_bin.2_k141_3130_52	CARD|gb|AAC75429.1|ARO:3000833|evgS	28.6	426	909	1197	1.63e-30	129
GibsonMK_2016_SRR3131800_bin.2_k141_3130_52	CARD|gb|AAD51347.1|ARO:3003067|smeS	24.7	304	909	467	2.64e-16	81.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_52	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	29.8	114	909	231	2.09e-10	60.8
GibsonMK_2016_SRR3131800_bin.2_k141_3130_52	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	28.3	138	909	232	5.18e-10	59.7
GibsonMK_2016_SRR3131800_bin.2_k141_3130_52	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	29.8	104	909	233	1.98e-07	52.0
GibsonMK_2016_SRR3131800_bin.2_k141_3130_52	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	28.8	104	909	235	2.02e-07	52.0
GibsonMK_2016_SRR3131800_bin.2_k141_3130_52	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	27.1	107	909	232	6.35e-07	50.4
GibsonMK_2016_SRR3131800_bin.2_k141_3130_52	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	27.2	103	909	232	8.53e-07	50.1
GibsonMK_2016_SRR3131800_bin.2_k141_3130_52	CARD|gb|ADM92605.1|ARO:3000553|adeR	26.9	104	909	247	1.32e-06	49.7
GibsonMK_2016_SRR3131800_bin.2_k141_3130_52	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	29.0	107	909	231	3.67e-06	48.1
GibsonMK_2016_SRR3131800_bin.2_k141_3130_80	SARG|DQ212986.1.gene8.p01	35.3	346	307	349	1.85e-51	172
GibsonMK_2016_SRR3131800_bin.2_k141_3130_80	SARG|gi|405945042|pdb|4FU0|A	35.3	346	307	357	2.25e-51	172
GibsonMK_2016_SRR3131800_bin.2_k141_3130_80	SARG|gi|765411304|ref|WP_044689514.1|	35.3	346	307	349	3.65e-51	171
GibsonMK_2016_SRR3131800_bin.2_k141_3130_80	SARG|AAF71281	35.0	346	307	349	1.02e-50	170
GibsonMK_2016_SRR3131800_bin.2_k141_3130_80	SARG|gi|752682279|ref|WP_041330231.1|	33.8	346	307	349	7.83e-50	167
GibsonMK_2016_SRR3131800_bin.2_k141_3130_80	SARG|gi|1028100561|ref|WP_063856696.1|	33.8	346	307	349	7.83e-50	167
GibsonMK_2016_SRR3131800_bin.2_k141_3130_80	SARG|gi|355380870|gb|EHG28002.1|	32.9	343	307	344	7.51e-49	165
GibsonMK_2016_SRR3131800_bin.2_k141_3130_80	SARG|gi|257803688|gb|EEV32510.1|	32.9	343	307	344	7.51e-49	165
GibsonMK_2016_SRR3131800_bin.2_k141_3130_80	SARG|gi|1028100552|ref|WP_063856687.1|	32.9	340	307	343	1.45e-48	164
GibsonMK_2016_SRR3131800_bin.2_k141_3130_80	SARG|gi|748755610|ref|WP_040013725.1|	32.9	340	307	343	2.03e-48	164
GibsonMK_2016_SRR3131800_bin.2_k141_3130_88	ResF|penA_1_AF515059_1	38.8	546	588	581	1.05e-129	391
GibsonMK_2016_SRR3131800_bin.2_k141_3130_88	SARG|gi|686322767|ref|WP_031876626.1|	22.0	545	588	668	5.83e-19	89.7
GibsonMK_2016_SRR3131800_bin.2_k141_3130_88	SARG|gi|686195077|ref|WP_031806544.1|	22.0	545	588	668	1.02e-18	89.0
GibsonMK_2016_SRR3131800_bin.2_k141_3130_88	SARG|gi|686288520|ref|WP_031860875.1|	21.8	545	588	668	1.02e-18	89.0
GibsonMK_2016_SRR3131800_bin.2_k141_3130_88	SARG|gi|686132960|ref|WP_031774065.1|	21.8	545	588	668	1.02e-18	89.0
GibsonMK_2016_SRR3131800_bin.2_k141_3130_88	SARG|gi|446643961|ref|WP_000721307.1|	21.8	545	588	668	1.35e-18	88.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_88	SARG|gi|686196719|ref|WP_031807381.1|	22.0	545	588	668	1.35e-18	88.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_88	SARG|gi|486697816|ref|WP_001620256.1|	21.8	545	588	668	1.79e-18	88.2
GibsonMK_2016_SRR3131800_bin.2_k141_3130_88	SARG|gi|916178542|ref|WP_050963202.1|	21.8	545	588	668	1.79e-18	88.2
GibsonMK_2016_SRR3131800_bin.2_k141_3130_88	SARG|gi|487387906|ref|WP_001659608.1|	21.8	545	588	668	2.37e-18	87.8
GibsonMK_2016_SRR3131800_bin.2_k141_3130_97	CARD|gb|VWQ00850.1|ARO:3003843|leuO	57.3	309	316	314	2.97e-117	339
GibsonMK_2016_SRR3131800_bin.2_k141_3130_108	SARG|gb|AAK76136.1|ARO:3000025|patB	25.5	208	235	588	7.45e-10	57.4
GibsonMK_2016_SRR3131800_bin.2_k141_3130_108	SARG|gb|AYV52072.1|ARO:3002882|lmrD	24.3	214	235	664	1.40e-09	56.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_108	SARG|gb|CDO61516.1|ARO:3003949|efrB	28.3	180	235	362	2.83e-08	52.4
GibsonMK_2016_SRR3131800_bin.2_k141_3130_116	CARD|gb|AIA35096.1|ARO:3005059|LptD	67.8	760	757	782	0.0	1077
GibsonMK_2016_SRR3131800_bin.2_k141_3130_119	SARG|NC_007792.3912746.p01	28.0	257	273	244	6.13e-17	77.0
GibsonMK_2016_SRR3131800_bin.2_k141_3130_119	SARG|P13978	27.6	257	273	244	4.18e-16	74.7
GibsonMK_2016_SRR3131800_bin.2_k141_3130_119	SARG|NP_040462	27.6	257	273	244	4.18e-16	74.7
GibsonMK_2016_SRR3131800_bin.2_k141_3130_119	SARG|gi|503924494|ref|WP_014158488.1|	27.2	257	273	244	5.76e-16	74.3
GibsonMK_2016_SRR3131800_bin.2_k141_3130_119	SARG|CAJ43792	28.0	254	273	244	5.76e-16	74.3
GibsonMK_2016_SRR3131800_bin.2_k141_3130_119	NCBI|WP_011276921.1|1|1|erm(C)|erm(C)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B/TYLOSIN|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(C)|AMR|multidrug	27.6	257	273	244	5.76e-16	74.3
GibsonMK_2016_SRR3131800_bin.2_k141_3130_119	SARG|gi|157058876|gb|ABV03165.1|	27.6	257	273	244	5.76e-16	74.3
GibsonMK_2016_SRR3131800_bin.2_k141_3130_119	SARG|NC_010686.6295746.p01	27.6	257	273	244	5.76e-16	74.3
GibsonMK_2016_SRR3131800_bin.2_k141_3130_119	SARG|gi|353127769|gb|AEQ67361.1|	27.6	257	273	244	5.76e-16	74.3
GibsonMK_2016_SRR3131800_bin.2_k141_3130_119	SARG|CAA70207	27.6	257	273	244	5.76e-16	74.3
GibsonMK_2016_SRR3131800_bin.2_k141_3130_123	SARG|gb|AAA25550.1|ARO:3003105|dfrA3	58.4	161	161	162	7.21e-60	182
GibsonMK_2016_SRR3131800_bin.2_k141_3130_123	SARG|gb|ABO40886.1|ARO:3004645|dfrI	48.1	160	161	191	4.47e-45	145
GibsonMK_2016_SRR3131800_bin.2_k141_3130_123	SARG|CAL48457	42.7	164	161	183	1.95e-39	130
GibsonMK_2016_SRR3131800_bin.2_k141_3130_123	NCBI|WP_434062363.1|1|1|dfrA53|dfrA53|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA53|AMR|diaminopyrimidine	40.6	160	161	166	1.26e-36	123
GibsonMK_2016_SRR3131800_bin.2_k141_3130_123	SARG|gb|ASF80997.1|ARO:3005164|dfrA35	42.8	138	161	170	8.00e-36	121
GibsonMK_2016_SRR3131800_bin.2_k141_3130_123	NCBI|WP_012655890.1|1|1|dfrE|dfrE|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrE|AMR|diaminopyrimidine	46.1	141	161	164	9.55e-36	120
GibsonMK_2016_SRR3131800_bin.2_k141_3130_123	SARG|gb|AAO04716.1|ARO:3002865|dfrC	39.8	161	161	161	1.61e-33	115
GibsonMK_2016_SRR3131800_bin.2_k141_3130_123	NCBI|WP_000175735.1|1|1|dfrS1|dfrC|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrS1|AMR|diaminopyrimidine	39.8	161	161	161	2.27e-33	114
GibsonMK_2016_SRR3131800_bin.2_k141_3130_123	SARG|CAX16467	41.7	151	161	165	3.25e-31	109
GibsonMK_2016_SRR3131800_bin.2_k141_3130_123	SARG|gb|CAF31623.1|ARO:3005354|dfr22	42.4	151	161	165	3.25e-31	109
GibsonMK_2016_SRR3131800_bin.2_k141_3130_127	SARG|AAS61092	28.9	501	618	563	5.69e-50	181
GibsonMK_2016_SRR3131800_bin.2_k141_3130_127	SARG|YP_001605795	29.1	501	618	562	3.78e-49	179
GibsonMK_2016_SRR3131800_bin.2_k141_3130_127	SARG|ZP_04631861	29.7	498	618	543	5.23e-49	178
GibsonMK_2016_SRR3131800_bin.2_k141_3130_127	SARG|YP_001401994	28.7	501	618	563	5.28e-49	178
GibsonMK_2016_SRR3131800_bin.2_k141_3130_127	SARG|ZP_04623897	29.5	498	618	543	2.57e-48	176
GibsonMK_2016_SRR3131800_bin.2_k141_3130_127	SARG|ZP_04612557	29.4	493	618	543	3.54e-48	176
GibsonMK_2016_SRR3131800_bin.2_k141_3130_127	SARG|ZP_04638974	29.4	504	618	563	9.18e-48	175
GibsonMK_2016_SRR3131800_bin.2_k141_3130_127	SARG|YP_001007250	29.4	504	618	563	2.37e-47	174
GibsonMK_2016_SRR3131800_bin.2_k141_3130_127	SARG|ZP_04635128	29.7	498	618	543	2.38e-47	173
GibsonMK_2016_SRR3131800_bin.2_k141_3130_127	SARG|gi|318604694|emb|CBY26192.1|	29.3	495	618	540	4.27e-47	172
GibsonMK_2016_SRR3131800_bin.2_k141_3130_135	megares|MEG_1992|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	29.9	134	309	291	9.56e-11	60.5
GibsonMK_2016_SRR3131800_bin.2_k141_3130_146	SARG|gb|ABO11759.2|ARO:3004573|Acinetobacter	27.8	414	436	429	2.69e-44	159
GibsonMK_2016_SRR3131800_bin.2_k141_3130_155	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	35.5	242	239	252	2.81e-45	150
GibsonMK_2016_SRR3131800_bin.2_k141_3130_155	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	36.6	227	239	229	9.15e-41	138
GibsonMK_2016_SRR3131800_bin.2_k141_3130_155	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.4	227	239	231	3.65e-37	129
GibsonMK_2016_SRR3131800_bin.2_k141_3130_155	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.9	227	239	231	7.25e-37	128
GibsonMK_2016_SRR3131800_bin.2_k141_3130_155	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	32.5	228	239	235	1.13e-36	128
GibsonMK_2016_SRR3131800_bin.2_k141_3130_155	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.5	227	239	231	2.85e-36	127
GibsonMK_2016_SRR3131800_bin.2_k141_3130_155	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	33.0	230	239	239	1.37e-35	125
GibsonMK_2016_SRR3131800_bin.2_k141_3130_155	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	31.7	227	239	231	1.58e-35	125
GibsonMK_2016_SRR3131800_bin.2_k141_3130_155	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	31.7	227	239	231	1.58e-35	125
GibsonMK_2016_SRR3131800_bin.2_k141_3130_155	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	31.6	234	239	231	3.13e-35	124
GibsonMK_2016_SRR3131800_bin.2_k141_3130_157	megares|MEG_7070|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|TETD_1	60.0	105	290	138	7.10e-39	132
GibsonMK_2016_SRR3131800_bin.2_k141_3130_157	CARD|gb|BAA15221.2|ARO:3000263|marA	50.0	98	290	127	6.35e-29	106
GibsonMK_2016_SRR3131800_bin.2_k141_3130_157	CARD|gb|AFK13828.1|ARO:3000823|ramA	47.2	108	290	124	1.61e-28	105
GibsonMK_2016_SRR3131800_bin.2_k141_3130_165	SARG|gb|APB03219.1|ARO:3003986|TaeA	41.1	509	556	648	1.29e-116	358
GibsonMK_2016_SRR3131800_bin.2_k141_3130_165	SARG|M80346.gene.p01	33.5	541	556	551	2.43e-67	226
GibsonMK_2016_SRR3131800_bin.2_k141_3130_165	megares|MEG_1491|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|CARA_1	33.5	541	556	551	2.43e-67	226
GibsonMK_2016_SRR3131800_bin.2_k141_3130_165	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.2	534	556	655	2.69e-67	229
GibsonMK_2016_SRR3131800_bin.2_k141_3130_165	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.7	539	556	655	3.75e-67	228
GibsonMK_2016_SRR3131800_bin.2_k141_3130_165	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.7	539	556	655	3.75e-67	228
GibsonMK_2016_SRR3131800_bin.2_k141_3130_165	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.7	539	556	655	3.75e-67	228
GibsonMK_2016_SRR3131800_bin.2_k141_3130_165	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.7	539	556	655	3.75e-67	228
GibsonMK_2016_SRR3131800_bin.2_k141_3130_165	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.7	539	556	655	3.75e-67	228
GibsonMK_2016_SRR3131800_bin.2_k141_3130_165	SARG|gb|AKA86814|ARO:3003746|optrA	32.7	539	556	655	3.75e-67	228
GibsonMK_2016_SRR3131800_bin.2_k141_3130_187	SARG|gi|672386269|gb|AIJ27535.1|	26.2	451	530	639	1.82e-38	148
GibsonMK_2016_SRR3131800_bin.2_k141_3130_187	SARG|AAR29485	26.2	451	530	639	2.48e-38	147
GibsonMK_2016_SRR3131800_bin.2_k141_3130_187	SARG|gi|544707441|ref|WP_021137831.1|	26.2	451	530	639	2.48e-38	147
GibsonMK_2016_SRR3131800_bin.2_k141_3130_187	SARG|gi|319894056|gb|ADV76307.1|	26.8	447	530	639	1.14e-37	145
GibsonMK_2016_SRR3131800_bin.2_k141_3130_187	SARG|ABB70054	26.6	447	530	639	2.85e-37	144
GibsonMK_2016_SRR3131800_bin.2_k141_3130_187	SARG|ABI81214	26.6	447	530	639	2.85e-37	144
GibsonMK_2016_SRR3131800_bin.2_k141_3130_187	SARG|YP_002738300	26.6	447	530	639	2.85e-37	144
GibsonMK_2016_SRR3131800_bin.2_k141_3130_187	SARG|X04388.gene.p01	26.8	447	530	639	2.85e-37	144
GibsonMK_2016_SRR3131800_bin.2_k141_3130_187	SARG|BAB71968	26.4	447	530	639	9.62e-37	143
GibsonMK_2016_SRR3131800_bin.2_k141_3130_187	megares|MEG_7165|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.4	449	530	639	2.69e-35	139
GibsonMK_2016_SRR3131800_bin.2_k141_3130_192	CARD|gb|ALH22601.1|ARO:3000620|adeL	43.3	289	315	337	5.51e-73	227
GibsonMK_2016_SRR3131800_bin.2_k141_3130_198	CARD|gb|ALH22601.1|ARO:3000620|adeL	37.7	289	304	337	1.56e-56	184
GibsonMK_2016_SRR3131800_bin.2_k141_3130_208	megares|MEG_729|Drugs|beta-lactam|Penicillin_binding_protein|AMPH_1	65.8	371	381	385	9.03e-165	465
GibsonMK_2016_SRR3131800_bin.2_k141_3130_208	megares|MEG_730|Drugs|beta-lactam|Penicillin_binding_protein|AMPH_1	64.2	374	381	386	6.37e-158	448
GibsonMK_2016_SRR3131800_bin.2_k141_3130_208	SARG|AB300358.1.gene1.p01	25.9	355	381	381	5.58e-18	83.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_208	SARG|AAM11668	25.1	359	381	381	5.58e-18	83.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_208	SARG|JQ733575.1.gene2.p01	25.1	359	381	381	7.53e-18	83.2
GibsonMK_2016_SRR3131800_bin.2_k141_3130_208	SARG|HE819404.1.gene1.p01	25.1	359	381	381	7.53e-18	83.2
GibsonMK_2016_SRR3131800_bin.2_k141_3130_208	SARG|P05193	25.1	359	381	381	7.53e-18	83.2
GibsonMK_2016_SRR3131800_bin.2_k141_3130_208	SARG|gb|AKO62865.1|ARO:3003136|CMY-128	25.1	359	381	381	1.37e-17	82.4
GibsonMK_2016_SRR3131800_bin.2_k141_3130_208	SARG|gb|WP_109791215.1|ARO:3005183|CMY-160	25.6	359	381	381	1.85e-17	82.0
GibsonMK_2016_SRR3131800_bin.2_k141_3130_208	SARG|DQ463751.1.gene1.p01	25.6	359	381	381	1.85e-17	82.0
GibsonMK_2016_SRR3131800_bin.2_k141_3130_238	megares|MEG_1992|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	41.3	63	310	291	3.78e-06	46.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_250	CARD|gb|BAA15221.2|ARO:3000263|marA	49.0	98	292	127	3.37e-29	107
GibsonMK_2016_SRR3131800_bin.2_k141_3130_260	CARD|gb|ALH22601.1|ARO:3000620|adeL	28.7	143	306	337	2.87e-10	59.3
GibsonMK_2016_SRR3131800_bin.2_k141_3130_271	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	26.2	202	264	578	8.77e-14	69.7
GibsonMK_2016_SRR3131800_bin.2_k141_3130_271	SARG|gb|AVI44920.1|ARO:3004470|poxtA	26.2	221	264	542	3.42e-10	58.9
GibsonMK_2016_SRR3131800_bin.2_k141_3130_271	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	26.2	221	264	544	3.43e-10	58.9
GibsonMK_2016_SRR3131800_bin.2_k141_3130_272	SARG|gb|CAA09666.1|ARO:3004122|Klebsiella	50.8	378	361	374	3.29e-125	363
GibsonMK_2016_SRR3131800_bin.2_k141_3130_272	megares|MEG_4285|Drugs|beta-lactam|Mutant_porin_proteins|OMPD_1	44.1	363	361	357	5.99e-90	273
GibsonMK_2016_SRR3131800_bin.2_k141_3130_273	SARG|gb|AVI44920.1|ARO:3004470|poxtA	23.0	269	260	542	1.34e-10	60.1
GibsonMK_2016_SRR3131800_bin.2_k141_3130_273	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	23.0	269	260	544	1.34e-10	60.1
GibsonMK_2016_SRR3131800_bin.2_k141_3130_311	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	22.1	894	959	1033	5.37e-54	203
GibsonMK_2016_SRR3131800_bin.2_k141_3130_311	SARG|gb|AEY83581|ARO:3000510|mupB	22.1	894	959	1033	5.37e-54	203
GibsonMK_2016_SRR3131800_bin.2_k141_3130_311	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	23.3	853	959	1024	1.79e-46	179
GibsonMK_2016_SRR3131800_bin.2_k141_3130_311	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.3	853	959	1024	1.79e-46	179
GibsonMK_2016_SRR3131800_bin.2_k141_3130_311	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.3	853	959	1024	5.53e-46	178
GibsonMK_2016_SRR3131800_bin.2_k141_3130_311	SARG|gb|CAA53189|ARO:3000521|mupA	23.3	853	959	1024	5.53e-46	178
GibsonMK_2016_SRR3131800_bin.2_k141_3130_328	CARD|gb|CAA79966.1|ARO:3003665|NmcR	34.5	139	305	295	2.29e-13	68.2
GibsonMK_2016_SRR3131800_bin.2_k141_3130_341	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	30.7	231	263	343	2.48e-21	90.5
GibsonMK_2016_SRR3131800_bin.2_k141_3130_341	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	31.2	221	263	293	5.64e-18	80.5
GibsonMK_2016_SRR3131800_bin.2_k141_3130_341	SARG|gb|AAA26793|ARO:3003748|oleC	27.9	229	263	325	1.09e-17	80.1
GibsonMK_2016_SRR3131800_bin.2_k141_3130_341	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	27.9	229	263	325	1.49e-17	79.7
GibsonMK_2016_SRR3131800_bin.2_k141_3130_341	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	25.9	239	263	351	2.13e-12	65.1
GibsonMK_2016_SRR3131800_bin.2_k141_3130_341	SARG|gb|AAR96051.1|ARO:3002894|otrC	25.9	239	263	351	2.87e-12	64.7
GibsonMK_2016_SRR3131800_bin.2_k141_3130_342	SARG|gi|926400371|ref|WP_053728483.1|	31.8	192	235	603	1.56e-11	62.4
GibsonMK_2016_SRR3131800_bin.2_k141_3130_342	SARG|gi|748767925|ref|WP_040019608.1|	31.6	193	235	623	3.85e-11	61.2
GibsonMK_2016_SRR3131800_bin.2_k141_3130_342	SARG|gi|754608317|ref|WP_041998010.1|	32.1	196	235	612	5.17e-11	60.8
GibsonMK_2016_SRR3131800_bin.2_k141_3130_342	SARG|gi|944009777|ref|WP_055601444.1|	31.3	195	235	628	5.21e-11	60.8
GibsonMK_2016_SRR3131800_bin.2_k141_3130_342	SARG|gi|664170108|ref|WP_030704355.1|	31.4	191	235	603	9.34e-11	60.1
GibsonMK_2016_SRR3131800_bin.2_k141_3130_342	SARG|gi|501350226|ref|WP_012381861.1|	31.4	191	235	603	9.34e-11	60.1
GibsonMK_2016_SRR3131800_bin.2_k141_3130_342	SARG|gi|490068471|ref|WP_003970646.1|	31.4	191	235	603	9.34e-11	60.1
GibsonMK_2016_SRR3131800_bin.2_k141_3130_342	SARG|gi|702897513|ref|WP_033300957.1|	31.3	195	235	601	1.26e-10	59.7
GibsonMK_2016_SRR3131800_bin.2_k141_3130_342	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	26.6	184	235	574	1.67e-10	59.3
GibsonMK_2016_SRR3131800_bin.2_k141_3130_342	SARG|gi|517787730|ref|WP_018957938.1|	31.6	196	235	610	1.70e-10	59.3
GibsonMK_2016_SRR3131800_bin.2_k141_3130_345	SARG|ABF20240	36.3	171	201	210	3.11e-24	94.0
GibsonMK_2016_SRR3131800_bin.2_k141_3130_345	SARG|ACD03314	35.7	171	201	210	4.36e-24	93.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_345	SARG|AY259086.1.gene4.p01	35.7	171	201	210	4.36e-24	93.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_345	NCBI|WP_071846347.1|1|1|catB3|catB3|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB3|AMR|phenicol	35.7	171	201	210	4.36e-24	93.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_345	NCBI|WP_071846350.1|1|1|catB3|catB3|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB3|AMR|phenicol	35.7	171	201	210	4.36e-24	93.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_345	NCBI|WP_071846375.1|1|1|catB3|catB3|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB3|AMR|phenicol	35.7	171	201	210	4.36e-24	93.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_345	SARG|ABC69169	35.7	171	201	210	4.36e-24	93.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_345	NCBI|WP_071846363.1|1|1|catB3|catB3|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB3|AMR|phenicol	35.7	171	201	210	6.12e-24	93.2
GibsonMK_2016_SRR3131800_bin.2_k141_3130_345	SARG|ABP35557	36.1	169	201	210	6.12e-24	93.2
GibsonMK_2016_SRR3131800_bin.2_k141_3130_345	NCBI|WP_071846207.1|1|1|catB3|catB3|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB3|AMR|phenicol	35.7	171	201	210	6.12e-24	93.2
GibsonMK_2016_SRR3131800_bin.2_k141_3130_373	SARG|AUI09862.1	42.9	268	279	287	4.37e-67	209
GibsonMK_2016_SRR3131800_bin.2_k141_3130_373	SARG|AJ459418.gene.p01	32.8	262	279	263	1.55e-38	135
GibsonMK_2016_SRR3131800_bin.2_k141_3130_373	SARG|gi|970263436|ref|WP_058647620.1|	32.8	262	279	263	2.18e-38	134
GibsonMK_2016_SRR3131800_bin.2_k141_3130_373	NCBI|WP_001043265.1|1|1|sul2|sul2|insensitivity|2|sulfonamide|sulfonamide|sulfonamide-resistant_dihydropteroate_synthase_Sul2|AMR|sulfonamide	34.0	259	279	271	3.07e-36	129
GibsonMK_2016_SRR3131800_bin.2_k141_3130_373	SARG|gi|487670925|ref|WP_001756235.1|	34.0	259	279	271	4.30e-36	129
GibsonMK_2016_SRR3131800_bin.2_k141_3130_373	SARG|gi|553729091|ref|WP_023063817.1|	33.6	259	279	271	6.04e-36	128
GibsonMK_2016_SRR3131800_bin.2_k141_3130_373	SARG|gi|486033774|ref|WP_001505252.1|	34.0	259	279	271	6.04e-36	128
GibsonMK_2016_SRR3131800_bin.2_k141_3130_373	SARG|DQ464881.1.gene2.p01	34.0	259	279	271	1.19e-35	127
GibsonMK_2016_SRR3131800_bin.2_k141_3130_373	SARG|gi|638947703|ref|WP_024439711.1|	33.6	259	279	271	1.67e-35	127
GibsonMK_2016_SRR3131800_bin.2_k141_3130_373	SARG|gi|916164813|ref|WP_050960181.1|	33.6	259	279	271	1.67e-35	127
GibsonMK_2016_SRR3131800_bin.2_k141_3130_379	CARD|gb|AAG06465.1|ARO:3005063|cprR	40.2	219	221	223	4.94e-40	135
GibsonMK_2016_SRR3131800_bin.2_k141_3130_379	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	36.8	220	221	225	7.15e-37	127
GibsonMK_2016_SRR3131800_bin.2_k141_3130_379	CARD|gb|AAC73788.1|ARO:3003841|kdpE	36.8	220	221	225	7.15e-37	127
GibsonMK_2016_SRR3131800_bin.2_k141_3130_379	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.7	218	221	220	1.25e-36	127
GibsonMK_2016_SRR3131800_bin.2_k141_3130_379	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.2	218	221	219	1.71e-36	126
GibsonMK_2016_SRR3131800_bin.2_k141_3130_379	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.2	218	221	219	3.40e-36	125
GibsonMK_2016_SRR3131800_bin.2_k141_3130_379	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.2	218	221	220	3.49e-36	125
GibsonMK_2016_SRR3131800_bin.2_k141_3130_379	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.5	217	221	219	6.77e-36	125
GibsonMK_2016_SRR3131800_bin.2_k141_3130_379	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.2	218	221	220	9.79e-36	124
GibsonMK_2016_SRR3131800_bin.2_k141_3130_379	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	37.9	219	221	225	2.21e-35	124
GibsonMK_2016_SRR3131800_bin.2_k141_3130_380	CARD|gb|AEX49906.1|ARO:3003583|basS	32.8	271	354	477	6.11e-37	137
GibsonMK_2016_SRR3131800_bin.2_k141_3130_443	megares|MEG_497|Drugs|beta-lactam|Class_C_betalactamases|ACT_1	58.4	77	178	77	2.53e-26	94.7
GibsonMK_2016_SRR3131800_bin.2_k141_3130_444	SARG|gi|489421661|ref|WP_003327389.1|	42.7	103	106	105	3.85e-16	67.0
GibsonMK_2016_SRR3131800_bin.2_k141_3130_444	SARG|gi|1044625135|gb|OCB99622.1|	38.1	105	106	163	1.99e-15	66.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_444	SARG|gi|307606148|emb|CBI42519.1|	37.1	105	106	163	7.79e-15	65.1
GibsonMK_2016_SRR3131800_bin.2_k141_3130_444	SARG|ABS73653	34.3	105	106	112	5.80e-14	61.6
GibsonMK_2016_SRR3131800_bin.2_k141_3130_444	SARG|gi|505052607|ref|WP_015239709.1|	33.3	105	106	112	8.19e-14	61.2
GibsonMK_2016_SRR3131800_bin.2_k141_3130_444	SARG|gi|494649292|ref|WP_007407236.1|	33.3	105	106	112	8.19e-14	61.2
GibsonMK_2016_SRR3131800_bin.2_k141_3130_444	SARG|gi|489246603|ref|WP_003154767.1|	36.2	105	106	112	8.19e-14	61.2
GibsonMK_2016_SRR3131800_bin.2_k141_3130_444	SARG|gi|489311090|ref|WP_003218499.1|	36.2	105	106	112	8.19e-14	61.2
GibsonMK_2016_SRR3131800_bin.2_k141_3130_444	SARG|gi|1036316000|gb|OAZ59366.1|	36.2	105	106	163	8.46e-14	62.4
GibsonMK_2016_SRR3131800_bin.2_k141_3130_444	SARG|gi|503879533|ref|WP_014113527.1|	35.2	105	106	112	1.63e-13	60.5
GibsonMK_2016_SRR3131800_bin.2_k141_3130_472	NCBI|WP_252944138.1|1|1|almE|almE||2|COLISTIN|COLISTIN|lipid_A_modification_system_glycine--protein_ligase_AlmE|AMR|peptide	29.9	371	1032	556	7.54e-27	115
GibsonMK_2016_SRR3131800_bin.2_k141_3193_16	SARG|gb|AML99881.1|ARO:3001327|mdtK	82.3	474	478	474	4.44e-287	783
GibsonMK_2016_SRR3131800_bin.2_k141_3193_16	SARG|gb|ADO96486.1|ARO:3003953|hmrM	22.7	410	478	464	1.79e-19	89.7
GibsonMK_2016_SRR3131800_bin.2_k141_3193_16	NCBI|AAC23256.1|1|1|hmrM|hmrM|efflux|1|EFFLUX|EFFLUX|sodium-coupled_multidrug_efflux_MATE_transporter_HmrM|AMR|efflux	22.7	410	478	464	2.40e-19	89.4
GibsonMK_2016_SRR3131800_bin.2_k141_3193_32	NCBI|WP_061345584.1|1|1|cml_Ochro|cml_Ochro|efflux|2|CHLORAMPHENICOL|PHENICOL|Cml_family_phenicol_efflux_MFS_transporter|AMR|phenicol	26.4	182	459	397	9.18e-12	65.5
GibsonMK_2016_SRR3131800_bin.2_k141_3193_32	SARG|gb|ALV80601.1|ARO:3003801|bcr-1	27.5	167	459	402	2.20e-11	64.3
GibsonMK_2016_SRR3131800_bin.2_k141_3193_32	NCBI|WP_031633255.1|1|1|cmlA_floR|cmlA_floR|efflux|2|CHLORAMPHENICOL|PHENICOL|CmlA/FloR_family_phenicol_efflux_MFS_transporter|AMR|phenicol	24.1	170	459	395	5.06e-11	63.2
GibsonMK_2016_SRR3131800_bin.2_k141_3193_32	megares|MEG_8019|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CML_1	28.8	163	459	411	5.19e-10	60.1
GibsonMK_2016_SRR3131800_bin.2_k141_3193_32	NCBI|WP_011552636.1|1|1|cml_Myxo|cml_Myxo|efflux|2|CHLORAMPHENICOL|PHENICOL|Cml_family_phenicol_efflux_MFS_transporter|AMR|phenicol	28.8	163	459	411	5.19e-10	60.1
GibsonMK_2016_SRR3131800_bin.2_k141_3193_32	SARG|YP_001419960	25.0	176	459	510	6.37e-10	60.1
GibsonMK_2016_SRR3131800_bin.2_k141_3193_32	NCBI|WP_115421099.1|1|1|cml_Ensi|cml_Ensi|efflux|2|CHLORAMPHENICOL|PHENICOL|Cml_family_phenicol_efflux_MFS_transporter|AMR|phenicol	27.9	165	459	400	8.86e-10	59.3
GibsonMK_2016_SRR3131800_bin.2_k141_3193_32	megares|MEG_8021|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CML_1	27.9	165	459	400	8.86e-10	59.3
GibsonMK_2016_SRR3131800_bin.2_k141_3193_32	SARG|gi|730661043|ref|WP_034065992.1|	26.6	158	459	404	3.70e-09	57.4
GibsonMK_2016_SRR3131800_bin.2_k141_3193_32	SARG|AF332662.1.gene1.p01	25.9	158	459	404	6.52e-09	56.6
GibsonMK_2016_SRR3131800_bin.2_k141_3193_40	SARG|gi|921979807|ref|WP_053271336.1|	33.5	209	247	648	5.77e-23	96.3
GibsonMK_2016_SRR3131800_bin.2_k141_3193_40	SARG|gi|517381192|ref|WP_018555350.1|	26.8	205	247	602	9.07e-10	57.4
GibsonMK_2016_SRR3131800_bin.2_k141_3193_40	SARG|gi|664458452|ref|WP_030980047.1|	30.5	187	247	601	1.64e-09	56.6
GibsonMK_2016_SRR3131800_bin.2_k141_3193_40	SARG|gi|948137056|ref|WP_056795395.1|	28.2	188	247	602	1.73e-08	53.5
GibsonMK_2016_SRR3131800_bin.2_k141_3193_40	ResF|poxtA-Ef_1_WP094899500.1_1	24.4	197	247	538	3.00e-08	52.8
GibsonMK_2016_SRR3131800_bin.2_k141_3193_40	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	24.4	197	247	543	3.01e-08	52.8
GibsonMK_2016_SRR3131800_bin.2_k141_3193_40	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	24.4	197	247	543	3.01e-08	52.8
GibsonMK_2016_SRR3131800_bin.2_k141_3193_40	SARG|gi|686436876|ref|WP_031922735.1|	27.7	184	247	491	4.06e-07	49.3
GibsonMK_2016_SRR3131800_bin.2_k141_3193_40	SARG|ABA02367	25.3	182	247	488	2.33e-06	47.0
GibsonMK_2016_SRR3131800_bin.2_k141_3193_40	SARG|gi|127359|sp|P23212.1|MSRA_STAEP	25.3	182	247	488	2.33e-06	47.0
GibsonMK_2016_SRR3131800_bin.2_k141_3216_7	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	44.0	1368	1343	1186	0.0	1048
GibsonMK_2016_SRR3131800_bin.2_k141_3216_7	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	44.0	1368	1343	1186	0.0	1048
GibsonMK_2016_SRR3131800_bin.2_k141_3216_7	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	44.7	1362	1343	1162	0.0	1031
GibsonMK_2016_SRR3131800_bin.2_k141_3289_7	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	33.6	113	229	225	1.23e-09	55.5
GibsonMK_2016_SRR3131800_bin.2_k141_3289_7	CARD|gb|AAC73788.1|ARO:3003841|kdpE	33.6	113	229	225	1.23e-09	55.5
GibsonMK_2016_SRR3131800_bin.2_k141_3289_18	CARD|gb|ALH22601.1|ARO:3000620|adeL	27.5	251	297	337	3.47e-16	76.6
GibsonMK_2016_SRR3131800_bin.2_k141_3289_21	SARG|gb|MBW0764195.1|ARO:3007027|salC	22.8	202	256	541	1.79e-09	56.6
GibsonMK_2016_SRR3131800_bin.2_k141_3289_21	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	22.7	194	256	579	2.67e-07	50.1
GibsonMK_2016_SRR3131800_bin.2_k141_3289_21	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	22.2	194	256	579	3.58e-07	49.7
GibsonMK_2016_SRR3131800_bin.2_k141_3289_25	SARG|CP001581.1.gene725.p01	28.5	393	457	477	3.84e-45	162
GibsonMK_2016_SRR3131800_bin.2_k141_3289_25	SARG|gi|917770481|ref|WP_052284485.1|	27.3	411	457	512	3.37e-28	115
GibsonMK_2016_SRR3131800_bin.2_k141_3289_25	SARG|gi|636832416|ref|WP_024358423.1|	26.3	410	457	512	9.36e-27	111
GibsonMK_2016_SRR3131800_bin.2_k141_3289_25	SARG|gi|745784185|ref|WP_039077609.1|	26.7	408	457	512	9.36e-27	111
GibsonMK_2016_SRR3131800_bin.2_k141_3289_25	SARG|gi|751932149|ref|WP_041146857.1|	27.1	410	457	512	9.36e-27	111
GibsonMK_2016_SRR3131800_bin.2_k141_3289_25	SARG|gi|695768008|ref|WP_032691019.1|	26.8	410	457	512	1.27e-26	111
GibsonMK_2016_SRR3131800_bin.2_k141_3289_25	SARG|gi|505182965|ref|WP_015370067.1|	26.6	410	457	512	1.27e-26	111
GibsonMK_2016_SRR3131800_bin.2_k141_3289_25	SARG|gi|928828252|ref|WP_053886868.1|	26.7	408	457	512	1.27e-26	111
GibsonMK_2016_SRR3131800_bin.2_k141_3289_25	SARG|gi|823312318|ref|WP_047066733.1|	26.6	410	457	512	1.27e-26	111
GibsonMK_2016_SRR3131800_bin.2_k141_3289_25	SARG|gi|779946719|ref|WP_045395214.1|	26.6	410	457	512	1.27e-26	111
GibsonMK_2016_SRR3131800_bin.2_k141_3289_27	megares|MEG_4285|Drugs|beta-lactam|Mutant_porin_proteins|OMPD_1	25.0	352	351	357	4.15e-25	103
GibsonMK_2016_SRR3131800_bin.2_k141_3289_42	megares|MEG_2614|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|DHAP_1	25.5	376	397	395	5.38e-23	98.6
GibsonMK_2016_SRR3131800_bin.2_k141_3289_46	SARG|gi|822022298|ref|WP_046882271.1|	30.6	248	239	646	1.66e-17	80.1
GibsonMK_2016_SRR3131800_bin.2_k141_3289_46	SARG|gi|695840638|ref|WP_032753940.1|	32.9	213	239	646	2.25e-17	79.7
GibsonMK_2016_SRR3131800_bin.2_k141_3289_46	SARG|Q83LR7	29.3	229	239	648	2.26e-17	79.7
GibsonMK_2016_SRR3131800_bin.2_k141_3289_46	SARG|gi|647325472|ref|WP_025760953.1|	29.3	229	239	648	2.26e-17	79.7
GibsonMK_2016_SRR3131800_bin.2_k141_3289_46	SARG|gi|647323678|ref|WP_025760497.1|	29.3	229	239	648	2.26e-17	79.7
GibsonMK_2016_SRR3131800_bin.2_k141_3289_46	SARG|gi|1033064422|ref|WP_064375412.1|	29.9	224	239	648	2.26e-17	79.7
GibsonMK_2016_SRR3131800_bin.2_k141_3289_46	SARG|gi|751930065|ref|WP_041144773.1|	31.7	202	239	648	2.26e-17	79.7
GibsonMK_2016_SRR3131800_bin.2_k141_3289_46	SARG|gi|852138723|ref|WP_048293411.1|	30.6	248	239	646	3.05e-17	79.3
GibsonMK_2016_SRR3131800_bin.2_k141_3289_46	SARG|gi|496081332|ref|WP_008805839.1|	30.6	248	239	646	3.05e-17	79.3
GibsonMK_2016_SRR3131800_bin.2_k141_3289_46	SARG|gi|1016530977|ref|WP_063106245.1|	30.6	248	239	646	3.05e-17	79.3
GibsonMK_2016_SRR3131800_bin.2_k141_3289_47	SARG|gi|542061059|gb|ERI11611.1|	29.3	147	292	316	4.36e-15	73.2
GibsonMK_2016_SRR3131800_bin.2_k141_3289_47	SARG|gi|488042066|ref|WP_002113463.1|	29.7	165	292	309	1.41e-14	71.6
GibsonMK_2016_SRR3131800_bin.2_k141_3289_47	SARG|gi|445996708|ref|WP_000074563.1|	32.0	150	292	309	2.60e-14	70.9
GibsonMK_2016_SRR3131800_bin.2_k141_3289_47	SARG|gi|895736250|emb|COF64653.1|	31.3	150	292	309	3.53e-14	70.5
GibsonMK_2016_SRR3131800_bin.2_k141_3289_47	SARG|gi|446110087|ref|WP_000187942.1|	31.3	150	292	309	3.53e-14	70.5
GibsonMK_2016_SRR3131800_bin.2_k141_3289_47	SARG|gi|445996714|ref|WP_000074569.1|	31.3	150	292	309	3.53e-14	70.5
GibsonMK_2016_SRR3131800_bin.2_k141_3289_47	SARG|gi|895808656|emb|COR83787.1|	31.3	150	292	309	3.53e-14	70.5
GibsonMK_2016_SRR3131800_bin.2_k141_3289_47	SARG|gi|445996709|ref|WP_000074564.1|	31.3	150	292	309	4.79e-14	70.1
GibsonMK_2016_SRR3131800_bin.2_k141_3289_47	SARG|gi|814314593|emb|CKF49145.1|	31.3	150	292	309	4.79e-14	70.1
GibsonMK_2016_SRR3131800_bin.2_k141_3289_47	SARG|gi|445996719|ref|WP_000074574.1|	31.3	150	292	309	6.51e-14	69.7
GibsonMK_2016_SRR3131800_bin.2_k141_3289_74	SARG|gi|942489450|ref|WP_055329626.1|	32.1	187	436	377	1.31e-14	73.9
GibsonMK_2016_SRR3131800_bin.2_k141_3289_74	SARG|gi|742394783|ref|WP_038873908.1|	32.1	187	436	378	1.32e-14	73.9
GibsonMK_2016_SRR3131800_bin.2_k141_3289_74	SARG|gi|851962897|ref|WP_048233629.1|	32.1	187	436	378	1.32e-14	73.9
GibsonMK_2016_SRR3131800_bin.2_k141_3289_74	SARG|AAK64454	31.6	187	436	378	2.36e-14	73.2
GibsonMK_2016_SRR3131800_bin.2_k141_3289_74	SARG|AY524276.3.gene1.p3	31.6	187	436	378	3.15e-14	72.8
GibsonMK_2016_SRR3131800_bin.2_k141_3289_74	SARG|AAQ90024	31.6	187	436	374	4.12e-14	72.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_74	SARG|gi|896236319|ref|WP_049234464.1|	31.6	187	436	378	4.22e-14	72.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_74	SARG|gi|763152412|ref|WP_044032075.1|	30.3	211	436	378	4.22e-14	72.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_74	SARG|ABC33904	31.6	187	436	378	4.22e-14	72.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_74	SARG|AAK15701	31.6	187	436	378	4.22e-14	72.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_83	SARG|gi|1035686596|ref|WP_064530178.1|	32.3	257	497	648	3.54e-25	108
GibsonMK_2016_SRR3131800_bin.2_k141_3289_83	SARG|gi|643601187|ref|WP_025237288.1|	30.7	251	497	648	1.51e-24	106
GibsonMK_2016_SRR3131800_bin.2_k141_3289_83	SARG|gi|974628291|ref|WP_059215695.1|	30.7	251	497	648	1.51e-24	106
GibsonMK_2016_SRR3131800_bin.2_k141_3289_83	SARG|gi|446110298|ref|WP_000188153.1|	30.7	251	497	648	1.51e-24	106
GibsonMK_2016_SRR3131800_bin.2_k141_3289_83	SARG|gi|974633183|ref|WP_059219858.1|	30.7	251	497	648	1.51e-24	106
GibsonMK_2016_SRR3131800_bin.2_k141_3289_83	SARG|gi|974684692|ref|WP_059267998.1|	30.7	251	497	648	1.51e-24	106
GibsonMK_2016_SRR3131800_bin.2_k141_3289_83	SARG|gi|446110305|ref|WP_000188160.1|	31.3	227	497	648	2.01e-24	105
GibsonMK_2016_SRR3131800_bin.2_k141_3289_83	SARG|gi|974672242|ref|WP_059256507.1|	30.7	251	497	648	2.69e-24	105
GibsonMK_2016_SRR3131800_bin.2_k141_3289_83	SARG|gi|974641719|ref|WP_059227752.1|	30.7	251	497	648	2.69e-24	105
GibsonMK_2016_SRR3131800_bin.2_k141_3289_83	SARG|gi|446110299|ref|WP_000188154.1|	30.7	251	497	648	2.69e-24	105
GibsonMK_2016_SRR3131800_bin.2_k141_3289_153	SARG|gi|514904648|ref|WP_016630030.1|	22.3	512	504	498	2.83e-08	55.1
GibsonMK_2016_SRR3131800_bin.2_k141_3289_153	SARG|gi|895824744|ref|WP_048947239.1|	21.9	512	504	499	8.65e-08	53.5
GibsonMK_2016_SRR3131800_bin.2_k141_3289_153	SARG|gi|488303094|ref|WP_002374069.1|	22.3	512	504	498	1.14e-07	53.1
GibsonMK_2016_SRR3131800_bin.2_k141_3289_153	SARG|ZP_04437889	22.1	512	504	498	1.14e-07	53.1
GibsonMK_2016_SRR3131800_bin.2_k141_3289_153	SARG|AAW30456	22.7	512	504	498	1.14e-07	53.1
GibsonMK_2016_SRR3131800_bin.2_k141_3289_153	SARG|gi|488340851|ref|WP_002410236.1|	22.1	512	504	498	1.51e-07	52.8
GibsonMK_2016_SRR3131800_bin.2_k141_3289_153	SARG|ZP_03984253	22.1	512	504	498	1.51e-07	52.8
GibsonMK_2016_SRR3131800_bin.2_k141_3289_153	SARG|ZP_04646474	22.3	512	504	498	1.51e-07	52.8
GibsonMK_2016_SRR3131800_bin.2_k141_3289_153	SARG|gi|498523386|ref|WP_010823123.1|	22.1	512	504	498	2.00e-07	52.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_153	SARG|gi|498524203|ref|WP_010823919.1|	22.1	512	504	498	2.64e-07	52.0
GibsonMK_2016_SRR3131800_bin.2_k141_3289_157	SARG|gi|493394434|ref|WP_006350564.1|	28.3	233	263	602	4.19e-12	64.7
GibsonMK_2016_SRR3131800_bin.2_k141_3289_157	SARG|gi|748767925|ref|WP_040019608.1|	30.6	216	263	623	1.03e-11	63.5
GibsonMK_2016_SRR3131800_bin.2_k141_3289_157	SARG|gi|664395661|ref|WP_030922045.1|	28.8	208	263	601	1.84e-11	62.8
GibsonMK_2016_SRR3131800_bin.2_k141_3289_157	SARG|gi|817122037|ref|WP_046494699.1|	27.0	204	263	613	1.85e-11	62.8
GibsonMK_2016_SRR3131800_bin.2_k141_3289_157	SARG|gi|655401130|ref|WP_028800283.1|	25.4	213	263	599	2.47e-11	62.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_157	SARG|gi|664458452|ref|WP_030980047.1|	28.4	208	263	601	3.32e-11	62.0
GibsonMK_2016_SRR3131800_bin.2_k141_3289_157	SARG|gi|930482089|ref|WP_054228897.1|	26.7	225	263	599	4.46e-11	61.6
GibsonMK_2016_SRR3131800_bin.2_k141_3289_157	SARG|gi|985844137|ref|WP_060895163.1|	26.7	225	263	599	4.46e-11	61.6
GibsonMK_2016_SRR3131800_bin.2_k141_3289_157	SARG|gi|516795764|ref|WP_018105258.1|	28.4	208	263	601	4.46e-11	61.6
GibsonMK_2016_SRR3131800_bin.2_k141_3289_157	SARG|gi|695842130|ref|WP_032755430.1|	28.6	224	263	603	6.01e-11	61.2
GibsonMK_2016_SRR3131800_bin.2_k141_3289_185	SARG|gi|974633183|ref|WP_059219858.1|	33.2	235	537	648	1.54e-22	100
GibsonMK_2016_SRR3131800_bin.2_k141_3289_185	SARG|gi|974684692|ref|WP_059267998.1|	33.2	235	537	648	1.54e-22	100
GibsonMK_2016_SRR3131800_bin.2_k141_3289_185	SARG|gi|487373439|ref|WP_001646908.1|	32.8	235	537	648	2.73e-22	99.8
GibsonMK_2016_SRR3131800_bin.2_k141_3289_185	SARG|Q83LR7	33.3	234	537	648	3.63e-22	99.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_185	SARG|gi|647325472|ref|WP_025760953.1|	33.3	234	537	648	3.63e-22	99.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_185	SARG|gi|647323678|ref|WP_025760497.1|	33.3	234	537	648	3.63e-22	99.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_185	SARG|gi|693054987|ref|WP_032223114.1|	32.8	235	537	648	4.83e-22	99.0
GibsonMK_2016_SRR3131800_bin.2_k141_3289_185	SARG|gi|446110305|ref|WP_000188160.1|	33.3	234	537	648	4.83e-22	99.0
GibsonMK_2016_SRR3131800_bin.2_k141_3289_185	SARG|gi|742409107|ref|WP_038888226.1|	32.8	253	537	647	6.41e-22	98.6
GibsonMK_2016_SRR3131800_bin.2_k141_3289_185	SARG|gi|643601187|ref|WP_025237288.1|	32.8	235	537	648	6.43e-22	98.6
GibsonMK_2016_SRR3131800_bin.2_k141_3289_187	SARG|gb|ALV80601.1|ARO:3003801|bcr-1	39.8	329	399	402	2.30e-68	220
GibsonMK_2016_SRR3131800_bin.2_k141_3289_187	SARG|AM296481.1.gene2.p01	30.3	393	399	421	2.49e-35	133
GibsonMK_2016_SRR3131800_bin.2_k141_3289_187	megares|MEG_1775|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMLB_1	30.3	393	399	421	2.49e-35	133
GibsonMK_2016_SRR3131800_bin.2_k141_3289_187	SARG|AF313472.2.gene8.p01	29.0	386	399	419	1.21e-34	131
GibsonMK_2016_SRR3131800_bin.2_k141_3289_187	megares|MEG_1764|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMLA_1	29.0	386	399	419	1.21e-34	131
GibsonMK_2016_SRR3131800_bin.2_k141_3289_187	megares|MEG_1766|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMLA_1	29.0	386	399	419	1.68e-34	131
GibsonMK_2016_SRR3131800_bin.2_k141_3289_187	SARG|AY115475.1.gene4.p01	29.0	386	399	419	1.68e-34	131
GibsonMK_2016_SRR3131800_bin.2_k141_3289_187	SARG|YP_001338812	29.0	386	399	435	2.13e-34	131
GibsonMK_2016_SRR3131800_bin.2_k141_3289_187	SARG|ABK51578	29.0	386	399	437	2.19e-34	131
GibsonMK_2016_SRR3131800_bin.2_k141_3289_187	megares|MEG_1772|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMLA_1	29.0	386	399	437	2.19e-34	131
GibsonMK_2016_SRR3131800_bin.2_k141_3289_210	SARG|gb|CAA09666.1|ARO:3004122|Klebsiella	60.5	387	377	374	3.20e-154	438
GibsonMK_2016_SRR3131800_bin.2_k141_3289_210	megares|MEG_4285|Drugs|beta-lactam|Mutant_porin_proteins|OMPD_1	45.8	369	377	357	1.88e-98	295
GibsonMK_2016_SRR3131800_bin.2_k141_3289_215	CARD|gb|AAC75429.1|ARO:3000833|evgS	29.8	514	954	1197	5.83e-53	200
GibsonMK_2016_SRR3131800_bin.2_k141_3289_215	CARD|gb|AAD51347.1|ARO:3003067|smeS	29.2	236	954	467	7.11e-18	86.7
GibsonMK_2016_SRR3131800_bin.2_k141_3289_236	SARG|NC_011595.7060598.p01	27.1	384	412	369	1.35e-19	88.6
GibsonMK_2016_SRR3131800_bin.2_k141_3289_236	SARG|gi|446988854|ref|WP_001066110.1|	26.7	393	412	400	1.75e-19	88.6
GibsonMK_2016_SRR3131800_bin.2_k141_3289_236	SARG|gi|1015784039|gb|KZA89304.1|	26.5	393	412	400	1.42e-18	85.9
GibsonMK_2016_SRR3131800_bin.2_k141_3289_271	SARG|gi|921979807|ref|WP_053271336.1|	37.6	237	258	648	5.92e-37	136
GibsonMK_2016_SRR3131800_bin.2_k141_3289_271	SARG|gb|AYV52072.1|ARO:3002882|lmrD	26.4	231	258	664	2.75e-13	68.2
GibsonMK_2016_SRR3131800_bin.2_k141_3289_271	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	22.9	214	258	461	1.40e-07	50.8
GibsonMK_2016_SRR3131800_bin.2_k141_3289_271	SARG|AAG08983	22.6	212	258	524	2.70e-06	47.0
GibsonMK_2016_SRR3131800_bin.2_k141_3289_284	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	32.9	158	393	314	1.52e-17	81.6
GibsonMK_2016_SRR3131800_bin.2_k141_3289_287	CARD|gb|AEX49906.1|ARO:3003583|basS	33.6	253	473	477	1.16e-32	128
GibsonMK_2016_SRR3131800_bin.2_k141_3289_287	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	40.2	97	473	384	8.62e-09	56.2
GibsonMK_2016_SRR3131800_bin.2_k141_3289_287	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.2	97	473	384	8.62e-09	56.2
GibsonMK_2016_SRR3131800_bin.2_k141_3289_287	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	37.1	97	473	386	1.47e-07	52.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_287	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	37.1	97	473	386	1.47e-07	52.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_287	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	37.1	97	473	386	3.43e-07	51.2
GibsonMK_2016_SRR3131800_bin.2_k141_3289_287	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	37.1	97	473	386	3.43e-07	51.2
GibsonMK_2016_SRR3131800_bin.2_k141_3289_287	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	36.1	97	473	382	1.84e-06	48.9
GibsonMK_2016_SRR3131800_bin.2_k141_3289_287	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	36.1	97	473	382	1.84e-06	48.9
GibsonMK_2016_SRR3131800_bin.2_k141_3289_287	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.4	127	473	381	3.23e-06	48.1
GibsonMK_2016_SRR3131800_bin.2_k141_3289_288	CARD|gb|ATC67679.1|ARO:3000838|arlR	33.5	221	225	219	2.46e-37	129
GibsonMK_2016_SRR3131800_bin.2_k141_3289_288	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	36.7	221	225	231	4.76e-37	128
GibsonMK_2016_SRR3131800_bin.2_k141_3289_288	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.4	228	225	231	8.13e-35	122
GibsonMK_2016_SRR3131800_bin.2_k141_3289_288	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.4	228	225	231	1.14e-34	122
GibsonMK_2016_SRR3131800_bin.2_k141_3289_288	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	35.3	221	225	233	1.20e-34	122
GibsonMK_2016_SRR3131800_bin.2_k141_3289_288	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.4	228	225	231	2.27e-34	121
GibsonMK_2016_SRR3131800_bin.2_k141_3289_288	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.6	228	225	231	1.93e-32	116
GibsonMK_2016_SRR3131800_bin.2_k141_3289_288	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	31.9	232	225	235	4.20e-32	115
GibsonMK_2016_SRR3131800_bin.2_k141_3289_288	CARD|gb|AAD51348.1|ARO:3003066|smeR	34.2	222	225	229	7.19e-32	115
GibsonMK_2016_SRR3131800_bin.2_k141_3289_288	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	31.0	226	225	231	8.19e-31	112
GibsonMK_2016_SRR3131800_bin.2_k141_3289_293	NCBI|WP_031281281.1|1|1|catB|catB|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B_phenicol_O-acetyltransferase|AMR|phenicol	42.5	200	210	210	1.89e-45	149
GibsonMK_2016_SRR3131800_bin.2_k141_3289_293	SARG|AF036933.1.gene1.p01	42.8	201	210	212	2.83e-45	148
GibsonMK_2016_SRR3131800_bin.2_k141_3289_293	SARG|YP_002085096	42.8	201	210	212	4.00e-45	148
GibsonMK_2016_SRR3131800_bin.2_k141_3289_293	SARG|1XAT	42.7	199	210	212	1.13e-44	147
GibsonMK_2016_SRR3131800_bin.2_k141_3289_293	SARG|AF462019.1.gene1.p01	41.8	196	210	209	1.17e-43	144
GibsonMK_2016_SRR3131800_bin.2_k141_3289_293	SARG|ZP_01950974	41.8	196	210	209	1.17e-43	144
GibsonMK_2016_SRR3131800_bin.2_k141_3289_293	SARG|ZP_04417104	41.3	196	210	209	6.62e-43	142
GibsonMK_2016_SRR3131800_bin.2_k141_3289_293	SARG|CAW29378	41.8	201	210	206	9.69e-42	139
GibsonMK_2016_SRR3131800_bin.2_k141_3289_293	NCBI|KGT34314.1|1|1|catC|catC|acetyltransferase|1|CHLORAMPHENICOL|PHENICOL|type_C_phenicol_O-acetyltransferase|AMR|phenicol	41.5	183	210	219	5.54e-41	137
GibsonMK_2016_SRR3131800_bin.2_k141_3289_293	NCBI|WP_071846207.1|1|1|catB3|catB3|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB3|AMR|phenicol	39.3	201	210	210	1.72e-40	136
GibsonMK_2016_SRR3131800_bin.2_k141_3289_331	SARG|AAA50325	36.9	176	211	569	4.12e-14	69.3
GibsonMK_2016_SRR3131800_bin.2_k141_3289_331	SARG|M57437.gene.p01	51.1	47	211	548	1.17e-09	56.2
GibsonMK_2016_SRR3131800_bin.2_k141_3289_331	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	26.8	164	211	494	1.01e-07	50.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_331	SARG|gb|AAK76137.1|ARO:3000024|patA	25.0	168	211	564	4.97e-06	45.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_334	CARD|gb|BAA15221.2|ARO:3000263|marA	49.5	95	267	127	5.78e-23	90.1
GibsonMK_2016_SRR3131800_bin.2_k141_3289_380	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	26.0	235	275	568	1.74e-09	57.0
GibsonMK_2016_SRR3131800_bin.2_k141_3289_380	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	24.7	215	275	524	9.71e-09	54.7
GibsonMK_2016_SRR3131800_bin.2_k141_3289_380	SARG|U82085.gene.p01	23.1	216	275	552	3.18e-08	53.1
GibsonMK_2016_SRR3131800_bin.2_k141_3289_380	SARG|FR772051.1.gene9.p01	24.7	215	275	524	4.16e-08	52.8
GibsonMK_2016_SRR3131800_bin.2_k141_3289_380	SARG|gi|581672381|gb|EVQ77821.1|	25.9	205	275	394	4.78e-08	52.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_380	SARG|gi|587321226|gb|EWW03298.1|	25.9	205	275	413	4.92e-08	52.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_380	SARG|gi|580336413|gb|EVD62957.1|	25.9	205	275	478	5.33e-08	52.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_380	SARG|YP_001569068	25.9	205	275	488	5.39e-08	52.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_380	SARG|gi|686379454|ref|WP_031899389.1|	25.9	205	275	488	5.39e-08	52.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_380	SARG|gi|727749040|ref|WP_033861720.1|	25.9	205	275	488	5.39e-08	52.4
GibsonMK_2016_SRR3131800_bin.2_k141_3289_386	megares|MEG_1992|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	28.3	233	301	291	1.74e-16	77.0
GibsonMK_2016_SRR3131800_bin.2_k141_3289_401	CARD|gb|BAB38260.1|ARO:3000830|cpxA	34.4	308	442	457	6.70e-41	150
GibsonMK_2016_SRR3131800_bin.2_k141_3289_401	CARD|gb|AAD51347.1|ARO:3003067|smeS	31.4	309	442	467	6.47e-33	128
GibsonMK_2016_SRR3131800_bin.2_k141_3289_402	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	41.7	223	227	225	3.84e-53	169
GibsonMK_2016_SRR3131800_bin.2_k141_3289_402	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	38.1	236	227	252	2.41e-49	160
GibsonMK_2016_SRR3131800_bin.2_k141_3289_402	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	40.4	223	227	228	3.44e-49	159
GibsonMK_2016_SRR3131800_bin.2_k141_3289_402	CARD|gb|AAD51348.1|ARO:3003066|smeR	39.2	222	227	229	1.13e-47	155
GibsonMK_2016_SRR3131800_bin.2_k141_3289_402	CARD|gb|AAG05188.1|ARO:3005068|ParR	37.8	222	227	235	7.54e-47	154
GibsonMK_2016_SRR3131800_bin.2_k141_3289_402	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	36.9	225	227	229	2.85e-45	149
GibsonMK_2016_SRR3131800_bin.2_k141_3289_402	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	37.7	223	227	231	8.49e-45	148
GibsonMK_2016_SRR3131800_bin.2_k141_3289_402	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.1	230	227	232	1.54e-42	142
GibsonMK_2016_SRR3131800_bin.2_k141_3289_402	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	36.1	230	227	232	1.54e-42	142
GibsonMK_2016_SRR3131800_bin.2_k141_3289_402	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.9	225	227	219	6.05e-42	140
GibsonMK_2016_SRR3131800_bin.2_k141_3289_404	SARG|gi|896325272|ref|WP_049294291.1|	39.1	225	363	648	1.29e-31	124
GibsonMK_2016_SRR3131800_bin.2_k141_3289_404	SARG|gi|922960663|ref|WP_053388845.1|	37.3	241	363	648	2.37e-31	124
GibsonMK_2016_SRR3131800_bin.2_k141_3289_404	SARG|gi|639216333|ref|WP_024554080.1|	39.1	225	363	648	2.37e-31	124
GibsonMK_2016_SRR3131800_bin.2_k141_3289_404	SARG|gi|757799695|ref|WP_043016897.1|	37.3	241	363	648	3.22e-31	123
GibsonMK_2016_SRR3131800_bin.2_k141_3289_404	SARG|gi|1045891604|ref|WP_065554100.1|	37.3	241	363	648	3.22e-31	123
GibsonMK_2016_SRR3131800_bin.2_k141_3289_404	SARG|gi|507082903|ref|WP_016153652.1|	37.3	241	363	648	3.22e-31	123
GibsonMK_2016_SRR3131800_bin.2_k141_3289_404	SARG|gi|936194420|ref|WP_054528571.1|	39.6	212	363	648	4.37e-31	123
GibsonMK_2016_SRR3131800_bin.2_k141_3289_404	SARG|gi|835233765|ref|WP_047410073.1|	37.3	241	363	648	4.37e-31	123
GibsonMK_2016_SRR3131800_bin.2_k141_3289_404	SARG|gi|740856590|ref|WP_038641842.1|	38.1	226	363	648	4.37e-31	123
GibsonMK_2016_SRR3131800_bin.2_k141_3289_404	SARG|gi|505807117|ref|WP_015704872.1|	38.2	233	363	648	4.37e-31	123
GibsonMK_2016_SRR3131800_bin.2_k141_3395_33	SARG|CP004022.1.gene3225.p01	72.1	394	395	394	3.29e-199	553
GibsonMK_2016_SRR3131800_bin.2_k141_3395_33	SARG|YP_002043045	72.1	394	395	394	6.64e-199	553
GibsonMK_2016_SRR3131800_bin.2_k141_3395_33	SARG|CP001138.1.gene3995.p01	72.1	394	395	394	9.42e-199	552
GibsonMK_2016_SRR3131800_bin.2_k141_3395_33	SARG|YP_001572785	71.8	394	395	394	3.82e-198	551
GibsonMK_2016_SRR3131800_bin.2_k141_3395_33	SARG|NP_462699	71.8	394	395	394	5.43e-198	550
GibsonMK_2016_SRR3131800_bin.2_k141_3395_33	SARG|YP_002639394	71.8	394	395	394	5.43e-198	550
GibsonMK_2016_SRR3131800_bin.2_k141_3395_33	SARG|CAD03195	71.8	394	395	394	5.43e-198	550
GibsonMK_2016_SRR3131800_bin.2_k141_3395_33	SARG|YP_002245675	71.6	394	395	394	1.55e-197	549
GibsonMK_2016_SRR3131800_bin.2_k141_3395_33	SARG|YP_002217746	71.6	394	395	394	2.20e-197	549
GibsonMK_2016_SRR3131800_bin.2_k141_3395_33	SARG|YP_002228414	71.3	394	395	394	1.27e-196	547
GibsonMK_2016_SRR3131800_bin.2_k141_3395_43	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	46.9	228	233	225	4.50e-64	197
GibsonMK_2016_SRR3131800_bin.2_k141_3395_43	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	39.7	232	233	252	1.31e-50	164
GibsonMK_2016_SRR3131800_bin.2_k141_3395_43	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.6	226	233	232	5.96e-47	154
GibsonMK_2016_SRR3131800_bin.2_k141_3395_43	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.3	233	233	231	1.16e-46	153
GibsonMK_2016_SRR3131800_bin.2_k141_3395_43	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	37.8	230	233	230	1.59e-46	153
GibsonMK_2016_SRR3131800_bin.2_k141_3395_43	CARD|gb|AAG05188.1|ARO:3005068|ParR	35.8	229	233	235	2.58e-46	152
GibsonMK_2016_SRR3131800_bin.2_k141_3395_43	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	39.6	225	233	228	3.00e-46	152
GibsonMK_2016_SRR3131800_bin.2_k141_3395_43	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.0	230	233	231	3.26e-46	152
GibsonMK_2016_SRR3131800_bin.2_k141_3395_43	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	35.7	230	233	233	4.87e-46	152
GibsonMK_2016_SRR3131800_bin.2_k141_3395_43	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.6	229	233	219	6.54e-46	151
GibsonMK_2016_SRR3131800_bin.2_k141_3395_44	CARD|gb|BAB38260.1|ARO:3000830|cpxA	84.6	454	465	457	1.05e-282	770
GibsonMK_2016_SRR3131800_bin.2_k141_3395_44	CARD|gb|ADM92606.1|ARO:3000549|adeS	29.9	274	465	361	6.13e-22	95.9
GibsonMK_2016_SRR3131800_bin.2_k141_3395_44	CARD|gb|CYF42523.1|ARO:3004047|kdpD	23.1	221	465	885	3.29e-12	67.8
GibsonMK_2016_SRR3131800_bin.2_k141_3395_119	SARG|FN594949.1.gene24.p01	48.1	131	608	640	3.39e-26	112
GibsonMK_2016_SRR3131800_bin.2_k141_3395_119	NCBI|WP_003454408.1|1|1|tet(44)|tet(44)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(44)|AMR|tetracycline	48.1	131	608	640	3.39e-26	112
GibsonMK_2016_SRR3131800_bin.2_k141_3395_122	CARD|gb|AAK37618.1|ARO:3005008|TxR	42.3	248	471	318	2.68e-57	191
GibsonMK_2016_SRR3131800_bin.2_k141_3395_122	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.8	111	471	219	5.03e-09	55.5
GibsonMK_2016_SRR3131800_bin.2_k141_3395_122	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.8	111	471	219	5.03e-09	55.5
GibsonMK_2016_SRR3131800_bin.2_k141_3395_122	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.8	111	471	220	5.09e-09	55.5
GibsonMK_2016_SRR3131800_bin.2_k141_3395_122	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.8	111	471	220	6.86e-09	55.1
GibsonMK_2016_SRR3131800_bin.2_k141_3395_122	SARG|ZP_02848503	30.1	103	471	221	2.29e-08	53.5
GibsonMK_2016_SRR3131800_bin.2_k141_3395_122	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	27.9	111	471	220	2.45e-07	50.4
GibsonMK_2016_SRR3131800_bin.2_k141_3600_28	CARD|gb|AAC75429.1|ARO:3000833|evgS	32.0	122	130	1197	3.05e-14	67.0
GibsonMK_2016_SRR3131800_bin.2_k141_3600_28	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.6	111	130	231	1.31e-12	61.2
GibsonMK_2016_SRR3131800_bin.2_k141_3600_68	CARD|gb|ALH22601.1|ARO:3000620|adeL	33.7	288	306	337	9.51e-43	149
GibsonMK_2016_SRR3131800_bin.2_k141_3600_80	SARG|gi|736472622|ref|WP_034494292.1|	40.7	241	251	648	1.60e-45	160
GibsonMK_2016_SRR3131800_bin.2_k141_3600_80	SARG|gi|1035717981|ref|WP_064557480.1|	40.7	241	251	648	4.22e-45	159
GibsonMK_2016_SRR3131800_bin.2_k141_3600_80	SARG|gi|1035670474|ref|WP_064517458.1|	40.7	241	251	648	5.83e-45	158
GibsonMK_2016_SRR3131800_bin.2_k141_3600_80	SARG|gi|1035706844|ref|WP_064548272.1|	40.2	241	251	648	5.83e-45	158
GibsonMK_2016_SRR3131800_bin.2_k141_3600_80	SARG|gi|896325272|ref|WP_049294291.1|	41.4	239	251	648	4.05e-44	156
GibsonMK_2016_SRR3131800_bin.2_k141_3600_80	SARG|gi|657888313|ref|WP_029592374.1|	41.0	239	251	648	1.07e-43	155
GibsonMK_2016_SRR3131800_bin.2_k141_3600_80	SARG|gi|639216333|ref|WP_024554080.1|	41.4	239	251	648	1.07e-43	155
GibsonMK_2016_SRR3131800_bin.2_k141_3600_80	SARG|gi|639225329|ref|WP_024561799.1|	41.4	239	251	648	1.47e-43	154
GibsonMK_2016_SRR3131800_bin.2_k141_3600_80	SARG|gi|639218559|ref|WP_024556062.1|	41.4	239	251	648	1.47e-43	154
GibsonMK_2016_SRR3131800_bin.2_k141_3600_80	SARG|gi|671541568|ref|WP_031525212.1|	41.8	220	251	648	5.33e-43	153
GibsonMK_2016_SRR3131800_bin.2_k141_3600_101	CARD|gb|BAB36671.1|ARO:3000832|evgA	25.1	207	217	204	1.80e-21	87.0
GibsonMK_2016_SRR3131800_bin.2_k141_3600_101	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	27.5	171	217	228	2.45e-11	60.1
GibsonMK_2016_SRR3131800_bin.2_k141_3600_101	CARD|gb|ATC67679.1|ARO:3000838|arlR	29.3	133	217	219	1.48e-10	57.8
GibsonMK_2016_SRR3131800_bin.2_k141_3600_101	CARD|gb|AAG05188.1|ARO:3005068|ParR	23.7	177	217	235	3.41e-08	51.2
GibsonMK_2016_SRR3131800_bin.2_k141_3600_101	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	27.9	122	217	231	4.50e-08	50.8
GibsonMK_2016_SRR3131800_bin.2_k141_3600_101	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	26.4	140	217	252	1.44e-06	46.6
GibsonMK_2016_SRR3131800_bin.2_k141_3600_101	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	25.4	114	217	233	3.23e-06	45.4
GibsonMK_2016_SRR3131800_bin.2_k141_3600_135	NCBI|WP_011906899.1|1|1|estDL136|estDL136||2|CHLORAMPHENICOL/FLORFENICOL|PHENICOL|phenicol_hydrolase|AMR|phenicol	38.2	293	325	308	8.95e-61	195
GibsonMK_2016_SRR3131800_bin.2_k141_3600_135	megares|MEG_2865|Drugs|Phenicol|Chloramphenicol_hydrolase|ESTD_1	39.8	261	325	310	3.44e-54	178
GibsonMK_2016_SRR3131800_bin.2_k141_3600_141	SARG|gb|CAA09666.1|ARO:3004122|Klebsiella	60.0	380	361	374	3.13e-150	427
GibsonMK_2016_SRR3131800_bin.2_k141_3600_141	megares|MEG_4285|Drugs|beta-lactam|Mutant_porin_proteins|OMPD_1	49.3	357	361	357	2.48e-105	312
GibsonMK_2016_SRR3131800_bin.2_k141_3600_148	CARD|gb|AFK13828.1|ARO:3000823|ramA	41.6	101	129	124	5.39e-26	93.6
GibsonMK_2016_SRR3131800_bin.2_k141_3600_148	CARD|gb|BAA15221.2|ARO:3000263|marA	40.2	92	129	127	7.81e-21	80.5
GibsonMK_2016_SRR3131800_bin.2_k141_3600_153	SARG|gb|BAP18892.1|ARO:3003210|FosA4	66.4	137	136	138	6.59e-63	187
GibsonMK_2016_SRR3131800_bin.2_k141_3600_153	SARG|gi|851997245|ref|WP_048247864.1|	66.9	136	136	141	1.46e-62	187
GibsonMK_2016_SRR3131800_bin.2_k141_3600_153	SARG|gi|970307692|ref|WP_058677530.1|	66.9	136	136	141	2.08e-62	186
GibsonMK_2016_SRR3131800_bin.2_k141_3600_153	SARG|gi|1016946750|ref|WP_063148083.1|	66.9	136	136	141	2.08e-62	186
GibsonMK_2016_SRR3131800_bin.2_k141_3600_153	SARG|gi|970319314|ref|WP_058686534.1|	66.9	136	136	141	2.08e-62	186
GibsonMK_2016_SRR3131800_bin.2_k141_3600_153	NCBI|WP_004857515.1|1|1|fosA_gen|fosA_gen|thiol_transferase|2|phosphonic	68.6	137	136	139	2.77e-62	186
GibsonMK_2016_SRR3131800_bin.2_k141_3600_153	SARG|gi|975912206|ref|WP_059294105.1|	66.9	136	136	141	2.95e-62	186
GibsonMK_2016_SRR3131800_bin.2_k141_3600_153	NCBI|WP_063277905.1|1|1|fosA8|fosA8_fam|thiol_transferase|2|phosphonic	65.4	136	136	141	2.95e-62	186
GibsonMK_2016_SRR3131800_bin.2_k141_3600_153	SARG|Q56415	66.9	136	136	141	2.95e-62	186
GibsonMK_2016_SRR3131800_bin.2_k141_3600_153	SARG|gi|695626268|ref|WP_032608424.1|	66.9	136	136	141	2.95e-62	186
GibsonMK_2016_SRR3131800_bin.2_k141_3600_158	megares|MEG_1246|Drugs|beta-lactam|Class_A_betalactamases|BLAA_1	42.1	252	345	339	7.00e-61	197
GibsonMK_2016_SRR3131800_bin.2_k141_3600_161	SARG|gb|AJD73064.1|ARO:3001301|RlmA(II)	33.3	246	273	282	4.83e-29	110
GibsonMK_2016_SRR3131800_bin.2_k141_3600_185	SARG|gi|491303286|ref|WP_005161289.1|	86.3	400	402	401	3.44e-251	686
GibsonMK_2016_SRR3131800_bin.2_k141_3600_185	SARG|gi|915698768|ref|WP_050870466.1|	86.3	400	402	401	4.88e-251	685
GibsonMK_2016_SRR3131800_bin.2_k141_3600_185	SARG|gi|1000366883|ref|WP_061111273.1|	86.0	400	402	401	2.82e-250	683
GibsonMK_2016_SRR3131800_bin.2_k141_3600_185	SARG|gi|490859158|ref|WP_004721200.1|	84.5	401	402	401	7.36e-246	672
GibsonMK_2016_SRR3131800_bin.2_k141_3600_185	SARG|gi|902970937|ref|WP_049689667.1|	84.3	401	402	401	1.05e-245	672
GibsonMK_2016_SRR3131800_bin.2_k141_3600_185	SARG|gi|902507037|ref|WP_049597664.1|	84.3	400	402	401	1.22e-244	669
GibsonMK_2016_SRR3131800_bin.2_k141_3600_185	SARG|gi|1035666299|ref|WP_064513438.1|	84.0	400	402	401	4.95e-244	667
GibsonMK_2016_SRR3131800_bin.2_k141_3600_185	SARG|gi|552947993|ref|WP_023046226.1|	81.3	400	402	401	3.91e-234	642
GibsonMK_2016_SRR3131800_bin.2_k141_3600_185	SARG|gi|544915359|ref|WP_021325095.1|	81.3	400	402	401	1.59e-233	641
GibsonMK_2016_SRR3131800_bin.2_k141_3600_185	SARG|gi|503835766|ref|WP_014069760.1|	79.1	401	402	402	1.35e-232	639
GibsonMK_2016_SRR3131800_bin.2_k141_3600_209	SARG|gi|445996719|ref|WP_000074574.1|	35.5	203	253	309	2.63e-27	105
GibsonMK_2016_SRR3131800_bin.2_k141_3600_209	SARG|gi|445996710|ref|WP_000074565.1|	35.0	203	253	309	1.38e-26	103
GibsonMK_2016_SRR3131800_bin.2_k141_3600_209	SARG|gi|445996729|ref|WP_000074584.1|	35.0	203	253	309	1.92e-26	103
GibsonMK_2016_SRR3131800_bin.2_k141_3600_209	SARG|gi|1043490477|ref|WP_065382463.1|	35.0	203	253	309	1.92e-26	103
GibsonMK_2016_SRR3131800_bin.2_k141_3600_209	SARG|gi|445996726|ref|WP_000074581.1|	35.0	203	253	309	1.92e-26	103
GibsonMK_2016_SRR3131800_bin.2_k141_3600_209	SARG|gi|445996723|ref|WP_000074578.1|	35.0	203	253	309	1.92e-26	103
GibsonMK_2016_SRR3131800_bin.2_k141_3600_209	SARG|gi|507054395|ref|WP_016125339.1|	35.0	203	253	309	1.92e-26	103
GibsonMK_2016_SRR3131800_bin.2_k141_3600_209	SARG|gi|895808656|emb|COR83787.1|	35.0	203	253	309	1.92e-26	103
GibsonMK_2016_SRR3131800_bin.2_k141_3600_209	SARG|gi|445996724|ref|WP_000074579.1|	34.5	203	253	309	2.67e-26	103
GibsonMK_2016_SRR3131800_bin.2_k141_3600_209	SARG|gi|895736250|emb|COF64653.1|	35.0	203	253	309	2.67e-26	103
GibsonMK_2016_SRR3131800_bin.2_k141_3600_218	CARD|gb|BAH63251.1|ARO:3004580|Kpne_KpnE	63.1	122	123	120	1.60e-42	135
GibsonMK_2016_SRR3131800_bin.2_k141_3600_218	SARG|gb|AAC44316.1|ARO:3005010|qacEdelta1	28.8	111	123	115	3.61e-11	55.1
GibsonMK_2016_SRR3131800_bin.2_k141_3600_218	SARG|NC_010410.6003348.p01	30.6	98	123	109	4.46e-11	54.7
GibsonMK_2016_SRR3131800_bin.2_k141_3600_218	SARG|NC_002695.1.913273.p01	33.7	101	123	110	6.42e-11	54.3
GibsonMK_2016_SRR3131800_bin.2_k141_3600_218	SARG|P23895	32.7	101	123	110	6.42e-11	54.3
GibsonMK_2016_SRR3131800_bin.2_k141_3600_218	SARG|ZP_03048536	32.7	101	123	110	9.04e-11	53.9
GibsonMK_2016_SRR3131800_bin.2_k141_3600_218	SARG|ZP_04003442	32.7	101	123	117	1.05e-10	53.9
GibsonMK_2016_SRR3131800_bin.2_k141_3600_218	SARG|gi|116668015|pdb|2I68|A	32.7	101	123	137	1.11e-10	54.3
GibsonMK_2016_SRR3131800_bin.2_k141_3600_218	SARG|ABG69871	32.7	101	123	165	2.48e-10	53.9
GibsonMK_2016_SRR3131800_bin.2_k141_3600_218	SARG|gi|643599925|ref|WP_025237077.1|	32.1	106	123	110	2.52e-10	52.8
GibsonMK_2016_SRR3131800_bin.2_k141_3600_219	CARD|gb|BAH63252.1|ARO:3004583|Kpne_KpnF	73.4	109	110	109	4.11e-51	155
GibsonMK_2016_SRR3131800_bin.2_k141_3600_219	SARG|gb|AEH26330.1|ARO:3005009|qacE	39.8	98	110	110	2.20e-17	70.5
GibsonMK_2016_SRR3131800_bin.2_k141_3600_219	NCBI|EAC4468893.1|1|1|emrC_Lis|emrC_Lis||1|QUATERNARY_AMMONIUM|QUATERNARY_AMMONIUM|multidrug_efflux_transporter_outer_membrane_subunit_EmrC|AMR|quaternary	39.8	98	110	128	5.40e-16	67.4
GibsonMK_2016_SRR3131800_bin.2_k141_3600_240	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	30.4	358	358	700	8.22e-31	122
GibsonMK_2016_SRR3131800_bin.2_k141_3600_240	SARG|gb|ABA71733.1|ARO:3002972|vanTG	27.4	365	358	712	1.14e-30	122
GibsonMK_2016_SRR3131800_bin.2_k141_3600_240	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	30.5	357	358	700	6.84e-30	119
GibsonMK_2016_SRR3131800_bin.2_k141_3600_240	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	29.8	356	358	700	4.66e-28	114
GibsonMK_2016_SRR3131800_bin.2_k141_3600_240	NCBI|WP_063856758.1|1|1|vanTc2|vanTc2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	29.5	356	358	706	8.56e-28	113
GibsonMK_2016_SRR3131800_bin.2_k141_3600_240	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	27.0	363	358	711	3.14e-26	108
GibsonMK_2016_SRR3131800_bin.2_k141_3600_241	NCBI|WP_115421099.1|1|1|cml_Ensi|cml_Ensi|efflux|2|CHLORAMPHENICOL|PHENICOL|Cml_family_phenicol_efflux_MFS_transporter|AMR|phenicol	33.2	349	398	400	1.73e-44	157
GibsonMK_2016_SRR3131800_bin.2_k141_3600_241	megares|MEG_8021|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CML_1	33.2	349	398	400	1.73e-44	157
GibsonMK_2016_SRR3131800_bin.2_k141_3600_241	SARG|YP_001451669	33.2	352	398	390	3.82e-44	156
GibsonMK_2016_SRR3131800_bin.2_k141_3600_241	SARG|gi|730661043|ref|WP_034065992.1|	33.1	335	398	404	5.10e-44	156
GibsonMK_2016_SRR3131800_bin.2_k141_3600_241	SARG|gi|665823882|gb|AIF79467.1|	33.8	349	398	404	7.10e-44	156
GibsonMK_2016_SRR3131800_bin.2_k141_3600_241	SARG|AF332662.1.gene1.p01	34.1	349	398	404	7.10e-44	156
GibsonMK_2016_SRR3131800_bin.2_k141_3600_241	SARG|gi|742921897|ref|WP_039023559.1|	34.1	349	398	404	1.38e-43	155
GibsonMK_2016_SRR3131800_bin.2_k141_3600_241	SARG|gi|505244440|ref|WP_015431542.1|	33.8	349	398	404	1.92e-43	155
GibsonMK_2016_SRR3131800_bin.2_k141_3600_241	SARG|gi|504091830|ref|WP_014325824.1|	33.8	349	398	404	1.92e-43	155
GibsonMK_2016_SRR3131800_bin.2_k141_3600_241	SARG|gi|1028086699|ref|WP_063845073.1|	34.0	335	398	404	1.92e-43	155
GibsonMK_2016_SRR3131800_bin.2_k141_3600_271	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	34.3	102	338	228	7.84e-12	63.2
GibsonMK_2016_SRR3131800_bin.2_k141_3600_271	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	30.7	101	338	233	5.82e-06	45.8
GibsonMK_2016_SRR3131800_bin.2_k141_3600_275	CARD|gb|BAB35162.1|ARO:3000676|H-NS	83.7	135	136	137	9.32e-72	210
GibsonMK_2016_SRR3131800_bin.2_k141_3600_283	SARG|gi|1032819400|ref|WP_064325534.1|	31.9	251	339	646	3.66e-23	99.4
GibsonMK_2016_SRR3131800_bin.2_k141_3600_283	SARG|gi|974633183|ref|WP_059219858.1|	34.1	217	339	648	6.66e-23	98.6
GibsonMK_2016_SRR3131800_bin.2_k141_3600_283	SARG|gi|974684692|ref|WP_059267998.1|	34.1	217	339	648	6.66e-23	98.6
GibsonMK_2016_SRR3131800_bin.2_k141_3600_283	SARG|Q83LR7	34.1	217	339	648	8.98e-23	98.2
GibsonMK_2016_SRR3131800_bin.2_k141_3600_283	SARG|gi|647325472|ref|WP_025760953.1|	34.1	217	339	648	8.98e-23	98.2
GibsonMK_2016_SRR3131800_bin.2_k141_3600_283	SARG|gi|647323678|ref|WP_025760497.1|	34.1	217	339	648	8.98e-23	98.2
GibsonMK_2016_SRR3131800_bin.2_k141_3600_283	SARG|gi|446110308|ref|WP_000188163.1|	33.6	217	339	648	1.63e-22	97.4
GibsonMK_2016_SRR3131800_bin.2_k141_3600_283	SARG|gi|446110305|ref|WP_000188160.1|	33.6	217	339	648	1.63e-22	97.4
GibsonMK_2016_SRR3131800_bin.2_k141_3600_283	SARG|gi|510923671|ref|WP_016244456.1|	33.2	217	339	648	2.20e-22	97.1
GibsonMK_2016_SRR3131800_bin.2_k141_3600_283	SARG|gi|545248218|ref|WP_021546584.1|	31.8	245	339	648	2.20e-22	97.1
GibsonMK_2016_SRR3131800_bin.2_k141_3600_284	SARG|Q83LR7	30.6	235	334	648	9.69e-21	92.0
GibsonMK_2016_SRR3131800_bin.2_k141_3600_284	SARG|gi|647325472|ref|WP_025760953.1|	30.6	235	334	648	9.69e-21	92.0
GibsonMK_2016_SRR3131800_bin.2_k141_3600_284	SARG|gi|647323678|ref|WP_025760497.1|	30.6	235	334	648	9.69e-21	92.0
GibsonMK_2016_SRR3131800_bin.2_k141_3600_284	SARG|gi|446110305|ref|WP_000188160.1|	30.6	235	334	648	3.18e-20	90.5
GibsonMK_2016_SRR3131800_bin.2_k141_3600_284	SARG|gi|693256048|ref|WP_032359333.1|	31.1	235	334	648	5.76e-20	89.7
GibsonMK_2016_SRR3131800_bin.2_k141_3600_284	SARG|gi|754724054|ref|WP_042095806.1|	30.0	247	334	648	7.74e-20	89.4
GibsonMK_2016_SRR3131800_bin.2_k141_3600_284	SARG|gi|693106883|ref|WP_032260279.1|	31.1	235	334	648	7.74e-20	89.4
GibsonMK_2016_SRR3131800_bin.2_k141_3600_284	SARG|gi|693238509|ref|WP_032348033.1|	30.0	247	334	648	7.74e-20	89.4
GibsonMK_2016_SRR3131800_bin.2_k141_3600_284	SARG|gi|485870849|ref|WP_001467831.1|	30.0	247	334	648	7.74e-20	89.4
GibsonMK_2016_SRR3131800_bin.2_k141_3600_284	SARG|gi|748767925|ref|WP_040019608.1|	31.3	249	334	623	1.02e-19	89.0
GibsonMK_2016_SRR3131800_bin.2_k141_3600_288	NCBI|BAE79899.1|1|1|smfY|smfY||1|EFFLUX|EFFLUX|multidrug_efflux_MFS_transporter_SmfY|AMR|efflux	95.9	490	491	490	1.64e-317	861
GibsonMK_2016_SRR3131800_bin.2_k141_3600_288	NCBI|AMD83542.1|1|1|aadT|aadT||1|EFFLUX|EFFLUX|multidrug_efflux_MFS_transporter_AadT|AMR|efflux	41.5	477	491	504	8.75e-111	336
GibsonMK_2016_SRR3131800_bin.2_k141_3600_288	SARG|gb|ACQ82816.1|ARO:3004577|Acinetobacter	41.2	476	491	492	8.54e-108	328
GibsonMK_2016_SRR3131800_bin.2_k141_3600_288	SARG|gb|AAC43550.1|ARO:3003967|lrfA	39.3	489	491	504	4.02e-92	288
GibsonMK_2016_SRR3131800_bin.2_k141_3600_288	NCBI|WP_109638756.1|1|1|qepA8|qepA|efflux|2|quinolone|quinolone|quinolone_efflux_MFS_transporter_QepA8|AMR|quinolone	36.4	492	491	513	2.61e-80	258
GibsonMK_2016_SRR3131800_bin.2_k141_3600_288	SARG|gi|446545432|ref|WP_000622778.1|	36.6	423	491	514	2.67e-80	258
GibsonMK_2016_SRR3131800_bin.2_k141_3600_288	SARG|gi|488380213|ref|WP_002449598.1|	36.6	423	491	514	3.76e-80	257
GibsonMK_2016_SRR3131800_bin.2_k141_3600_288	SARG|gb|BAJ09383.1|ARO:3003046|qacA	36.4	423	491	514	5.28e-80	257
GibsonMK_2016_SRR3131800_bin.2_k141_3600_288	SARG|gb|AEZ36150.1|ARO:3000448|qepA	36.8	492	491	511	9.64e-80	256
GibsonMK_2016_SRR3131800_bin.2_k141_3600_288	SARG|AAK38457	36.4	423	491	514	1.04e-79	256
GibsonMK_2016_SRR3131800_bin.2_k141_3600_292	SARG|gi|446048013|ref|WP_000125868.1|	26.3	213	502	648	4.39e-17	83.2
GibsonMK_2016_SRR3131800_bin.2_k141_3600_292	SARG|gi|542061059|gb|ERI11611.1|	26.5	215	502	316	1.45e-14	73.6
GibsonMK_2016_SRR3131800_bin.2_k141_3600_292	SARG|gi|445996719|ref|WP_000074574.1|	26.5	215	502	309	3.28e-14	72.4
GibsonMK_2016_SRR3131800_bin.2_k141_3600_292	SARG|gi|445996722|ref|WP_000074577.1|	27.0	215	502	309	4.41e-14	72.0
GibsonMK_2016_SRR3131800_bin.2_k141_3600_292	SARG|gi|445996723|ref|WP_000074578.1|	26.5	215	502	309	5.91e-14	71.6
GibsonMK_2016_SRR3131800_bin.2_k141_3600_292	SARG|gi|884875933|emb|CKG93789.1|	27.0	215	502	309	7.94e-14	71.2
GibsonMK_2016_SRR3131800_bin.2_k141_3600_292	SARG|gi|445996724|ref|WP_000074579.1|	26.5	215	502	309	1.07e-13	70.9
GibsonMK_2016_SRR3131800_bin.2_k141_3600_292	SARG|gi|445996710|ref|WP_000074565.1|	26.0	215	502	309	1.07e-13	70.9
GibsonMK_2016_SRR3131800_bin.2_k141_3600_292	SARG|gi|445996729|ref|WP_000074584.1|	26.0	215	502	309	1.43e-13	70.5
GibsonMK_2016_SRR3131800_bin.2_k141_3600_292	SARG|gi|1043490477|ref|WP_065382463.1|	26.0	215	502	309	1.43e-13	70.5
GibsonMK_2016_SRR3131800_bin.2_k141_3600_336	SARG|gb|APB03219.1|ARO:3003986|TaeA	22.7	493	500	648	2.63e-19	90.1
GibsonMK_2016_SRR3131800_bin.2_k141_3600_336	SARG|gb|AAC74000.1|ARO:3003950|msbA	31.1	225	500	582	9.68e-19	88.2
GibsonMK_2016_SRR3131800_bin.2_k141_3600_336	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	25.4	228	500	343	7.36e-16	77.8
GibsonMK_2016_SRR3131800_bin.2_k141_3600_336	SARG|gb|AAA26793|ARO:3003748|oleC	25.8	209	500	325	8.30e-16	77.4
GibsonMK_2016_SRR3131800_bin.2_k141_3600_336	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	25.8	209	500	325	8.30e-16	77.4
GibsonMK_2016_SRR3131800_bin.2_k141_3600_336	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	27.3	209	500	293	1.52e-14	73.2
GibsonMK_2016_SRR3131800_bin.2_k141_3600_336	ResF|poxtA-Ef_1_WP094899500.1_1	26.2	214	500	538	1.55e-11	65.5
GibsonMK_2016_SRR3131800_bin.2_k141_3600_336	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	26.2	214	500	543	1.56e-11	65.5
GibsonMK_2016_SRR3131800_bin.2_k141_3600_336	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	26.2	214	500	543	1.56e-11	65.5
GibsonMK_2016_SRR3131800_bin.2_k141_3600_336	SARG|gi|694064328|ref|WP_032410816.1|	24.9	221	500	646	1.77e-11	65.5
GibsonMK_2016_SRR3131800_bin.2_k141_3666_26	SARG|WP_000345069.1	34.9	435	436	434	3.64e-84	263
GibsonMK_2016_SRR3131800_bin.2_k141_3742_11	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	33.3	219	378	255	8.25e-34	125
GibsonMK_2016_SRR3131800_bin.2_k141_3742_11	SARG|gb|ADZ12699.1|ARO:3005091|RanA	29.5	244	378	258	1.78e-30	116
GibsonMK_2016_SRR3131800_bin.2_k141_3742_11	SARG|gi|895865878|ref|WP_048974758.1|	33.8	225	378	646	3.74e-27	112
GibsonMK_2016_SRR3131800_bin.2_k141_3742_11	SARG|gi|639209604|ref|WP_024547784.1|	31.4	226	378	648	3.60e-24	103
GibsonMK_2016_SRR3131800_bin.2_k141_3742_39	SARG|gi|970309907|ref|WP_058679282.1|	68.6	360	372	371	6.82e-166	467
GibsonMK_2016_SRR3131800_bin.2_k141_3742_39	SARG|gi|829850806|ref|WP_047354351.1|	69.2	360	372	371	1.37e-165	466
GibsonMK_2016_SRR3131800_bin.2_k141_3742_39	SARG|gi|560398941|ref|WP_023622163.1|	68.6	360	372	371	1.95e-165	466
GibsonMK_2016_SRR3131800_bin.2_k141_3742_39	SARG|gi|1022698496|ref|WP_063449191.1|	69.2	360	372	371	3.92e-165	465
GibsonMK_2016_SRR3131800_bin.2_k141_3742_39	SARG|gi|970315539|ref|WP_058684013.1|	68.6	360	372	371	3.92e-165	465
GibsonMK_2016_SRR3131800_bin.2_k141_3742_39	SARG|gi|504644165|ref|WP_014831267.1|	68.3	360	372	371	5.56e-165	465
GibsonMK_2016_SRR3131800_bin.2_k141_3742_39	SARG|CP001918.1.gene2796.p01	68.3	360	372	371	7.89e-165	464
GibsonMK_2016_SRR3131800_bin.2_k141_3742_39	SARG|gi|695652614|ref|WP_032619987.1|	68.9	360	372	371	7.89e-165	464
GibsonMK_2016_SRR3131800_bin.2_k141_3742_39	SARG|gi|1016932842|ref|WP_063135292.1|	69.2	360	372	371	7.89e-165	464
GibsonMK_2016_SRR3131800_bin.2_k141_3742_39	SARG|gi|1020118981|ref|WP_063252810.1|	68.3	360	372	371	7.89e-165	464
GibsonMK_2016_SRR3131800_bin.2_k141_3742_40	SARG|gi|696411918|ref|WP_032982657.1|	74.3	647	648	647	0.0	910
GibsonMK_2016_SRR3131800_bin.2_k141_3742_40	SARG|gi|696402390|ref|WP_032974230.1|	74.3	647	648	647	0.0	910
GibsonMK_2016_SRR3131800_bin.2_k141_3742_40	SARG|YP_001438541	74.0	647	648	647	0.0	909
GibsonMK_2016_SRR3131800_bin.2_k141_3742_40	SARG|gi|565651791|ref|WP_023899061.1|	74.3	647	648	647	0.0	909
GibsonMK_2016_SRR3131800_bin.2_k141_3742_40	SARG|gi|490522515|ref|WP_004387938.1|	74.0	647	648	647	0.0	908
GibsonMK_2016_SRR3131800_bin.2_k141_3742_40	SARG|gi|504542119|ref|WP_014729221.1|	74.0	647	648	647	0.0	908
GibsonMK_2016_SRR3131800_bin.2_k141_3742_40	SARG|gi|938460528|ref|WP_054624864.1|	74.0	647	648	647	0.0	907
GibsonMK_2016_SRR3131800_bin.2_k141_3742_40	SARG|gi|696423952|ref|WP_032993748.1|	74.2	647	648	647	0.0	907
GibsonMK_2016_SRR3131800_bin.2_k141_3742_40	SARG|gi|938461734|ref|WP_054625806.1|	73.9	647	648	647	0.0	906
GibsonMK_2016_SRR3131800_bin.2_k141_3742_40	SARG|gi|696420214|ref|WP_032990021.1|	73.9	647	648	647	0.0	905
GibsonMK_2016_SRR3131800_bin.2_k141_3742_46	SARG|gb|AAC74000.1|ARO:3003950|msbA	31.5	378	580	582	8.80e-52	186
GibsonMK_2016_SRR3131800_bin.2_k141_3742_46	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	37.5	232	580	579	1.30e-39	151
GibsonMK_2016_SRR3131800_bin.2_k141_3742_46	SARG|gb|AAK76137.1|ARO:3000024|patA	29.8	326	580	564	2.77e-39	150
GibsonMK_2016_SRR3131800_bin.2_k141_3742_46	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	36.6	232	580	579	4.46e-39	150
GibsonMK_2016_SRR3131800_bin.2_k141_3742_46	SARG|gb|AYV52072.1|ARO:3002882|lmrD	25.4	496	580	664	1.58e-36	143
GibsonMK_2016_SRR3131800_bin.2_k141_3742_46	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	34.0	212	580	528	1.33e-24	106
GibsonMK_2016_SRR3131800_bin.2_k141_3742_46	SARG|gi|554685678|ref|WP_023185565.1|	33.5	230	580	648	1.60e-24	107
GibsonMK_2016_SRR3131800_bin.2_k141_3742_46	SARG|gi|555268367|ref|WP_023249730.1|	32.1	243	580	648	3.76e-24	105
GibsonMK_2016_SRR3131800_bin.2_k141_3742_46	SARG|gi|1027935297|ref|WP_063809363.1|	32.1	243	580	648	3.76e-24	105
GibsonMK_2016_SRR3131800_bin.2_k141_3742_46	SARG|gi|779838942|ref|WP_045343641.1|	32.1	243	580	648	5.00e-24	105
GibsonMK_2016_SRR3131800_bin.2_k141_3742_47	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	24.4	520	562	578	3.16e-33	132
GibsonMK_2016_SRR3131800_bin.2_k141_3742_47	SARG|gb|AYV52072.1|ARO:3002882|lmrD	22.1	488	562	664	2.61e-29	121
GibsonMK_2016_SRR3131800_bin.2_k141_3742_47	SARG|gb|AAK76137.1|ARO:3000024|patA	31.9	210	562	564	4.31e-27	114
GibsonMK_2016_SRR3131800_bin.2_k141_3742_47	SARG|gb|CDO61516.1|ARO:3003949|efrB	25.5	369	562	362	1.54e-20	92.4
GibsonMK_2016_SRR3131800_bin.2_k141_3742_47	SARG|gb|WP_082039181.1|ARO:3007028|salD	28.2	188	562	544	1.89e-07	52.8
GibsonMK_2016_SRR3131800_bin.2_k141_3742_68	SARG|gb|AAC74000.1|ARO:3003950|msbA	87.5	582	583	582	0.0	958
GibsonMK_2016_SRR3131800_bin.2_k141_3742_68	SARG|gi|1045390184|ref|WP_065479071.1|	33.7	572	583	605	4.28e-89	286
GibsonMK_2016_SRR3131800_bin.2_k141_3742_68	SARG|gi|948137056|ref|WP_056795395.1|	33.9	575	583	602	5.93e-88	283
GibsonMK_2016_SRR3131800_bin.2_k141_3742_68	SARG|gi|695865802|ref|WP_032778631.1|	33.6	575	583	605	3.45e-87	281
GibsonMK_2016_SRR3131800_bin.2_k141_3742_68	SARG|gi|764446018|ref|WP_044369325.1|	33.4	575	583	605	1.33e-86	280
GibsonMK_2016_SRR3131800_bin.2_k141_3742_68	SARG|gi|948040364|ref|WP_056699531.1|	33.4	575	583	603	2.49e-86	279
GibsonMK_2016_SRR3131800_bin.2_k141_3742_68	SARG|gi|695887424|ref|WP_032788534.1|	33.4	575	583	605	3.66e-86	278
GibsonMK_2016_SRR3131800_bin.2_k141_3742_68	SARG|gi|951183771|ref|WP_057661487.1|	33.0	575	583	603	4.89e-86	278
GibsonMK_2016_SRR3131800_bin.2_k141_3742_68	SARG|gi|664180077|ref|WP_030714054.1|	32.9	586	583	605	5.13e-86	278
GibsonMK_2016_SRR3131800_bin.2_k141_3742_68	SARG|gi|928900436|ref|WP_053931243.1|	33.2	575	583	600	6.37e-86	278
GibsonMK_2016_SRR3131800_bin.2_k141_3742_86	SARG|gb|CAA09666.1|ARO:3004122|Klebsiella	65.8	389	376	374	3.92e-181	506
GibsonMK_2016_SRR3131800_bin.2_k141_3742_86	megares|MEG_4285|Drugs|beta-lactam|Mutant_porin_proteins|OMPD_1	52.8	371	376	357	2.59e-124	361
GibsonMK_2016_SRR3131800_bin.2_k141_3742_91	SARG|gi|895865878|ref|WP_048974758.1|	38.1	236	258	646	1.24e-29	115
GibsonMK_2016_SRR3131800_bin.2_k141_3742_91	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	32.7	211	258	343	3.07e-21	90.1
GibsonMK_2016_SRR3131800_bin.2_k141_3742_99	SARG|gb|APB03216.1|ARO:3003982|LlmA	27.6	156	721	287	1.76e-08	55.5
GibsonMK_2016_SRR3131800_bin.2_k141_3742_100	SARG|gb|AVI44920.1|ARO:3004470|poxtA	31.7	508	635	542	5.56e-70	235
GibsonMK_2016_SRR3131800_bin.2_k141_3742_100	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	31.7	508	635	544	5.83e-70	235
GibsonMK_2016_SRR3131800_bin.2_k141_3742_100	ResF|poxtA-Ef_1_WP094899500.1_1	30.2	510	635	538	1.95e-68	231
GibsonMK_2016_SRR3131800_bin.2_k141_3742_100	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	30.2	510	635	543	2.18e-68	231
GibsonMK_2016_SRR3131800_bin.2_k141_3742_100	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	30.2	510	635	543	2.18e-68	231
GibsonMK_2016_SRR3131800_bin.2_k141_3742_100	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.6	526	635	655	4.21e-67	230
GibsonMK_2016_SRR3131800_bin.2_k141_3742_100	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.6	526	635	655	8.09e-67	229
GibsonMK_2016_SRR3131800_bin.2_k141_3742_100	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	526	635	655	1.55e-66	229
GibsonMK_2016_SRR3131800_bin.2_k141_3742_100	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	526	635	655	2.98e-66	228
GibsonMK_2016_SRR3131800_bin.2_k141_3742_100	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	526	635	655	2.98e-66	228
GibsonMK_2016_SRR3131800_bin.2_k141_3742_109	megares|MEG_8288|Drugs|beta-lactam|Mutant_porin_proteins|OMPA_1	78.9	360	360	374	3.52e-194	538
GibsonMK_2016_SRR3131800_bin.2_k141_3742_109	CARD|gb|CDO13836.1|ARO:3005044|OmpA	78.9	360	360	374	3.52e-194	538
GibsonMK_2016_SRR3131800_bin.2_k141_3742_135	CARD|gb|AAG05661.1|ARO:3004107|Paer_soxR	58.0	143	157	156	7.95e-57	174
GibsonMK_2016_SRR3131800_bin.2_k141_3742_136	SARG|gb|AAG07592.1|ARO:3000806|mexG	63.7	135	143	148	1.19e-55	170
GibsonMK_2016_SRR3131800_bin.2_k141_3742_137	SARG|gi|553764859|ref|WP_023097180.1|	65.6	346	361	370	6.55e-139	398
GibsonMK_2016_SRR3131800_bin.2_k141_3742_137	SARG|gi|730343260|ref|WP_033991900.1|	65.9	346	361	370	9.30e-139	398
GibsonMK_2016_SRR3131800_bin.2_k141_3742_137	SARG|gi|730659516|ref|WP_034065722.1|	65.6	346	361	370	9.30e-139	398
GibsonMK_2016_SRR3131800_bin.2_k141_3742_137	SARG|gi|496670785|ref|WP_009313275.1|	65.6	346	361	370	1.32e-138	397
GibsonMK_2016_SRR3131800_bin.2_k141_3742_137	SARG|gi|553776434|ref|WP_023108253.1|	65.6	346	361	370	1.32e-138	397
GibsonMK_2016_SRR3131800_bin.2_k141_3742_137	SARG|gi|685983188|ref|WP_031690361.1|	65.6	346	361	370	1.32e-138	397
GibsonMK_2016_SRR3131800_bin.2_k141_3742_137	SARG|gi|685899386|ref|WP_031640016.1|	65.6	346	361	370	1.32e-138	397
GibsonMK_2016_SRR3131800_bin.2_k141_3742_137	SARG|gi|518226703|ref|WP_019396911.1|	65.6	346	361	370	1.87e-138	397
GibsonMK_2016_SRR3131800_bin.2_k141_3742_137	SARG|gi|489205684|ref|WP_003114726.1|	65.6	346	361	370	2.65e-138	397
GibsonMK_2016_SRR3131800_bin.2_k141_3742_137	SARG|gi|553773159|ref|WP_023105016.1|	65.6	346	361	370	2.65e-138	397
GibsonMK_2016_SRR3131800_bin.2_k141_3742_138	CARD|gb|AAG07594.1|ARO:3000808|MexI	83.0	1022	1027	1029	0.0	1595
GibsonMK_2016_SRR3131800_bin.2_k141_3742_138	SARG|YP_001186705	51.6	1009	1027	1017	0.0	952
GibsonMK_2016_SRR3131800_bin.2_k141_3742_138	SARG|YP_001350280	52.0	1009	1027	1018	0.0	952
GibsonMK_2016_SRR3131800_bin.2_k141_3742_138	SARG|YP_350221	51.8	1006	1027	1009	0.0	950
GibsonMK_2016_SRR3131800_bin.2_k141_3742_138	SARG|YP_001266290	51.5	1013	1027	1014	0.0	948
GibsonMK_2016_SRR3131800_bin.2_k141_3742_138	SARG|CAY51926	51.1	1006	1027	1008	0.0	946
GibsonMK_2016_SRR3131800_bin.2_k141_3742_138	SARG|YP_792720	51.6	1009	1027	1018	0.0	945
GibsonMK_2016_SRR3131800_bin.2_k141_3742_138	SARG|AAG07763	51.5	1009	1027	1018	0.0	944
GibsonMK_2016_SRR3131800_bin.2_k141_3742_138	SARG|YP_001670703	51.4	1005	1027	1014	0.0	941
GibsonMK_2016_SRR3131800_bin.2_k141_3742_138	SARG|YP_606823	51.3	1005	1027	1011	0.0	933
GibsonMK_2016_SRR3131800_bin.2_k141_3742_147	SARG|WP_000345069.1	34.3	379	438	434	2.73e-69	225
GibsonMK_2016_SRR3131800_bin.2_k141_3742_152	megares|MEG_2614|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|DHAP_1	28.2	341	391	395	4.05e-30	118
GibsonMK_2016_SRR3131800_bin.2_k141_3742_156	CARD|gb|AAL20862.1|ARO:3000826|sdiA	31.0	239	239	240	3.36e-28	106
GibsonMK_2016_SRR3131800_bin.2_k141_3742_172	CARD|gb|BAB36671.1|ARO:3000832|evgA	26.8	205	219	204	7.97e-18	77.4
GibsonMK_2016_SRR3131800_bin.2_k141_3742_172	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	25.5	149	219	228	7.95e-06	44.3
GibsonMK_2016_SRR3131800_bin.2_k141_3742_180	SARG|gb|ABO11759.2|ARO:3004573|Acinetobacter	33.9	428	501	429	1.41e-76	246
GibsonMK_2016_SRR3131800_bin.2_k141_3742_181	SARG|NC_011595.7058890.p01	40.5	454	456	468	4.15e-98	301
GibsonMK_2016_SRR3131800_bin.2_k141_3742_181	SARG|ZP_02904358	24.9	405	456	488	1.19e-21	96.3
GibsonMK_2016_SRR3131800_bin.2_k141_3742_181	SARG|gi|693058885|ref|WP_032226462.1|	24.4	405	456	488	2.29e-19	89.4
GibsonMK_2016_SRR3131800_bin.2_k141_3742_182	SARG|gi|639225329|ref|WP_024561799.1|	52.9	650	646	648	1.07e-212	608
GibsonMK_2016_SRR3131800_bin.2_k141_3742_182	SARG|gi|639218559|ref|WP_024556062.1|	52.9	650	646	648	1.07e-212	608
GibsonMK_2016_SRR3131800_bin.2_k141_3742_182	SARG|gi|554685678|ref|WP_023185565.1|	51.5	650	646	648	4.30e-212	606
GibsonMK_2016_SRR3131800_bin.2_k141_3742_182	SARG|gi|671541568|ref|WP_031525212.1|	52.2	651	646	648	2.45e-211	604
GibsonMK_2016_SRR3131800_bin.2_k141_3742_182	SARG|YP_001571041	51.5	654	646	648	6.96e-211	603
GibsonMK_2016_SRR3131800_bin.2_k141_3742_182	SARG|gi|657888313|ref|WP_029592374.1|	52.5	650	646	648	9.86e-211	603
GibsonMK_2016_SRR3131800_bin.2_k141_3742_182	SARG|gi|959109145|ref|WP_058113944.1|	51.5	652	646	648	9.86e-211	603
GibsonMK_2016_SRR3131800_bin.2_k141_3742_182	SARG|gi|960873409|ref|WP_058345546.1|	51.5	654	646	648	9.86e-211	603
GibsonMK_2016_SRR3131800_bin.2_k141_3742_182	SARG|gi|446048047|ref|WP_000125902.1|	51.1	655	646	648	1.40e-210	602
GibsonMK_2016_SRR3131800_bin.2_k141_3742_182	SARG|gi|639209604|ref|WP_024547784.1|	52.4	653	646	648	3.97e-210	601
GibsonMK_2016_SRR3131800_bin.2_k141_3742_183	SARG|gi|487980711|ref|WP_002053440.1|	36.3	438	397	446	4.84e-72	231
GibsonMK_2016_SRR3131800_bin.2_k141_3742_183	SARG|gi|490848588|ref|WP_004710651.1|	36.3	438	397	446	4.84e-72	231
GibsonMK_2016_SRR3131800_bin.2_k141_3742_183	SARG|gi|518287882|ref|WP_019458090.1|	35.6	438	397	446	1.04e-70	228
GibsonMK_2016_SRR3131800_bin.2_k141_3742_183	SARG|gi|935509353|ref|WP_054428282.1|	36.1	385	397	371	1.19e-69	223
GibsonMK_2016_SRR3131800_bin.2_k141_3742_183	SARG|gi|585355297|ref|WP_024236900.1|	36.1	385	397	371	4.69e-69	221
GibsonMK_2016_SRR3131800_bin.2_k141_3742_183	SARG|gi|657686580|ref|WP_029487409.1|	36.1	385	397	371	4.69e-69	221
GibsonMK_2016_SRR3131800_bin.2_k141_3742_183	SARG|gi|446669094|ref|WP_000746440.1|	36.1	385	397	371	6.61e-69	221
GibsonMK_2016_SRR3131800_bin.2_k141_3742_183	SARG|gi|757751310|ref|WP_042972661.1|	36.1	385	397	371	1.31e-68	220
GibsonMK_2016_SRR3131800_bin.2_k141_3742_183	SARG|gi|823646750|ref|WP_047090888.1|	35.8	385	397	371	1.31e-68	220
GibsonMK_2016_SRR3131800_bin.2_k141_3742_183	SARG|gi|585350765|ref|WP_024232378.1|	35.8	385	397	371	1.85e-68	219
GibsonMK_2016_SRR3131800_bin.2_k141_3742_204	CARD|gb|ABV18113.1|ARO:3001329|mdtG	80.9	393	413	408	1.36e-227	627
GibsonMK_2016_SRR3131800_bin.2_k141_3742_204	SARG|WP_000136147.1	46.5	381	413	399	2.99e-109	326
GibsonMK_2016_SRR3131800_bin.2_k141_3742_204	NCBI|EHE72460.1|1|1|pmrA|pmrA|efflux|1|quinolone|quinolone|multidrug_efflux_MFS_transporter_PmrA|AMR|quinolone	43.6	381	413	371	4.39e-96	291
GibsonMK_2016_SRR3131800_bin.2_k141_3742_204	SARG|gi|446964022|ref|WP_001041278.1|	23.5	362	413	388	1.31e-18	85.9
GibsonMK_2016_SRR3131800_bin.2_k141_3742_204	SARG|gi|446964023|ref|WP_001041279.1|	23.5	362	413	388	1.76e-18	85.5
GibsonMK_2016_SRR3131800_bin.2_k141_3742_204	SARG|gi|686391947|ref|WP_031906419.1|	23.5	362	413	388	1.76e-18	85.5
GibsonMK_2016_SRR3131800_bin.2_k141_3742_204	SARG|gi|686115864|ref|WP_031765718.1|	23.5	362	413	388	2.38e-18	85.1
GibsonMK_2016_SRR3131800_bin.2_k141_3742_204	SARG|gi|446964030|ref|WP_001041286.1|	23.2	362	413	388	3.20e-18	84.7
GibsonMK_2016_SRR3131800_bin.2_k141_3742_204	SARG|gi|446964029|ref|WP_001041285.1|	23.2	362	413	388	4.31e-18	84.3
GibsonMK_2016_SRR3131800_bin.2_k141_3742_204	SARG|gi|686242310|ref|WP_031833515.1|	23.2	362	413	388	4.31e-18	84.3
GibsonMK_2016_SRR3131800_bin.2_k141_3742_253	NCBI|AAO18187.2|1|1|sdeB|sdeB|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_SdeB|AMR|efflux	98.5	1046	1048	1047	0.0	1940
GibsonMK_2016_SRR3131800_bin.2_k141_3742_253	NCBI|WP_012967412.1|1|1|oqxB9|oqxB|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_OqxB9|AMR|multidrug	87.2	1045	1048	1050	0.0	1750
GibsonMK_2016_SRR3131800_bin.2_k141_3742_253	NCBI|WP_023323140.1|1|1|oqxB15|oqxB|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_OqxB15|AMR|multidrug	87.1	1045	1048	1050	0.0	1749
GibsonMK_2016_SRR3131800_bin.2_k141_3742_253	NCBI|WP_021312368.1|1|1|oqxB20|oqxB|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_OqxB20|AMR|multidrug	87.1	1045	1048	1050	0.0	1749
GibsonMK_2016_SRR3131800_bin.2_k141_3742_253	NCBI|WP_004899982.1|1|1|oqxB17|oqxB|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_OqxB17|AMR|multidrug	87.1	1045	1048	1050	0.0	1749
GibsonMK_2016_SRR3131800_bin.2_k141_3742_253	NCBI|WP_063865569.1|1|1|oqxB7|oqxB|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_OqxB7|AMR|multidrug	87.1	1045	1048	1050	0.0	1748
GibsonMK_2016_SRR3131800_bin.2_k141_3742_253	NCBI|WP_004149399.1|1|1|oqxB19|oqxB|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_OqxB19|AMR|multidrug	87.0	1045	1048	1050	0.0	1748
GibsonMK_2016_SRR3131800_bin.2_k141_3742_253	NCBI|WP_063865552.1|1|1|oqxB4|oqxB|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_OqxB4|AMR|multidrug	87.0	1045	1048	1050	0.0	1748
GibsonMK_2016_SRR3131800_bin.2_k141_3742_253	NCBI|WP_023342632.1|1|1|oqxB32|oqxB|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_OqxB32|AMR|multidrug	87.0	1045	1048	1050	0.0	1747
GibsonMK_2016_SRR3131800_bin.2_k141_3742_253	NCBI|WP_063865430.1|1|1|oqxB16|oqxB|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_OqxB16|AMR|multidrug	87.1	1045	1048	1050	0.0	1747
GibsonMK_2016_SRR3131800_bin.2_k141_3742_254	NCBI|WP_063865358.1|1|1|oqxA2|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA2|AMR|multidrug	70.9	374	396	391	2.94e-178	500
GibsonMK_2016_SRR3131800_bin.2_k141_3742_254	NCBI|WP_063865399.1|1|1|oqxA9|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA9|AMR|multidrug	70.6	374	396	391	2.94e-178	500
GibsonMK_2016_SRR3131800_bin.2_k141_3742_254	SARG|gb|AAP43109.1|ARO:3003922|oqxA	70.6	374	396	391	4.18e-178	500
GibsonMK_2016_SRR3131800_bin.2_k141_3742_254	NCBI|WP_004149398.1|1|1|oqxA10|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA10|AMR|multidrug	70.6	374	396	391	8.41e-178	499
GibsonMK_2016_SRR3131800_bin.2_k141_3742_254	NCBI|WP_047693838.1|1|1|oqxA6|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA6|AMR|multidrug	70.3	374	396	391	1.19e-177	499
GibsonMK_2016_SRR3131800_bin.2_k141_3742_254	NCBI|WP_004212918.1|1|1|oqxA11|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA11|AMR|multidrug	70.3	374	396	391	1.69e-177	498
GibsonMK_2016_SRR3131800_bin.2_k141_3742_254	NCBI|WP_063865373.1|1|1|oqxA5|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA5|AMR|multidrug	70.3	374	396	391	1.69e-177	498
GibsonMK_2016_SRR3131800_bin.2_k141_3742_254	NCBI|WP_063865385.1|1|1|oqxA7|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA7|AMR|multidrug	70.3	374	396	391	2.40e-177	498
GibsonMK_2016_SRR3131800_bin.2_k141_3742_254	NCBI|WP_004890321.1|1|1|oqxA3|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA3|AMR|multidrug	70.3	374	396	391	2.40e-177	498
GibsonMK_2016_SRR3131800_bin.2_k141_3742_254	NCBI|WP_063865390.1|1|1|oqxA8|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA8|AMR|multidrug	70.7	372	396	391	4.84e-177	497
GibsonMK_2016_SRR3131800_bin.2_k141_3742_255	CARD|gb|BAA15221.2|ARO:3000263|marA	48.0	100	119	127	6.75e-30	103
GibsonMK_2016_SRR3131800_bin.2_k141_3742_255	CARD|gb|AFK13828.1|ARO:3000823|ramA	48.4	93	119	124	9.40e-27	95.1
GibsonMK_2016_SRR3131800_bin.2_k141_3742_255	megares|MEG_7070|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|TETD_1	44.1	102	119	138	4.45e-25	91.3
GibsonMK_2016_SRR3131800_bin.2_k141_3742_258	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	30.2	192	314	323	1.70e-13	68.9
GibsonMK_2016_SRR3131800_bin.2_k141_3742_284	SARG|gi|542061059|gb|ERI11611.1|	31.2	205	495	316	2.42e-15	75.9
GibsonMK_2016_SRR3131800_bin.2_k141_3742_284	SARG|gi|445996710|ref|WP_000074565.1|	30.0	217	495	309	1.32e-14	73.6
GibsonMK_2016_SRR3131800_bin.2_k141_3742_284	SARG|gi|507055561|ref|WP_016126482.1|	30.2	205	495	309	3.20e-14	72.4
GibsonMK_2016_SRR3131800_bin.2_k141_3742_284	SARG|P42332	30.4	204	495	306	7.52e-14	71.2
GibsonMK_2016_SRR3131800_bin.2_k141_3742_284	SARG|ABB80128	30.4	204	495	306	7.52e-14	71.2
GibsonMK_2016_SRR3131800_bin.2_k141_3742_284	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	30.4	204	495	306	7.52e-14	71.2
GibsonMK_2016_SRR3131800_bin.2_k141_3742_284	SARG|gi|445996719|ref|WP_000074574.1|	29.8	205	495	309	7.75e-14	71.2
GibsonMK_2016_SRR3131800_bin.2_k141_3742_284	SARG|gi|510143239|gb|AGN36970.1|	30.4	204	495	313	8.06e-14	71.2
GibsonMK_2016_SRR3131800_bin.2_k141_3742_284	SARG|gi|445996722|ref|WP_000074577.1|	30.2	205	495	309	1.40e-13	70.5
GibsonMK_2016_SRR3131800_bin.2_k141_3742_284	SARG|gi|814314593|emb|CKF49145.1|	29.9	204	495	309	1.40e-13	70.5
GibsonMK_2016_SRR3131800_bin.2_k141_3742_329	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	33.5	224	235	255	4.07e-41	140
GibsonMK_2016_SRR3131800_bin.2_k141_3742_329	SARG|gb|AAK76137.1|ARO:3000024|patA	27.1	207	235	564	3.75e-14	70.1
GibsonMK_2016_SRR3131800_bin.2_k141_3742_329	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	39.5	81	235	550	7.82e-09	54.3
GibsonMK_2016_SRR3131800_bin.2_k141_3742_329	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	38.0	79	235	568	2.58e-08	52.8
GibsonMK_2016_SRR3131800_bin.2_k141_3742_329	SARG|AAG08983	38.6	83	235	524	1.15e-06	47.8
GibsonMK_2016_SRR3131800_bin.2_k141_3742_329	SARG|KC539823.1.gene1.p01	42.3	78	235	522	6.68e-06	45.4
GibsonMK_2016_SRR3131800_bin.2_k141_3742_339	SARG|gb|AAK76137.1|ARO:3000024|patA	29.1	230	372	564	9.00e-20	89.7
GibsonMK_2016_SRR3131800_bin.2_k141_3742_339	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	26.7	232	372	574	4.51e-13	69.3
GibsonMK_2016_SRR3131800_bin.2_k141_3742_339	SARG|gb|APB03219.1|ARO:3003986|TaeA	24.2	244	372	648	5.85e-09	56.6
GibsonMK_2016_SRR3131800_bin.2_k141_3742_339	SARG|gb|WP_082039181.1|ARO:3007028|salD	25.7	183	372	544	3.89e-08	53.9
GibsonMK_2016_SRR3131800_bin.2_k141_3742_347	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	35.1	222	224	225	4.52e-39	133
GibsonMK_2016_SRR3131800_bin.2_k141_3742_347	CARD|gb|AAC73788.1|ARO:3003841|kdpE	35.1	222	224	225	4.52e-39	133
GibsonMK_2016_SRR3131800_bin.2_k141_3742_347	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	33.8	219	224	228	6.01e-37	128
GibsonMK_2016_SRR3131800_bin.2_k141_3742_347	CARD|gb|ATC67679.1|ARO:3000838|arlR	32.7	217	224	219	1.15e-34	122
GibsonMK_2016_SRR3131800_bin.2_k141_3742_347	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	33.6	223	224	233	3.26e-34	121
GibsonMK_2016_SRR3131800_bin.2_k141_3742_347	CARD|gb|AAG05188.1|ARO:3005068|ParR	33.9	224	224	235	2.06e-32	116
GibsonMK_2016_SRR3131800_bin.2_k141_3742_347	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	33.5	221	224	231	7.33e-32	115
GibsonMK_2016_SRR3131800_bin.2_k141_3742_347	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.1	222	224	219	1.08e-31	114
GibsonMK_2016_SRR3131800_bin.2_k141_3742_347	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.1	222	224	219	1.52e-31	114
GibsonMK_2016_SRR3131800_bin.2_k141_3742_347	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.1	222	224	220	1.56e-31	114
GibsonMK_2016_SRR3131800_bin.2_k141_3742_375	NCBI|WP_109545034.1|1|1|qnrB22|qnrB|target_protection|2|quinolone|quinolone|quinolone_resistance_pentapeptide_repeat_protein_QnrB22|AMR|quinolone	82.7	214	215	214	1.47e-94	274
GibsonMK_2016_SRR3131800_bin.2_k141_3742_375	SARG|gb|ACS71746.1|ARO:3002737|QnrB22	82.7	214	215	215	1.52e-94	274
GibsonMK_2016_SRR3131800_bin.2_k141_3742_375	SARG|YP_001478290	79.0	214	215	214	1.39e-92	269
GibsonMK_2016_SRR3131800_bin.2_k141_3742_375	NCBI|WP_063866022.1|1|1|qnrB31|qnrB|target_protection|2|quinolone|quinolone|quinolone_resistance_pentapeptide_repeat_protein_QnrB31|AMR|quinolone	81.8	214	215	214	3.97e-92	268
GibsonMK_2016_SRR3131800_bin.2_k141_3742_375	SARG|gb|ADQ43424.1|ARO:3002746|QnrB31	81.8	214	215	226	5.95e-92	268
GibsonMK_2016_SRR3131800_bin.2_k141_3742_375	NCBI|WP_174771641.1|1|1|qnrB93|qnrB|target_protection|2|quinolone|quinolone|quinolone_resistance_pentapeptide_repeat_protein_QnrB93|AMR|quinolone	81.3	214	215	214	3.25e-91	265
GibsonMK_2016_SRR3131800_bin.2_k141_3742_375	NCBI|WP_063865948.1|1|1|qnrB23|qnrB|target_protection|2|quinolone|quinolone|quinolone_resistance_pentapeptide_repeat_protein_QnrB23|AMR|quinolone	80.4	214	215	214	1.53e-89	261
GibsonMK_2016_SRR3131800_bin.2_k141_3742_375	SARG|gb|AEL00451.1|ARO:3002748|QnrB33	79.4	214	215	214	2.17e-89	261
GibsonMK_2016_SRR3131800_bin.2_k141_3742_375	SARG|gb|ACS71747.1|ARO:3002738|QnrB23	80.4	214	215	226	2.28e-89	261
GibsonMK_2016_SRR3131800_bin.2_k141_3742_375	NCBI|WP_063865798.1|1|1|qnrB15|qnrB|target_protection|2|quinolone|quinolone|quinolone_resistance_pentapeptide_repeat_protein_QnrB15|AMR|quinolone	79.4	214	215	214	5.06e-88	257
GibsonMK_2016_SRR3131800_bin.2_k141_3742_401	SARG|gb|ABO11759.2|ARO:3004573|Acinetobacter	31.3	425	435	429	1.21e-58	197
GibsonMK_2016_SRR3131800_bin.2_k141_3742_426	SARG|CP001581.1.gene725.p01	31.3	393	465	477	4.66e-51	179
GibsonMK_2016_SRR3131800_bin.2_k141_3742_426	SARG|NP_826974	28.1	420	465	540	5.56e-42	155
GibsonMK_2016_SRR3131800_bin.2_k141_3742_426	SARG|YP_002181880	30.3	403	465	536	1.38e-41	154
GibsonMK_2016_SRR3131800_bin.2_k141_3742_426	SARG|YP_002203876	28.6	420	465	539	1.43e-41	154
GibsonMK_2016_SRR3131800_bin.2_k141_3742_426	SARG|NP_733568	28.0	404	465	536	6.78e-41	152
GibsonMK_2016_SRR3131800_bin.2_k141_3742_426	SARG|YP_002193132	28.3	420	465	537	4.64e-40	150
GibsonMK_2016_SRR3131800_bin.2_k141_3742_426	SARG|YP_002196817	27.4	427	465	536	1.63e-39	148
GibsonMK_2016_SRR3131800_bin.2_k141_3742_426	SARG|BAA07390	31.4	421	465	512	1.40e-37	142
GibsonMK_2016_SRR3131800_bin.2_k141_3742_426	SARG|gi|1039291348|ref|WP_064768701.1|	29.5	413	465	511	3.58e-37	141
GibsonMK_2016_SRR3131800_bin.2_k141_3742_426	SARG|gi|1039004533|ref|WP_064760451.1|	29.5	413	465	511	9.23e-37	140
GibsonMK_2016_SRR3131800_bin.2_k141_3742_430	SARG|gi|1022688710|ref|WP_063443532.1|	38.0	205	379	648	2.42e-31	124
GibsonMK_2016_SRR3131800_bin.2_k141_3742_430	SARG|gi|823326845|ref|WP_047080664.1|	37.6	205	379	648	4.44e-31	123
GibsonMK_2016_SRR3131800_bin.2_k141_3742_430	SARG|gi|695793471|ref|WP_032707680.1|	37.6	205	379	648	6.02e-31	123
GibsonMK_2016_SRR3131800_bin.2_k141_3742_430	SARG|gi|823302270|ref|WP_047057473.1|	37.6	205	379	648	6.02e-31	123
GibsonMK_2016_SRR3131800_bin.2_k141_3742_430	SARG|gi|976146774|ref|WP_059305359.1|	37.6	205	379	648	6.02e-31	123
GibsonMK_2016_SRR3131800_bin.2_k141_3742_430	SARG|gi|1022664304|ref|WP_063420886.1|	37.6	205	379	648	6.02e-31	123
GibsonMK_2016_SRR3131800_bin.2_k141_3742_430	SARG|gi|823309640|ref|WP_047064288.1|	37.6	205	379	648	6.02e-31	123
GibsonMK_2016_SRR3131800_bin.2_k141_3742_430	SARG|gi|505807117|ref|WP_015704872.1|	37.6	205	379	648	6.02e-31	123
GibsonMK_2016_SRR3131800_bin.2_k141_3742_430	SARG|gi|505180394|ref|WP_015367496.1|	37.6	205	379	648	6.02e-31	123
GibsonMK_2016_SRR3131800_bin.2_k141_3742_430	SARG|gi|518923394|ref|WP_020079269.1|	37.6	205	379	648	6.02e-31	123
GibsonMK_2016_SRR3131800_bin.2_k141_3742_443	SARG|gi|500448961|gb|EOP61695.1|	25.8	244	297	306	5.56e-17	78.6
GibsonMK_2016_SRR3131800_bin.2_k141_3742_443	SARG|ZP_04081918	25.5	259	297	306	5.56e-17	78.6
GibsonMK_2016_SRR3131800_bin.2_k141_3742_443	SARG|gi|500465078|gb|EOP76697.1|	25.8	244	297	306	5.56e-17	78.6
GibsonMK_2016_SRR3131800_bin.2_k141_3742_443	SARG|gi|447195835|ref|WP_001273091.1|	27.0	211	297	306	1.04e-16	77.8
GibsonMK_2016_SRR3131800_bin.2_k141_3742_443	SARG|gi|507044560|ref|WP_016115614.1|	25.2	258	297	306	1.42e-16	77.4
GibsonMK_2016_SRR3131800_bin.2_k141_3742_443	SARG|gi|447195836|ref|WP_001273092.1|	26.5	211	297	306	2.64e-16	76.6
GibsonMK_2016_SRR3131800_bin.2_k141_3742_443	SARG|YP_001373621	24.8	262	297	318	1.02e-15	75.1
GibsonMK_2016_SRR3131800_bin.2_k141_3742_443	SARG|gb|AAC75271.1|ARO:3003952|yojI	31.0	213	297	547	1.16e-11	63.9
GibsonMK_2016_SRR3131800_bin.2_k141_3742_443	SARG|gi|763097172|ref|WP_043977684.1|	24.3	181	297	492	6.65e-09	55.5
GibsonMK_2016_SRR3131800_bin.2_k141_3742_443	SARG|gi|924355535|ref|WP_053488586.1|	24.9	181	297	492	8.88e-09	55.1
GibsonMK_2016_SRR3131800_bin.2_k141_3742_525	SARG|gb|AAC75314.1|ARO:3003578|pmrF	77.5	311	327	322	3.47e-180	499
GibsonMK_2016_SRR3131800_bin.2_k141_3742_526	SARG|gi|489117806|ref|WP_003027650.1|	72.5	652	662	660	0.0	994
GibsonMK_2016_SRR3131800_bin.2_k141_3742_526	SARG|gi|851917461|ref|WP_048217311.1|	72.5	652	662	660	0.0	993
GibsonMK_2016_SRR3131800_bin.2_k141_3742_526	SARG|gi|696375142|ref|WP_032949690.1|	72.5	652	662	660	0.0	993
GibsonMK_2016_SRR3131800_bin.2_k141_3742_526	SARG|gi|765458296|ref|WP_044714032.1|	72.4	652	662	660	0.0	993
GibsonMK_2016_SRR3131800_bin.2_k141_3742_526	SARG|gi|851981245|ref|WP_048240645.1|	72.5	652	662	660	0.0	992
GibsonMK_2016_SRR3131800_bin.2_k141_3742_526	SARG|gi|507079934|ref|WP_016150692.1|	72.2	652	662	660	0.0	991
GibsonMK_2016_SRR3131800_bin.2_k141_3742_526	SARG|A7ZP73	72.2	652	662	660	0.0	989
GibsonMK_2016_SRR3131800_bin.2_k141_3742_526	SARG|gi|446783006|ref|WP_000860262.1|	72.4	652	662	660	0.0	989
GibsonMK_2016_SRR3131800_bin.2_k141_3742_526	SARG|gi|851935911|ref|WP_048224705.1|	71.9	652	662	660	0.0	989
GibsonMK_2016_SRR3131800_bin.2_k141_3742_526	SARG|gi|490001987|ref|WP_003904926.1|	72.2	652	662	660	0.0	989
GibsonMK_2016_SRR3131800_bin.2_k141_3742_528	SARG|gb|CDO12042.1|ARO:3005053|ArnT	54.9	554	555	551	5.37e-208	588
GibsonMK_2016_SRR3131800_bin.2_k141_3742_535	SARG|gi|542061059|gb|ERI11611.1|	24.8	214	262	316	1.78e-14	70.9
GibsonMK_2016_SRR3131800_bin.2_k141_3742_544	SARG|gb|APB03222.1|ARO:3003992|rphB	33.8	358	793	884	1.62e-46	177
GibsonMK_2016_SRR3131800_bin.2_k141_3742_544	NCBI|WP_087348261.1|1|1|rphD|rphD||2|rifamycin|rifamycin|rifamycin-inactivating_phosphotransferase_RphD|AMR|rifamycin	33.8	376	793	872	8.98e-45	172
GibsonMK_2016_SRR3131800_bin.2_k141_3742_544	NCBI|WP_087347987.1|1|1|rphC|rphC||2|rifamycin|rifamycin|rifamycin-inactivating_phosphotransferase_RphC|AMR|rifamycin	33.8	358	793	868	5.02e-44	170
GibsonMK_2016_SRR3131800_bin.2_k141_3742_544	SARG|gb|AIA08936.1|ARO:3000444|rphA	37.8	328	793	865	8.84e-44	169
GibsonMK_2016_SRR3131800_bin.2_k141_3742_551	SARG|gb|AYV52072.1|ARO:3002882|lmrD	25.2	230	249	664	2.87e-14	70.9
GibsonMK_2016_SRR3131800_bin.2_k141_3742_551	SARG|gi|446048013|ref|WP_000125868.1|	26.7	240	249	648	8.97e-11	60.5
GibsonMK_2016_SRR3131800_bin.2_k141_3742_551	SARG|YP_001176128	25.5	235	249	646	3.94e-10	58.5
GibsonMK_2016_SRR3131800_bin.2_k141_3742_551	SARG|gi|974588181|ref|WP_059178476.1|	27.0	211	249	646	5.30e-10	58.2
GibsonMK_2016_SRR3131800_bin.2_k141_3742_559	SARG|YP_001453247	76.9	458	459	457	2.71e-251	691
GibsonMK_2016_SRR3131800_bin.2_k141_3742_559	SARG|gi|970292942|ref|WP_058669058.1|	76.6	458	459	457	7.74e-251	689
GibsonMK_2016_SRR3131800_bin.2_k141_3742_559	SARG|gi|851908704|ref|WP_048214273.1|	76.6	458	459	457	2.22e-250	688
GibsonMK_2016_SRR3131800_bin.2_k141_3742_559	SARG|YP_002114436	76.0	458	459	457	4.46e-250	687
GibsonMK_2016_SRR3131800_bin.2_k141_3742_559	SARG|gi|757799242|ref|WP_043016444.1|	76.2	458	459	457	4.46e-250	687
GibsonMK_2016_SRR3131800_bin.2_k141_3742_559	SARG|YP_002849300	76.2	458	459	457	6.34e-250	687
GibsonMK_2016_SRR3131800_bin.2_k141_3742_559	SARG|gi|489929427|ref|WP_003832751.1|	76.2	458	459	457	6.34e-250	687
GibsonMK_2016_SRR3131800_bin.2_k141_3742_559	SARG|ZP_02665869	76.0	458	459	457	9.00e-250	687
GibsonMK_2016_SRR3131800_bin.2_k141_3742_559	SARG|gi|555222058|ref|WP_023214681.1|	76.0	458	459	457	1.28e-249	686
GibsonMK_2016_SRR3131800_bin.2_k141_3742_559	SARG|gi|696368298|ref|WP_032943310.1|	76.2	458	459	457	1.81e-249	686
GibsonMK_2016_SRR3131800_bin.2_k141_3742_563	SARG|gb|ALV80601.1|ARO:3003801|bcr-1	34.4	262	404	402	6.74e-33	126
GibsonMK_2016_SRR3131800_bin.2_k141_3742_563	megares|MEG_8019|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CML_1	29.9	344	404	411	8.64e-30	118
GibsonMK_2016_SRR3131800_bin.2_k141_3742_563	NCBI|WP_011552636.1|1|1|cml_Myxo|cml_Myxo|efflux|2|CHLORAMPHENICOL|PHENICOL|Cml_family_phenicol_efflux_MFS_transporter|AMR|phenicol	29.9	344	404	411	8.64e-30	118
GibsonMK_2016_SRR3131800_bin.2_k141_3742_563	SARG|gi|555231380|ref|WP_023218596.1|	32.6	236	404	413	2.09e-28	114
GibsonMK_2016_SRR3131800_bin.2_k141_3742_563	NCBI|WP_061345584.1|1|1|cml_Ochro|cml_Ochro|efflux|2|CHLORAMPHENICOL|PHENICOL|Cml_family_phenicol_efflux_MFS_transporter|AMR|phenicol	31.5	343	404	397	5.99e-28	112
GibsonMK_2016_SRR3131800_bin.2_k141_3742_563	SARG|gi|554682629|ref|WP_023182561.1|	32.6	236	404	413	1.00e-27	112
GibsonMK_2016_SRR3131800_bin.2_k141_3742_563	SARG|gi|554958315|ref|WP_023203355.1|	32.6	236	404	413	1.00e-27	112
GibsonMK_2016_SRR3131800_bin.2_k141_3742_563	SARG|gi|554963100|ref|WP_023207486.1|	32.2	236	404	413	1.37e-27	112
GibsonMK_2016_SRR3131800_bin.2_k141_3742_563	SARG|gi|1002473661|ref|WP_061389473.1|	32.2	236	404	413	1.37e-27	112
GibsonMK_2016_SRR3131800_bin.2_k141_3742_563	SARG|gi|447111661|ref|WP_001188917.1|	32.2	236	404	413	1.37e-27	112
GibsonMK_2016_SRR3131800_bin.2_k141_3742_574	SARG|gb|BAE78116.1|ARO:3003576|eptA	52.2	544	546	547	3.88e-202	573
GibsonMK_2016_SRR3131800_bin.2_k141_3742_574	NCBI|WP_072310976.1|1|1|mcr-8.2|mcr-8||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-8.2|AMR|peptide	44.6	549	546	565	5.99e-162	471
GibsonMK_2016_SRR3131800_bin.2_k141_3742_574	NCBI|WP_181726036.1|1|1|mcr-8.5|mcr-8||2|||phosphoethanolamine--lipid_A_transferase_MCR-8.5|AMR|peptide	44.6	549	546	565	1.70e-161	470
GibsonMK_2016_SRR3131800_bin.2_k141_3742_574	SARG|gb|AVX52225.1|ARO:3004516|MCR-8	44.6	549	546	565	2.40e-161	470
GibsonMK_2016_SRR3131800_bin.2_k141_3742_574	NCBI|WP_118860654.1|1|1|mcr-8.4|mcr-8||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-8.4|AMR|peptide	44.6	549	546	565	2.40e-161	470
GibsonMK_2016_SRR3131800_bin.2_k141_3742_574	NCBI|WP_150823497.1|1|1|mcr-8.3|mcr-8||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-8.3|AMR|peptide	44.6	549	546	565	3.40e-161	469
GibsonMK_2016_SRR3131800_bin.2_k141_3742_574	SARG|gb|AUN87920.1|ARO:3004500|MCR-3.11	44.7	497	546	541	2.61e-157	459
GibsonMK_2016_SRR3131800_bin.2_k141_3742_574	SARG|WP_065804663.1	44.7	497	546	541	5.22e-157	458
GibsonMK_2016_SRR3131800_bin.2_k141_3742_574	NCBI|WP_136512112.1|1|1|mcr-3.29|mcr-3||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-3.29|AMR|peptide	44.7	497	546	541	5.22e-157	458
GibsonMK_2016_SRR3131800_bin.2_k141_3742_574	NCBI|WP_150823496.1|1|1|mcr-3.28|mcr-3||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-3.28|AMR|peptide	44.7	497	546	541	7.39e-157	457
GibsonMK_2016_SRR3131800_bin.2_k141_3742_582	NCBI|CAQ45063.1|1|1|emrA-sm|emrA-sm||1|EFFLUX|EFFLUX|multidrug_efflux_MFS_transporter_periplasmic_adaptor_subunit_EmrA|AMR|efflux	28.9	315	288	393	1.65e-23	97.8
GibsonMK_2016_SRR3131800_bin.2_k141_3742_582	SARG|gb|AAF40763.1|ARO:3003961|farA	32.0	231	288	384	3.50e-19	85.5
GibsonMK_2016_SRR3131800_bin.2_k141_3742_582	NCBI|WP_063865399.1|1|1|oqxA9|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA9|AMR|multidrug	31.5	200	288	391	1.72e-18	83.6
GibsonMK_2016_SRR3131800_bin.2_k141_3742_582	SARG|gb|AAP43109.1|ARO:3003922|oqxA	31.5	200	288	391	4.32e-18	82.4
GibsonMK_2016_SRR3131800_bin.2_k141_3742_582	NCBI|WP_004149398.1|1|1|oqxA10|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA10|AMR|multidrug	31.5	200	288	391	4.32e-18	82.4
GibsonMK_2016_SRR3131800_bin.2_k141_3742_582	NCBI|WP_004212918.1|1|1|oqxA11|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA11|AMR|multidrug	31.5	200	288	391	4.32e-18	82.4
GibsonMK_2016_SRR3131800_bin.2_k141_3742_582	NCBI|WP_063865358.1|1|1|oqxA2|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA2|AMR|multidrug	31.5	200	288	391	4.32e-18	82.4
GibsonMK_2016_SRR3131800_bin.2_k141_3742_582	NCBI|WP_063865390.1|1|1|oqxA8|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA8|AMR|multidrug	31.5	200	288	391	5.87e-18	82.0
GibsonMK_2016_SRR3131800_bin.2_k141_3742_582	NCBI|WP_004890321.1|1|1|oqxA3|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA3|AMR|multidrug	31.5	200	288	391	5.87e-18	82.0
GibsonMK_2016_SRR3131800_bin.2_k141_3742_582	NCBI|WP_063865368.1|1|1|oqxA4|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA4|AMR|multidrug	31.5	200	288	391	1.08e-17	81.3
GibsonMK_2016_SRR3131800_bin.2_k141_3742_599	NCBI|WP_000116906.1|1|1|aph(6)-Ic|aph(6)-Ic|phosphotransferase|2|STREPTOMYCIN|aminoglycoside|aminoglycoside_O-phosphotransferase_APH(6)-Ic|AMR|aminoglycoside	49.5	273	285	280	2.06e-86	258
GibsonMK_2016_SRR3131800_bin.2_k141_3742_599	SARG|AAB00446	49.8	265	285	264	2.83e-85	255
GibsonMK_2016_SRR3131800_bin.2_k141_3742_599	SARG|X01702.1.gene3.p1	49.8	267	285	266	3.01e-85	255
GibsonMK_2016_SRR3131800_bin.2_k141_3742_599	NCBI|WP_063841666.1|1|1|aph(6)-Smalt|aph(6)-Smalt|phosphotransferase|2|aminoglycoside|aminoglycoside|APH(6)_family_putative_aminoglycoside_O-phosphotransferase|AMR|aminoglycoside	50.6	265	285	270	1.96e-84	253
GibsonMK_2016_SRR3131800_bin.2_k141_3742_599	NCBI|WP_012480135.1|1|1|aph(6)-Smalt|aph(6)-Smalt|phosphotransferase|2|aminoglycoside|aminoglycoside|APH(6)_family_putative_aminoglycoside_O-phosphotransferase|AMR|aminoglycoside	50.2	265	285	270	1.96e-84	253
GibsonMK_2016_SRR3131800_bin.2_k141_3742_609	megares|MEG_7070|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|TETD_1	46.3	108	298	138	5.24e-29	107
GibsonMK_2016_SRR3131800_bin.2_k141_3742_609	CARD|gb|BAA15221.2|ARO:3000263|marA	45.2	104	298	127	1.87e-24	94.7
GibsonMK_2016_SRR3131800_bin.2_k141_3742_609	CARD|gb|AFK13828.1|ARO:3000823|ramA	45.1	102	298	124	1.87e-22	89.4
GibsonMK_2016_SRR3131800_bin.2_k141_3742_624	CARD|gb|CAA79966.1|ARO:3003665|NmcR	55.3	284	294	295	3.32e-106	310
GibsonMK_2016_SRR3131800_bin.2_k141_3742_624	megares|MEG_1992|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	48.4	283	294	291	5.28e-84	253
GibsonMK_2016_SRR3131800_bin.2_k141_3742_625	NCBI|WP_249828069.1|1|1|blaSRT-4|blaSRT|hydrolase|2|CEPHALOSPORIN|beta-lactam|class_C_beta-lactamase_SRT-4|AMR|beta-lactam	98.7	378	379	378	3.41e-276	747
GibsonMK_2016_SRR3131800_bin.2_k141_3742_625	SARG|AAK15701	98.9	378	379	378	4.85e-276	746
GibsonMK_2016_SRR3131800_bin.2_k141_3742_625	SARG|gi|896201400|ref|WP_049208135.1|	98.7	377	379	378	9.78e-276	746
GibsonMK_2016_SRR3131800_bin.2_k141_3742_625	SARG|gi|983102004|ref|WP_060440035.1|	98.7	378	379	378	1.39e-275	745
GibsonMK_2016_SRR3131800_bin.2_k141_3742_625	SARG|gi|896236319|ref|WP_049234464.1|	98.7	378	379	378	1.97e-275	745
GibsonMK_2016_SRR3131800_bin.2_k141_3742_625	SARG|AY524276.3.gene1.p3	98.7	378	379	378	2.80e-275	744
GibsonMK_2016_SRR3131800_bin.2_k141_3742_625	SARG|ABC33904	98.4	378	379	378	2.80e-275	744
GibsonMK_2016_SRR3131800_bin.2_k141_3742_625	SARG|gi|983069570|ref|WP_060419126.1|	98.4	378	379	378	5.65e-275	744
GibsonMK_2016_SRR3131800_bin.2_k141_3742_625	SARG|gi|896193254|ref|WP_049201909.1|	98.4	378	379	378	5.65e-275	744
GibsonMK_2016_SRR3131800_bin.2_k141_3742_625	SARG|gi|665934413|ref|WP_031300463.1|	98.1	378	379	378	3.27e-274	742
GibsonMK_2016_SRR3131800_bin.2_k141_3742_632	SARG|gi|486458841|gb|EOE03251.1|	42.9	70	230	237	5.50e-10	56.6
GibsonMK_2016_SRR3131800_bin.2_k141_3742_637	NCBI|WP_031633255.1|1|1|cmlA_floR|cmlA_floR|efflux|2|CHLORAMPHENICOL|PHENICOL|CmlA/FloR_family_phenicol_efflux_MFS_transporter|AMR|phenicol	24.2	339	433	395	1.29e-07	52.4
GibsonMK_2016_SRR3131800_bin.2_k141_3742_644	SARG|gi|445996719|ref|WP_000074574.1|	32.4	262	380	309	2.02e-36	133
GibsonMK_2016_SRR3131800_bin.2_k141_3742_644	SARG|gi|895736250|emb|COF64653.1|	32.1	262	380	309	2.02e-36	133
GibsonMK_2016_SRR3131800_bin.2_k141_3742_644	SARG|gi|445996714|ref|WP_000074569.1|	32.1	262	380	309	2.02e-36	133
GibsonMK_2016_SRR3131800_bin.2_k141_3742_644	SARG|gi|446110087|ref|WP_000187942.1|	33.7	252	380	309	3.92e-36	132
GibsonMK_2016_SRR3131800_bin.2_k141_3742_644	SARG|gi|445996723|ref|WP_000074578.1|	34.6	234	380	309	5.46e-36	132
GibsonMK_2016_SRR3131800_bin.2_k141_3742_644	SARG|gi|445996696|ref|WP_000074551.1|	33.3	228	380	309	5.46e-36	132
GibsonMK_2016_SRR3131800_bin.2_k141_3742_644	SARG|gi|445996708|ref|WP_000074563.1|	34.1	252	380	309	7.61e-36	132
GibsonMK_2016_SRR3131800_bin.2_k141_3742_644	SARG|gi|445996722|ref|WP_000074577.1|	34.6	234	380	309	7.61e-36	132
GibsonMK_2016_SRR3131800_bin.2_k141_3742_644	SARG|gi|445996695|ref|WP_000074550.1|	34.2	228	380	309	1.06e-35	131
GibsonMK_2016_SRR3131800_bin.2_k141_3742_644	SARG|gi|447057509|ref|WP_001134765.1|	32.9	228	380	309	1.06e-35	131
GibsonMK_2016_SRR3131800_bin.2_k141_3742_648	SARG|ZP_03053667	33.3	507	496	506	7.09e-75	243
GibsonMK_2016_SRR3131800_bin.2_k141_3742_648	SARG|YP_001486998	33.8	494	496	530	9.08e-75	244
GibsonMK_2016_SRR3131800_bin.2_k141_3742_648	SARG|CAB12101	32.2	513	496	512	1.05e-70	233
GibsonMK_2016_SRR3131800_bin.2_k141_3742_648	SARG|YP_001419960	34.8	400	496	510	4.51e-67	223
GibsonMK_2016_SRR3131800_bin.2_k141_3742_648	SARG|AAC15775	33.5	403	496	536	7.37e-59	202
GibsonMK_2016_SRR3131800_bin.2_k141_3742_648	SARG|AAD04032	33.5	403	496	563	1.25e-58	202
GibsonMK_2016_SRR3131800_bin.2_k141_3742_648	megares|MEG_4380|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|OTRB_1	33.5	403	496	563	1.25e-58	202
GibsonMK_2016_SRR3131800_bin.2_k141_3742_648	megares|MEG_4381|Drugs|Tetracycline|Tetracycline_resistance_MFS_efflux_pumps|OTRB_1	33.5	403	496	563	1.25e-58	202
GibsonMK_2016_SRR3131800_bin.2_k141_3742_648	SARG|gb|BAB43261.1|ARO:3007013|sdrM	32.2	298	496	447	4.18e-41	152
GibsonMK_2016_SRR3131800_bin.2_k141_3742_648	SARG|YP_002181880	30.7	437	496	536	3.83e-39	148
GibsonMK_2016_SRR3131800_bin.2_k141_3742_659	SARG|gi|1033217078|gb|OAR27197.1|	27.9	562	700	601	3.82e-54	195
GibsonMK_2016_SRR3131800_bin.2_k141_3742_659	SARG|gi|516795764|ref|WP_018105258.1|	27.4	554	700	601	7.20e-54	194
GibsonMK_2016_SRR3131800_bin.2_k141_3742_659	SARG|gi|517347347|ref|WP_018522839.1|	27.5	567	700	601	9.89e-54	194
GibsonMK_2016_SRR3131800_bin.2_k141_3742_659	SARG|gi|639148059|ref|WP_024490169.1|	26.5	558	700	602	4.89e-53	192
GibsonMK_2016_SRR3131800_bin.2_k141_3742_659	SARG|gi|496018010|ref|WP_008742581.1|	27.9	560	700	623	1.28e-52	191
GibsonMK_2016_SRR3131800_bin.2_k141_3742_659	SARG|gi|664458452|ref|WP_030980047.1|	29.0	517	700	601	4.38e-52	189
GibsonMK_2016_SRR3131800_bin.2_k141_3742_659	SARG|gi|648667297|ref|WP_026359044.1|	26.7	555	700	605	6.38e-52	189
GibsonMK_2016_SRR3131800_bin.2_k141_3742_659	SARG|gi|928900436|ref|WP_053931243.1|	26.8	555	700	600	8.08e-52	188
GibsonMK_2016_SRR3131800_bin.2_k141_3742_659	SARG|gi|664579989|ref|WP_031094015.1|	26.8	555	700	601	8.21e-52	188
GibsonMK_2016_SRR3131800_bin.2_k141_3742_659	SARG|gi|695865802|ref|WP_032778631.1|	26.2	564	700	605	1.64e-51	187
GibsonMK_2016_SRR3131800_bin.2_k141_3742_663	NCBI|WP_252944138.1|1|1|almE|almE||2|COLISTIN|COLISTIN|lipid_A_modification_system_glycine--protein_ligase_AlmE|AMR|peptide	31.7	366	1269	556	1.87e-31	130
GibsonMK_2016_SRR3131800_bin.2_k141_3742_668	SARG|WP_000345069.1	40.3	414	437	434	1.64e-101	308
GibsonMK_2016_SRR3131800_bin.2_k141_3742_683	SARG|gi|664458452|ref|WP_030980047.1|	27.5	552	688	601	1.24e-54	196
GibsonMK_2016_SRR3131800_bin.2_k141_3742_683	SARG|gi|664395661|ref|WP_030922045.1|	27.0	552	688	601	1.57e-53	193
GibsonMK_2016_SRR3131800_bin.2_k141_3742_683	SARG|gi|493394434|ref|WP_006350564.1|	27.5	517	688	602	1.60e-53	193
GibsonMK_2016_SRR3131800_bin.2_k141_3742_683	SARG|gi|648667297|ref|WP_026359044.1|	27.4	544	688	605	1.68e-53	193
GibsonMK_2016_SRR3131800_bin.2_k141_3742_683	SARG|gi|695842130|ref|WP_032755430.1|	26.8	544	688	603	3.07e-53	192
GibsonMK_2016_SRR3131800_bin.2_k141_3742_683	SARG|gi|505420018|ref|WP_015607120.1|	26.8	544	688	603	4.21e-53	192
GibsonMK_2016_SRR3131800_bin.2_k141_3742_683	SARG|gi|517787730|ref|WP_018957938.1|	27.8	565	688	610	8.85e-53	191
GibsonMK_2016_SRR3131800_bin.2_k141_3742_683	SARG|gi|516795764|ref|WP_018105258.1|	26.3	552	688	601	1.44e-52	190
GibsonMK_2016_SRR3131800_bin.2_k141_3742_683	SARG|gi|501350226|ref|WP_012381861.1|	27.9	552	688	603	2.80e-52	189
GibsonMK_2016_SRR3131800_bin.2_k141_3742_683	SARG|gi|764446018|ref|WP_044369325.1|	28.0	561	688	605	2.89e-52	189
